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Abstract 
Erythropoietin (Epo), a kidney-produced cytokine, promotes the proliferation and 
differentiation of erythroid progenitors into mature red blood cells. 
The in vivo biological activity ofEpo is dependent on it being adequately 
glycosylated. Glycosylation is a variable process and its precise effect on clearance . 
mechanisms within the body has yet to be fully established. Studies have shown, 
however, that the loss of the terminal sialic acid residue, leading to exposure of the 
penultimate galactose residue, results in a dramatic reduction in activity, owing to the 
liver's galactose-dependent clearing action. Current in vitro cell-based bioassays for 
Epo are unaffected by such a phenomenon and therefore do not correlate with the in 
vivo bioassays. 
As part of this project, strategies were devised for rendering cell-based bioassays 
sensitive to sialylation. The strategies' common feature was the inclusion of a 
mechanism for depleting or sequestering desialylated Epo via a galactose-binding 
protein (derived from either plants or the human liver). The assays were tested using 
a range of Epo samples desialylated to various degrees by neuraminidase treatment. 
This provided proof of principle that rational manipulation of in vitro hioassays 
rendering them sensitive to a factor known to affect in vivo activity can allow the 
prediction ofbioactivity without the use oflive animals. 
Two Epo sample sets were investigated in addition to the neuraminidase-treated 
sample set - one produced by different culture and purification procedures, the other 
consisting of a batch of pharmaceutical-grade Epo separated into fractions by 
ion-exchange HPLC. Investigations were carried out by means of the most sensitive 
assay developed as well as a range of biological, biochemical and physico-chemical 
techniques with a view to producing an analytical and comparative study. The results 
suggested that the relationship between galactose exposure and in vivo biological 
activity might not be as straightforward as had been initially thought. 
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Chapter 1. Introduction 
1.1. Background 
The task of transporting oxygen from the lungs to tissue elsewhere in the body is 
performed by erythrocytes (red blood cells) via the high-affinity oxygen-binding 
molecule, haemoglobin. Since red blood cells have a finite lifespan - generally 
accepted as being 120 days, although this figure may have to be revised slightly in the 
light of recent research (Werre et aI, 2004) - new ones have to be produced all the 
time. * It is, however, essential to produce the right quantities, since excess production 
can make the blood become too viscous, with an attendant risk of high blood pressure, 
strokes and thrombosis (Anderson & Scotti, 1972), while underproduction can lead to 
the fatigue, shortness of breath and dizziness associated with anaemia (reviewed in 
Gabrilove, 2000). Erythropoiesis, the process whereby pluripotent haematopoietic 
stem cells within the bone marrow proliferate and differentiate into mature red blood 
cells in response to hypoxia (low oxygen levels), is stimulated by the glycohormone 
erythropoietin (Epo) (Gregory & Eaves, 1978;Bondurant & Koury, 1986;Erslev, 
1953). Since it was cloned in 1985 (Jacobs et aI, 1985;Lin et aI, 1985) and 
subsequently produced on an industrial scale, Epo has become one of the most 
successful biopharmaceutical products to date, freeing chronic renal failure patients 
from having to undergo the repeated blood transfusions needed to treat the anaemia 
associated with end-stage renal disease. 
In the case of Epo, and indeed any biological product, the physico-chemical, 
biological and immunochemical properties have to be fully characterised by 
procedures that conform to the guidelines set by the International Conference on 
'Around 2.3 million per second (Lappin, 2003) 
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Hannonisation (1999). According to the European Phannacopoeia (Fifth Edition, 
2005), the only means of evaluating the true biological activity of Epo is to use in vivo 
tests on mice - measuring reticulocyte production or 59Fe incorporation into newly 
synthesised red blood cells. Although there is a drive to replace in vivo bioassays with 
assays that do not involve animals, this has not yet been achieved in the case of Epo, 
as potencies obtained by the two procedures do not correlate, in particular because of 
the role the liver-expressed asialoglycoprotein receptor plays in clearing incompletely 
sialylated glycoproteins from the circulation (Fukuda et aI, 1989). Correct 
glycosylation is essential to the in vivo activity of Epo whereas it is more or less 
irrelevant to its in vitro activity as tested by immuno- or cell-based assays (Tsuda et 
aI, 1990). Manipulating in vitro bioassays - thereby rendering them responsive to 
factors known to affect bioactivity - is one option with potential for predicting in vivo 
activity without the need to use live animals. This could be done by depleting Epo 
solutions of certain glycoforms prior to use in an Epo-dependent cell-based assay or 
by genetically engineering Epo-dependent cells to express selective decoy receptors 
selective. The work described in this thesis investigates this possibility. 
1.2. Structure of Epo 
Human Epo is synthesised as a 193-amino acid polypeptide. A 27-amino acid signal 
sequence and a carboxy-terminal arginine residue are removed during processing to 
produce a 165-amino acid mature protein with a molecular mass of 30AkDa 
(reviewed in Moritz et aI, 1997). It has a compact globular structure consisting of 
four amphipathic a-helical bundles (Wen et aI, 1994;Elliott et aI, 1997). There are 
two disulfide bonds, between cysteines 29 and 33 and cysteines 7 and 161 
respectively, the latter bond being highly conserved across species owing to its critical 
role in stabilising the protein and maintaining it in the correct shape for receptor 
binding (Wen et ai, 1993;Elliott et ai, 1996). 
Sugar chains account for approximately 40% ofEpo's apparent molecular weight 
(unglycosylated Epo is 18 kDa). Epo is N-glycosylated at asparagines 24, 38 and 83 
while serine 126 is O-glycosylated. The N-glycan chains ofEpo are of the complex 
type (see Fig. 1.2.1. for a schematic representation of the primary structure of human 
Epo, and Fig. 1.2.2. for a ribbon model). 
Oligosaccharide chains can differ in a variety of ways: 
• by type of glycosylation: glycosylated on asparagine (N-glycosylation) or on 
serine or threonine residues (O-glycosylation); 
• by degree of branching: mono-antennary, bi-antennary, tri-antennary, 
tetra-antennary (1, 2, 3 or 4 branches respectively); 
• by level of sialylation: unsialylated, monosialylated, disialylated, trisialylated, 
tetrasial ylated; 
• i~ terms offucosylation, the presence ofpolylactosamines, etc. 
(see Fig. 1.2.3. for a description of the various types of glycosylation.) 
1.3. Site of Epo production 
In adults, Epo is produced by a population of interstitial cells in the cortex ofthe 
kidney (Maxwell et ai, 1993) and circulates in the blood to stimulate erythropoiesis in 
the bone marrow. In the foetus, Epo is produced by liver parenchymal cells, but soon 
after birth production switches to the kidneys (Zanjani et ai, 1977). 
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Fig. 1.2.1. Schematic representation of the primary structure of human 
Erythropoietin. 
Arginine 166 is cleaved during post-translational modification, as is a 27-amino 
acid signal peptide (not shown), to leave a 165-amino acid mature glycoprotein. 
There are two disulfide bonds, one between cysteines 29 and 33, the other 
between cysteines 7 and 161. Asparagines 24,38 and 83 are N-glycosylated and 
serine 126 is O-glycosylated, indicated by'andVSUgar chains respectively 
(modified from Jelkmann (1992». 
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Fig. 1.2.2. Ribbon model of erythropoietin; image of 
structure of erythropoietin (PDB code 1BUY) based on 
NMR structure published by Cheetham et ai, 1998 
(http://www.ebi.ac.uklthornton-srv/databases/cgi_ 
binlgenfigs/RunGenfigs.pl?call type=existingpdb&pdbco 
de=lbuy). 
----_ N 
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Fig. 1.2.3. (Facing page) (a) Schematic representation of an N-linked sugar 
chain of the complex type. The consensus site for N-glycosylation is 
Asn-X-Serffhr, where X can be any amino acid except Pro or Asp. The 
sugar may have four 'branches (tetra-antennary), three branches (tri-
antennary), two branches (bi-antennary) or just one branch (mono-
antennary). The illustration shows a tetra-antennary structure. Sialic acids 
mayor may not be present. Extended polylactosaminyl structures (denoted 
by an asterisk) may be formed by additional 
[Galactose-N -acetylglucosamine] moieties. 
N-acetylgalactosamine-sulphate sometimes replaces the galactose-sialic 
acid moiety. 
(b) Schematic representation of an O-linked bi-antennary sugar chain. 
Figs (a) and (b) modified from Lowe and Marth, 2003. 
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(a) (b) 
Legend: 
N-acetylglucosamine 
o Mannose 
o Galactose 
~ 
Sialic acid +/-
SerIThr D Fucose D N-acetylgalactosamine 
Asn-X-Serrrhr 
-.....J 
1.4. Erythropoiesis 
In adult bone marrow, pluripotent haematopoietic stem cells develop into erythroid 
progenitors (see Fig. 1.4.1. for a schematic representation of the various stages). 
The earliest erythroid-progenitors, burst-forming unit-erythroids (BFU-Es), mature in 
the presence of interleukin-3, granulocyte-macrophage colony-stimulating factor 
(GM-CSF) and stem cell factor (SCF), and begin to express erythropoietin receptors 
(Epo-R), consequently gaining the ability to respond weakly to Epo (Emerson et aI, 
1988;Dai et aI, 1991). After a few days, colony-forming erythroid units (CFU-E) 
develop which are highly responsive to Epo. These go on to become erythroblasts, by 
which time Epo sensitivity and the number of Epo receptors have declined until there 
is no longer a dependence on Epo (Gregory & Eaves, 1978;Gregory & Eaves, 1977). 
During erythropoiesis, calcium uptake by the cells increases, the Epo-R and other 
intracellular signalling proteins become phosphorylated, haemoglobin accumulates 
and, lastly, enucleation (exclusion of the nucleus) takes place (Mladenovic & Kay, 
1988;Dusanter-Fourt et aI, 1992;Quelle & Wojchowski, 1991;Koury et aI, 1987). 
This is the series of events that occurs in the presence of Epo. Physiological 
concentrations ofEpo are generally Iow, however, and ifEpo does not bind its 
receptor, the ceIIs undergo apoptosis (Muta & Krantz, 1993). 
1.5. O2 sensing and transcription control 
If there is a reduction in the Oz capacity of the blood (Le. a faIl in haemoglobin 
concentration), a decrease in arterial pOz (e.g. at high altitudes), or an increase in the 
blood's Oz affinity (for example, due to a mutant haemoglobin or an increase in blood 
alkalinity), Epo gene expression is triggered (Miller et aI, 1982;Lenfant & Sullivan, 
1971 ;Hebbel et aI, 1978;Mi11er et aI, 1973). The hypoxia-inducible factor (HIF)-1 
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Fig. 1.4.1. (Facing page) Schematic representation of the development stages 
of erythroid progenitors. 
-Burst-forming unit erythroids (BFU-Es) are less responsive to Epo and have 
few Epo receptors (thus requiring higher Epo concentrations for their 
amplification), but their numbers increase as the BFU-E matures into the 
colony-forming unit erythroid (CFU-E). Since they feature the highest 
number of Epo receptors, CFU-Es are more sensitive to Epo and require lower 
Epo concentrations for differentiation into reticulocytes and, ultimately, 
mature erythrocytes. The Epo receptors are no longer present in reticulocytes 
and mature erythrocytes (adapted from Fisher, 2003). 
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plays an integral role in this process. HIF-l is a dimer consisting of an a- and a 
f3-subunit. The a-subunit contains a C-terminal transactivation domain, whereas the 
f3-subunit is a transcription factor identical in sequence to the aryl-hydrocarbon 
nuclear translocator (ARNT). Messenger RNA (mRNA) encoding these subunits 
remains constant, whether or not the body is experiencing hypoxia. Protein levels of 
the f3-subunit also remain constant, but HIF-l a is unstable when oxygen levels are 
normal as it contains two oxygen-dependent proteolytic degradation domains. If the 
oxygen concentration is above a certain level in the cell, HIF-l a is hydroxylated at 
prolines 402 and 564, enabling binding to the von-Hippel-Lindau protein (pVHL), 
which in turn mediates the formation of a complex with E3 ubiquitin ligase. The final 
step is degradation by the proteasome. Under hypoxic conditions, the HIF-l a evades 
degradation, enters the nucleus, dimerises with HIF-l f3 and binds the Hypoxia 
Response Element (HRE) (reviewed in Jelkmann, 2004). 
1.6. The Epo receptor and its signalling pathways 
The Epo-R shares homology with receptors for Interleukin (IL)-3, IL-4, IL-6, IL-7, 
granulocyte and macrophage colony-stimulating factor, granulocyte 
colony-stimulating factor, growth hormone and prolactin (Finidori & Kelly, 1995), all 
of which are members of the cytokine class I receptor superfamily (Bazan, 1990). The 
class II receptor family contains the less structurally related receptors for 
interleukin-l0 and interferons a, f3, and A (Kelly et aI, 1993). 
The human Epo-R was first cloned in 1991 (Ehrenman & St John, 1991;Maouche et 
aI, 1991;Noguchi et aI, 1991). The mature form ofthe Epo-R is a 483 amino acid (aa) 
long (508 aa when the signal peptide is uncleaved) single transmembrane-spanning 
glycoprotein receptor with a molecular weight of 66 kDa when glycosylated with 
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complex-type sugars (Yoshimura et aI, 1990). Notable among the structural features 
of the Epo-R exoplasmic domain are its four conserved cysteine residues and the 
Trp-Ser-X-Trp-Ser (WSXWS) motif (where X is any amino acid, A in the case of the 
Epo-R) lying very close to the transmembrane domain. Site-directed mutations of the 
WSA WS motif have revealed it to be crucial to protein-folding, ligand-binding, and 
signal transduction (Y oshimura et aI, 1992). As with many members of the cytokine 
receptor family, the membrane-proximal regions contain two conserved motifs, called 
box 1 and box 2. Box 1 is proline-rich, while box 2 contains hydrophobic residues 
followed by positively charged amino acids. Their presence is required for the 
induction of proliferation-promoting signals (Murakami et aI, 1991;N arazaki et aI, 
1994). 
The Epo-R is a pre-formed dimer (Livnah et aI, 1999). The act ofEpo binding to its 
receptor has been shown by X-ray crystallography (Syed et aI, 1998) and nuclear 
magnetic resonance (Cheetham et aI, 1998) to force the receptor to take on a new 
conformation that allows optimised transduction signalling. Chimeric forms of the 
Epo-R have been created in which its transmembrane domain was replaced by various 
types of coiled coils. These coils constrained the subunits of the dimer receptor into 
different orientations and demonstrated that certain conformations facilitate activation , 
whereas one corresponds to the inactive form ofthe receptor. Additionally, if Argl29 
in the extracellular domain ofthe Epo-R is changed to a cysteine, constitutive dimers 
arise, accompanied by constitutive proliferation (Watowich et aI, 1992). One 
molecule of Epo binds two receptors at a time, one with high affinity and one with 
low affinity (Philo et aI, 1996). 
Unlike receptor tyrosine kinases, the Epo-R cytoplasmic domain contains no intrinsic 
tyrosine kinase activity and instead associates with a tyrosine kinase, Janus-activated 
kinase 2 (Jak2) (Witthuhn et ai, 1993). Conformational change of the two 
intracellular domains of a dimer initiates activation of the two associated Jak2 
molecules. The activated Jak2 proteins tyrosine phosphorylate each other, the EpoR 
and other signalling molecules, creating docking sites for signalling proteins 
containing Src homology 2 (SH2) domains. Many proliferative and anti-apoptotic 
signal-transduction pathways get activated, including the phosphatidyl-inositol 
3-kinase/ Akt, Ras/mitogen-activated protein (MAP) kinase, phospholipase C-protein 
kinase C (PLC-PKC), and Signal-Transducer and Activator of Transcription 5 
(STAT5) pathways (Damen et ai, 1993;Damen et ai, 1995a;Bao et ai, 1999;Bao et ai, 
1999;Torti et ai, 1992;Miura et ai, 1994;Ren et ai, 1994;Damen et ai, 1995b). 
Following activation by phosphorylation, the cytoplasmic transcription factor ST AT5 
dimerizes and translocates to the nucleus, where it binds to the Bel-xLPromoter, 
thereby driving expression of this anti-apoptotic protein member of the Bel family 
(Silva et ai, 1999). 
The maturation and proliferation pathways are distinct from the anti-apoptotic 
pathway. One line of evidence in support of this is the mutant cell-line J2E-NR, 
which has lost its ability to proliferate in the presence of Epo but does not undergo 
apoptosis (Tilbrook et ai, 1996). Moreover, treatment of the murine Epo-dependent 
HCD57 cell line with orthovanadate, a tyrosine phosphatase inhibitor, has been shown 
to result in increased levels oftyrosine protein phosphorylation and prevention of 
apoptosis while leaving proliferation unaffected. Conversely, blocking the 
pro-proliferative MAP kinase pathway with a chemical inhibitor did not cause 
apoptosis (Laws on et ai, 2000). 
The cytoplasmic region of the Epo-R closest to the transmembrane domain is involved 
in the transduction of signals that lead to proliferation, whereas the C-terminal end has 
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a role in negatively regulating these signals (D' Andrea et ai, 1991). The signalling 
pathways are strictly controlled and once activated are very promptly switched off. 
The dramatic decrease in response to Epo involves recruitment of phosphatases, such 
as SH2-containing protein tyrosine phosphatase 1 (SHP 1), to the receptor and the J ak2 
kinases. In addition, inhibitor proteins are produced and internalisation, ubiquitination 
and degradation ofreceptor-ligand complexes take place, thereby preventing the 
Epo-R from reappearing at the cell surface (Verdier et ai, 2000;Walrafen et ai, 2005). 
Signalling pathways then return to basal levels after 30-60 minutes (Verdier et ai, 
2000). Fig. 1.6.1. contains a schematic representation of the Epo-R and its associated 
signalling molecules. 
1.7. The history of re comb in ant Epo and its medical applications 
Hormones (from the Greek word hormon, to "set in motion") are defined as 
substances produced in a given region of the body (usually an endocrine gland) which 
affect other parts of the body after being transported there by the blood. In 1906, 
Carnot and DeFlandre showed that injecting plasma from anaemic rabbits into normal 
rabbits prompted an increase in the number of circulating red blood cells, thus 
demonstrating that erythropoiesis was hormonally controlled (Carnot & DeFlandre, 
1906). They gave the name "hemopoietine" to the substance they considered 
responsible. Having found that this factor caused only the precursors of red blood 
cells to proliferate, Bondsdorffrenamed it erythropoietin (Bondsdorff & Jalavisto E., 
1948). In 1950, Reissman demonstrated that Epo production was stimulated by 
hypoxia (Reissman, 1950). Some seven years later, Jacobson et al (1957) showed by 
nephrectomy that Epo was produced in the kidney, but it was not until 1977 that 
Miyake and co-workers purified human Epo from 2,550 litres of urine from patients 
Fig. 1.6.1. (Facing page) Structure of the human Epo receptor 
dimer and its associated signalling molecules. The human Epo 
receptor has a 225 aa extracellular domain, a 23 aa 
transmembrane_domain and a 235 aa cytoplasmic domain. A 
24 aa signal peptide is cleaved during post-translational 
processing. Epo binds the receptor's extracellular domain, 
inducing a conformational change that is transmitted to the 
cytosolic domain, leading to auto- or transphosphorylation of 
the Jak2 kinase. Jak2 then phosphorylates tyrosine residues of 
Epo-R, creating docking sites for the SH2 domains of several 
signal transduction proteins. Signalling is terminated 
principally by the protein tyrosine phosphatase SHPl 
(modified from Ghaffari et ai, 2003). 
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suffering from aplastic anaemia (Miyake et aI, 1977). This made possible 
part-sequencing of the Epo protein, leading to the independent cloning of its gene by 
two groups in 1985 (Jacobs et at (1985) and Lin et at (1985». The next step was 
expression of Epo in mammalian cells, thereby facilitating the production of greater 
quantities of the hormone. 
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The first clinical trials began in 1987 with purified human recombinant Epo 
(recHuEpo) being administered to patients with end-stage renal disease anaemia, as 
reported in reference (Eschbach et aI, 1987). These were highly successful in terms of 
eliminating the need for patients on dialysis to have regular blood transfusions and 
paved the way for recombinant Epo to be produced on an industrial scale. RecHuEpo 
has since become one of the most successful biopharmaceuticals to date, with 
worldwide sales of 7.1 billion dollars having been reported in 2002 alone (Nature 
Biotechnology, 2004). 
RecHuEpo is used not only for end-stage renal disease but also for chronic renal 
failure general1y (as anaemia can result at any stage due to the kidneys' inability to 
synthesise sufficient amounts of Epo), for the anaemia associated with cancer, HIV 
infection, rheumatoid arthritis, autologous blood donation, and the bone marrow 
suppression resulting from cancer chemotherapy (reviewed in Fisher, 2003). 
RecHuEpo has contributed enormously to improving the quality of life of anaemia 
sufferers by relieving such symptoms as fatigue, dizziness, shortness of breath, 
headaches, chest pain and reduced activity levels (reviewed in Gabrilove, 2000). 
An additional factor in recHuEpo's success is its protein sequence, which is identical 
to that of endogenous human Epo, thus ruling out, at least in theory, any risk of an 
immune reaction. A number of cases have been reported, however, in which patients 
have developed antibodies against the administered recHuEpo. These antibodies 
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neutralise all Epo, including endogenous Epo, resulting in cessation of erythropoiesis, 
a condition called Pure Red Cell Aplasia (PRCA) (Rossert et ai, 2004). 
Conversely, the rise in the number of red blood cells brought about when excessive 
amounts of Epo are produced can cause the blood to become too viscous, thus 
increasing the risk of high blood pressure, thrombosis, strokes, heart failure, 
myocardial infarction and pulmonary embolism (Anderson & Scotti, 1972). This can 
occur naturally, as in the case of chronic mountain sickness, but it can also be caused 
by illegal doping - some athletes take recHuEpo as it can improve aerobic 
performance (Wagner, 1991). 
1.8. Biologicals and batch testing 
Pharmaceuticals are, for regulatory purposes, regarded as falling into two groups: 
synthetic chemicals (small molecules, mostly) and biologicals (usually complex 
macromolecules). Biologicals have usually been defined as substances produced in 
biological systems which cannot be completely characterised by physico-chemical 
methods alone, and therefore also need to be tested by some form ofbioassay. Their 
physico-chemical, biological and immunochemical properties must be fully 
characterised by the types of procedures set out in the International Conference on 
Harmonisation guidelines (1999). Unglycosylated proteins, such as insulin, pose less 
of a problem as they can be produced in large quantities in bacteria and with high 
levels of both purity and homogeneity. Bacteria are not, however, regarded as suitable 
for expressing glycosylated proteins as bacteria hardly glycosylate proteins at all and 
the glycan structures that are produced by prokaryotes differ too much from those of 
mammalian glycoproteins to be of any therapeutic value (Messner, 2004;Lindenthal & 
Elsinghorst, 1999). Such glycoproteins need to be produced in mammalian cells, 
which are capable of complex glycosylation. 
The polypeptide backbone of glycoproteins, including Epo, is invariant and strictly 
controlled by the encoding DNA sequence but there can be batch-to-batch variations 
in glycosylation. Fluctuations in the availability of glycosyltransferases lead to 
heterogeneity in the protein's oligosaccharide chains - the number of branches can 
vary as can the level ofterminal sialylation. A range of possible factors have been 
suggested as being responsible, including host cell line, culture conditions, length of 
time in incubation, and method of purification (Goochee & Monica, 1990). 
Glycosidases and proteases may also affect recombinant protein secreted into the 
culture medium (Le Floch et aI, 2004). It is for this!eason that batch testing is 
required. 
There are two in vivo assays currently recognised by the European Pharmacopoeia 
(EP) for the batch testing of Epo (2005). Both are based on the premise that 
biologically active Epo stimulates proliferation of red blood cells. 
1.9. The post-hypoxic polycythaemic mouse bioassay 
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The post-hypoxic polycythaemic mouse bioassay involves placing mice in a hypobaric 
chamber with air at a pressure of half an atmosphere for 14 days. They become 
polycythaemic, eventually reaching a point where feedback inhibition takes place .. 
The consequential suppression of red blood cell production serves to create a low 
baseline from which to measure erythropoiesis stimulation (Cotes & Bangham, 1961). 
Epo samples intended for testing are then administered on Day 14+ 1. Radiolabelled 
iron (59Fe) is injected on Day 14+3, becoming incorporated into freshly made 
haemoglobin. The endpoint involves measuring the radioactivity in the red blood 
cells on Day 14+5. 
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Also available are the starved rat bioassay and the transfusion-induced polycythaemic 
mouse assay (the latter actually being more sensitive than the hypoxia-induced 
polycythaemic bioassay) but they are not used as they are more time, cost and labour 
intensive and place the animal in greater distress (Krumwieh et ai, 1988). 
1.10. The normocythaemic mouse bioassay· 
Reticulocytes are immature anucleate red blood cells that still contain RNA and can 
be distinguished from mature anucleate RNA-free red blood cells. Kawamura et ai 
(1991) developed a new in vivo bioassay based on measurement of immature 
reticulocytes in normal mice in response to subcutaneous Epo injections. 
Normal animals are not responsive to small doses of exogenous Epo as the effect of 
such doses is masked by endogenous Epo. It is for this reason that the polycythaemic 
bioassay - which is more sensitive because of the suppression of endogenous Epo - is 
used in such instances. 
The drawback of the polycythaemic mice bioassay is that it is time-consuming, 
cumbersome, expensive, and requires radioisotopes and elaborate animal preparations. 
Mice suffer less in the normocythaemic mouse bioassay, as there is no need to 
pre-treat animals in a hypobaric chamber. It is also more precise than the 
polycythaemic mouse assay; even more so when, instead of one injection, three 
injections are carried out on successive days (Ramos et ai, 2003). 
Immature reticulocytes can be measured in a variety of ways: selective haemolysis of 
mature red blood cells leaving immature reticulocytes that can be counted with an 
automated cell counter, fluorescent flow cytometry (which makes use ofthiazole 
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orange, a fluorescent dye that binds the RNA of immature red blood cells) or Cresyl 
Blue staining (a basic dye used for staining reticulocytes as it has a strong affinity for 
nucleic acid) (Kawamura et aI, 1991;Hayakawa et aI, 1992). The flow cytometry 
method combined with the multiple injection method has been found to give the 
greatest precision (Ramos et aI, 2003). Although the normocythaemic assay is less 
invasive, it is only suitable when larger amounts ofrecHuEpo are available (as is 
likely in the case of re comb in ant Epo batch production). 
Both assays involve comparing the Epo sample being tested with an international 
reference standard, the current one for Epo being the Second International Standard 
for Erythropoietin, NIBSC code: 88/574 (Storring & Gaines Das, 1992). By 
expressing potencies relative to a standard reference. material, some of the major 
sources of variability between laboratories can be removed. Measuring the 
parallelism between the two curves can reveal whether the sample being tested is 
behaving in the same way as the reference standard. Both assays are specific for Epo 
and, in terms of sensitivity, the polycythaemic assay can detect 0.05IU of Epo, 
whereas the detection limit of the normocythaemic assay is lIU (Hayakawa et aI, 
1992). Each assay uses 4-6 mice per treatment group. 
There are also in vitro tests for Epo employing cells derived from sacrificed animals. 
While very sensitive as regards detecting concentrations, they cannot be used as a 
substitute for measuring in vivo potency. Examples of such tests include measuring 
the incorporation of 59Pe into haem of rat bone marrow cells (Goldwasser et aI, 1975) 
or the proliferation and incorporation of 3H-Thymidine in spleen cells of 
phenylhydrazine-treated mice (Krystal, 1983). Treatment with phenylhydrazine is 
done because it results in fifty times more Epo-responsive cells being obtained from 
the spleen, an erythropoietic organ in mice (Rencricca et aI, 1970). 
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1.11. Ethical issues 
. As stated above, the general consensus on biopharmaceuticals has thus far been that 
their specific activity must be determined by some form of biological assay. In vivo 
assays are required in the case of certain glycoproteins, including Epo. Such tests can 
use large numbers of mice; no fewer than 42 are needed to test an unknown sample of 
Epo (six for each ofthree dilutions, the same again for the reference material, and six 
blanks). In 1959 William Russell and Rex Burch published "The Principles of 
Humane Experimental Technique", in which they outlined their 3Rs concept of 
refining, reducing or replacing animal experiments (Russell & Burch, 1959). They 
suggested that if animals had to be used in the course of experiments, every effort 
should be taken to refine those experiments so as to cause the animals the least 
possible pain and distress, and investigations should be aimed at reducing the number 
of animals needed while still maintaining statistical validity. The ideal course of 
action, however, would be to replace all in vivo tests with in vitro or physico-chemical 
alternatives. The European Union is committed to pursuing the same goal of 
improving the welfare of animals used in medical testing. According to directive 
86/609/EEC of24 November 1986 of the European Council, there is a requirement to 
support the development and validation of methods that have the potential to reduce, 
refine or replace the use oflaboratory animals. Article 7.2 of the directive states that 
"an experiment shall not be performed if another scientifically satisfactory method of 
obtaining the result sought, not entailing the use of the animal, is reasonably and 
practically available". The European Centre for the Validation of Alternative 
Methods (EeV AM) was set up in response to this directive. Article 7.3 of the 
d· . . h' e between experiments, those which use the minimum IrectIve states that "tn a c OlC 
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number of animals ... cause the least pain, suffering, distress, and lasting harm and 
which are most likely to provide satisfactory results shall be selected". One of their 
recommendations is therefore that the polycythaemic assay should, wherever possible, 
be replaced by the less invasive normocythaemic assay. 
1.11.1. The suitability of replacing in vitro with in vivo assays 
Small unglycosylated peptide hormones, such as oxytocin and calcitonin (9 and 32 
amino acids long respectively), are examples of suitable for being quantified by High 
Performance Liquid Chromatography (HPLC), a physico-chemical method, and not 
by an animal test (Miethe, 2002). Immortalised cell line bioassays can be used to 
assess the potency ofnon-glycosylated proteins (or proteins for which glycosylation is 
not crucial to activity) such as interferons (Meager, 2002), colony-stimulating factors 
(Metcalf et ai, 1994), and interleukins (Mire-Sluis & Thorpe, 1998). Glycoproteins 
such as Epo pose more of a problem for researchers seeking to reduce the amount of 
testing done on animals. This is because the in vivo activity of Epo is dependent on its 
glycosylation state, most critically on its sugars being capped with sialic acid (also 
known as N-acetylneuraminic acid), a factor that is more or less irrelevant to its effect 
on receptor binding and in vitro activity. Glycosylation is not a tightly regulated 
process and results in Epo being made up of a mixture of glycoforms. Assigning a 
potency to such a heterogeneous pool of proteins using a technique such as HPLC is 
no simple matter; determining how much of a substance is present in a preparation in 
terms of mass or number of moles does not necessarily reveal how active that 
substance is. The data obtained by immunological and cell-based assays for Epo do 
not correlate with those obtained by in vivo bioassays. Proliferation of Epo-dependent 
1 h b· d'ng ofEpo to the erythropoietin receptor and on ce Is depends solely on t e III 1 
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successful transmission of a proliferative/anti-apoptotic signal from the exterior of the 
cell to its interior. In vivo activity, on the other hand, is dependent not only on these 
same events taking place in and on target cells but also on the hormone's 
pharmacokinetics, including how it is removed by the body's clearance mechanisms. 
1.12. Clearance mechanisms 
The faster a hormone is cleared from the body, the less time it will have to elicit a 
reaction from its target cells. There are a number of mechanisms by which a hormone 
is cleared from the body, and they will all have a bearing on its effective potency. 
1.12.1. Hepatic clearance of desialylated glycoproteins 
In their seminal paper, Morell et al (1968), reported the finding that radioactively 
labelled neuraminidase-treated ferroxidase, a copper transport glycoprotein found in 
the blood, cleared more rapidly from the circulation of rabbits than did the unmodified 
form ofthe glycoprotein. Radioactivity accumulated in parenchyma! cells of the liver. 
Replacing the missing sialic acids of desialylated ferroxidase or treating it with 
galactose oxidase or p-galactosidase, and thereby eliminating the presence of exposed 
terminal galactose residues, resulted in a return to the same pharmacokinetics as those 
witnessed for intact ferroxidase. These experiments were repeated by Spivak and 
Hogans, this time using Epo (1989), and showed that oxidation ofasialo-Epo's 
galactose residues again restored clearance rates to those of fully sialylated Epo 
despite the in vitro activity being abolished. Co-injection of excess asialo-alpha-l-
acid glycoprotein reduced the accumulation of asialo-Epo in the liver, something not 
achieved with sialylated alpha-I-acid glycoprotein. Goldwasser et al (1974) were the 
first to show that desialylation of Epo resulted in a loss of in vivo biological activity 
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while in vitro activity remained intact and similar effects have been reported in 
numerous papers (Dordal et ai, 1985;Wasley et ai, 1991;Tsuda et ai, 1990). 
Experiments ofthis kind have been carried out with a wide variety of glycoproteins in 
addition to Epo and ferroxidase: alpha-I-acid glycoprotein, fetuin, haptoglobin, 
<X2-macroglobulin, chorionic gonadotropin and follicle-stimulating hormone, 
demonstrating the apparent universality of this phenomenon (Morell et ai, 1971). 
Asialo-Epo clears from the circulation in six minutes whereas Epo produced in cells 
that can transfer only truncated glycan structures takes 90 minutes, showing that the 
exposed terminal galactose is the crucial determining factor in clearance (Wasley et 
ai, 1991). 
A galactose-specific liver receptor responsible for binding the penultimate galactose 
residues left: exposed through removal of terminal sialic acids by neuraminidase was 
postulated to exist. A candidate for such a receptor was isolated and characterised by 
Pricer et al (1974) and named the asialoglycoprotein receptor (ASGP-R). 
The role the liver's ASGP-R plays in clearing such experimentally desialylated 
glycoproteins is thus a widely reported and accepted phenomenon. This does not 
necessarily reflect what takes place in the body in actual physiological terms, 
however, or explain the true role of the ASGP-R. 
Tozawa et al (2001) speculate on how the ASGP-R may have evolved for a 
completely different reason - to protect mammals from viruses and/or bacteria. Some 
pathogens may use neuraminidase to invade their host and so galactose residues would 
be a sign of such an infection. The authors note that people with liver disease 
frequently develop serious infections such as spontaneous bacterial peritonitis and 
sepsis. Weigel (1994) expounds on the view that glycoproteins with exposed 
galactose residues could be harmful and need to be cleared but admits there is no 
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explicit evidence for this. The fact that birds and reptiles do not possess an ASGP-R 
and have a higher concentration of circulating asialo-glycoprotein than do mammals 
(Regoeczi et aI, 1975) mayor may not be of particular significance. The most widely 
held view is that glycoproteins are cleared by the ASGP-R after they have served a 
particular physiological function (Ashwell & Harford, 1982); a potential scenario 
being that a sialidase acts on circulating glycoproteins and that the chance of 
desialylation occurring increases with time. The theory relies on there being a 
circulating form of neuraminidase and one of these has already been reported 
(Corfield et aI, 1982). There is also a report of low levels of a neuraminidase in Cohn 
Fraction VI from mammalian plasma (Warren & Spearing1960). 
Appealing though this theory may be, it is unsupported by direct evidence (Drickamer, 
1988). There is, in fact, evidence to the contrary. Lefort et al (1984) injected intact 
human chorionic gonadotropin into rats and found that asialo-fetuin does not compete 
with its clearance nor is there accumulation of desialylated human chorionic 
gonadotropin in the circulation; evidence that any clearance mechanisms probably do 
not involve glycoproteins becoming desialylated (by a sialidase, for example), thereby 
mediating uptake via the ASGP-R. Wong et al (1974) assert that neither does 
transferrin undergo in vivo desialylation. 
Direct correlation has been claimed, however, between extent of liver damage or the 
size of a liver cell carcinoma and the amount of circulating asialoglycoproteins 
(Marshall et aI, 1974;Sawamura et aI, 1984). There is speculation that this could be 
due to the liver no longer being able to clear asialoglycoproteins from the circulation 
or, alternatively, that the liver could be incorrectly modifying proteins 
post-translationally. Coincidentally or otherwise, analysis of the hepatocytes of 
patients with cirrhotic liver disease revealed the ASGP-R (usually all but restricted to 
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the sinusoidal surface) to be redistributed around the cell (Burgess et aI, 1992). By 
contrast, Jensen et al (1995) found Epo phannacokinetics to be the same in advanced 
liver cirrhosis patients as in healthy volunteers. 
Tozawa et al (2001) reported on a knockout mouse lacking the ASGP-R gene. While 
in mice of this type artificially desialylated proteins (asialo-orosomucoid and 
asialo-fetuin) were not cleared at as fast a rate, plasma glycoproteins levels - as 
detected by blotting with lectins specific for galactose and sialic acid - did not 
increase. Deal et al found that the liver of ASGP-R-deficient mice still takes up 
radiolabelled galactosylated bovine serum albumin (BSA) but that more radioactivity 
accumulates in endothelial liver cells compared with wild-type mice - possible 
evidence for a compensatory mechanism or overlap. of function (Deal et aI, 1998). 
There is a macrophage galactoselN-acetylgalactosamine lectin that could be playing a 
part in compensating for the missing ASGP-R (Ii et aI, 1990;Suzuki et aI, 1996). 
1.12.2. Renal clearance 
It has been reported that urinary Epo contains more acidic isoforms than does serum 
Epo, leading to speculation that urinary Epo is Epo that appears in the urine because is 
it cleared less rapidly by the liver (Storring & Gaines Das, 1992;Tam et aI, 1991;Wide 
& Bengtsson, 1990). Fukuda et al (1989) injected radiolabelled desialylated Epo into 
rats and measured the radioactivity of four organs after 30 minutes. The liver 
accumulated the most radioactivity (85% of total radioactivity), followed by the 
kidneys (9%), lungs (4%) and spleen (2%). Intact, fully sialylated Epo was distributed 
as follows: liver 64%, kidney 24%, lung 9% and spleen 3%. Once again, 
accumulation took place mainly, but to a lesser extent, in the liver, and the kidneys 
became a site of further accumulation. This is additional support for the hypothesis 
that ifEpo does not lose sialic acids in time to engender clearance by the liver, then 
more acidic forms of Epo are cleared by the kidneys. 
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Interestingly, a form ofEpo called Epo-bi has been studied that is rich in bi-antennary 
sugars and accumulates to a greater extent in the kidneys compared with 
tetra-antennary Epo, making for faster clearance from the circulation (Takeuchi et ai, 
1989). The faster rate of clearance is not observed in rats whose kidneys have been 
removed (Misaizu et ai, 1995). The presence ofbi-antennary sugars on prolactin 
makes for a swifter clearance by the kidneys, whereas if there are no sugars it is 
cleared more slowly by the liver (Hoffmann et ai, 1993). This would imply that a 
smaller size due to bi-antennary sugars cannot be the sole reason for the clearance of 
bi-antennary glycosylated proteins by the kidneys as deglycosylated protein is smaller. 
This suggests that the kidney has a role in clearing Epo containing incomplete 
carbohydrate branching. 
1.12.3. Receptor-mediated clearance 
Studies of Epo clearance in sheep showed no difference before and after hepatectomy 
or nephrectomy, leading researchers to consider the possibility that receptor-mediated 
endocytosis is the most prevalent mechanism by which Epo is cleared (Widness et ai, 
1996). However, the glycosylation of the Epo used in this study was not characterised 
and if the Epo were well sialylated, a hepatectomy might not be expected to affect 
clearance. 
Support for receptor-mediated endocytosis is provided by the observation that Epo 
clearance is reduced following bone marrow ablation by busulfan (Chapel et ai, 2001), 
suggesting that Epo is cleared mainly by Epo receptor-displaying erythroid 
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progenitors within the bone marrow. In a contradictory study (Piroso et ai, 1991), the 
half-life of Epo was unaffected by suppression or stimulation of bone marrow. 
Studies of asialo-transferrin have revealed some interesting, if not completely 
resolved, results (Regoeczi et ai, 1980). The glycoprotein transferrin exists as two 
main isoforms that vary in terms of their sugar branching. It either possesses two 
bi-antennary glycans or one bi-antennary and one tri-antennary glycan. The 2x 
bi-antennary form has lower affinity for the liver lectin but is cleared earlier in rabbits. 
The authors found that it is cleared in the bone marrow and that the process is 
galactose-specific. Initially the 1 x bi-antennary 1 x tri-antennary is cleared at a faster 
rate but then the 2x bi-antennary overtakes and is depleted sooner, indicating an 
additional site of catabolism. Leucocytes have a preference for bi-antennary glycans 
whereas the liver has preference for tetra-antennary (Bezouska et ai, 1985). It is not 
simply the case that the removal of sugars may make it easier to bind its specific 
receptor as rabbit asialo-transferrin with just one bi-antennary type glycosylation site 
binds neither liver nor bone marrow. 
1.12.4. Additional roles of sugars 
Glycosylation plays a number of protective roles in addition to determining the rate of 
clearance by the liver and kidneys: it facilitates protein secretion, aids protein folding, 
reduces susceptibility to thermal inactivation (Tsuda et ai, 1990) and confers 
protection against degradation by proteases. Asialo-epo has been reported as being 
more sensitive to heat denaturation and trypsin action (Goldwasser et ai, 1974;Briggs 
et ai, 1974) whereas Carter et al (2004) observed that deglycosylated 
granulocyte-colony stimulating factor was rendered biologically inactive following 
incubation in serum, presumably owing to the action of pro teases. Lactoferrin was 
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also reported as exhibiting the same property when incubated with trypsin (van Berkel 
et aI, 1995;van Veen et aI, 2004). By contrast, the glycosylated fonns of these 
cytokines are protected from such degradation. Sugars can also potentially influence 
the binding affinity of a ligand for its receptor and activation of intracellular signal 
transduction (although Epo glycosylation does not affect the latter). 
1.13. Structure of the ASGP-R 
The role the liver's galactose-binding receptor plays in clearing asialoglycoproteins is 
one of the most widely studied clearance mechanisms. The receptor itself is very well 
characterised and was used in expression studies described in Chapter 4. The 
ASGP-R is predominantly expressed on the sinusoidal surface of the parenchymal 
cells of the liver (Wall & Hubbard, 1981). It is an oligomer consisting of two 
subunits, HI and H2, coded for by two different but highly homologous genes, sharing 
55% sequence identity (Bischoff & Lodish, 1987;Bischoff et aI, 1988;Spiess & 
Lodish, 1985). The mature and fully glycosylated fonns of the HI and H2 subunits 
are -46 and -50 kDa respectively (Bischoff & Lodish, 1987;Baenziger & Maynard, 
1980). The ASGP-R is a single-spanning membrane protein with an extracellular 
calcium-dependent galactoselN-acetylgalactosamine-binding domain and therefore 
belongs to the Ca2+ -dependent (C-type) family of animallectins 
(carbohydrate-binding proteins). It is a type II membrane receptor, characterised by a 
cytosolic amino-tenninal domain (-40 amino acids), a single-spanning 
transmembrane domain (-20 amino acids), a stalk segment (-80 amino acids), and an 
extracellular carboxy-tenninal carbohydrate recognition domain (-150 amino acids) 
(Bider et aI, 1996). This is in contrast to a Type I receptor, such as the Epo receptor, 
which has the reverse orientation in the membrane (see Fig. 1.13.1. for a schematic 
diagram of the ASGP-R). 
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Asialoglycoprotein binds to the ASGP-R on the surface of the cell at neutral pH. The 
asialoglycoprotein ligand becomes dissociated in the low-pH environment of the 
endosome, followed by degradation in the lysosome while the receptor is recycled 
back to the cell membrane (Geffen et aI, 1989). The HI subunit can be stably 
expressed by itself whereas in the absence of HI most ofH2 is unstable and is 
degraded in the endoplasmic reticulum (ER) (Shia & Lodish, 1989;Amara et aI, 
1989). Additional evidence for this was provided by Tozawa et al (2001), who 
reported that H2 was undetectable in a knock-out mouse lacking the gene for the HI 
analogue. HI is still expressed ifH2 has been knoc.ked out but in reduced amounts 
(lshibashi et aI, 1994). 
For high binding affinity, both subunits need to be expressed. HI expressed on its 
own forms homo-oligomers that can bind asialo-alpha-l-acid glycoprotein, but with 
low affinity and only if overexpressed (Bider et aI, 1995). It can be speculated that 
the presence ofH2 enhances the spatial organisation of the carbohydrate recognition 
domains, thereby facilitating optimised binding affinity. 
1.t4. Ht to H2 binding ratios 
The HI and H2 subunits are reported to oligomerise and indeed, their stalk regions 
contain heptad repeats that are characteristic of proteins which oligomerise via 
a-helical coiled coils (Bider et aI, 1996). Evidence differs, however, regarding the 
HI :H2 binding ratios with Lederkremer and Lodish (1991) putting it at 3:1 or 4:1, 
whereas according to Bider et al (1996) it is 2:2 if the subunits are at the concentration 
found in HepG2 cells (a human liver cell line). 
Fig. 1.13.1. (Facing page) Schematic representation of the two 
subunits of the asialoglycoprotein receptor (ASGP-R). Note the 
type IT receptor orientation, in which the N-terrnini are positioned 
inside the cell (derived from information in the ExPASy (Expert 
Protein Analysis System) proteornics server of the Swiss Institute 
of Bioinformatics). 
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In order to investigate this further, Rice et al (1990) designed a triantennary 
glycopeptide that had a photolyzable reagent attached to each of its three tenninal 
galactose residues. After binding to rat hepatocytes and subsequent photolysis, it was 
found that two of the galactose residues bound to the rat HI analogue and the third 
galactose bound to the rat H2 analogue. The authors concluded that the HI and H2 
subunits interact in such a way as to create a "specific geometric arrangement" of the 
carbohydrate recognition domains. 
1.15. ASGP-R binding properties 
The specificity and high-affinity binding characteristics of the ASGP-R are dependent 
on multiple low-affinity binding domains (Bider etal, 1995). Oligosaccharides bind 
to the ASGP-R with dissociation constants varying by several orders of magnitude 
whilst the number ofligand tenninal galactose residues increases only a few-fold - a 
phenomenon tenned the "cluster effect" (Lee et ai, 1983). Desialylated 
tetra-antennary oligosaccharides bind the ASGP-R with greater affinity than do 
desialylated tri-antennary oligosaccharides, which in turn bind the receptor with even 
greater affinity than bi-antennary and mono-antennary chains. Lee et al (1983) 
measured the inhibition of binding of a triantennary glycopeptide to rabbit hepatocytes 
by various ligands. The 50% inhibitory concentrations (ICso) oftetra-, tri-, bi-, and 
mono-antennary synthetic oligosaccharides were approximately 1 x 10-9, 5 x 10-9, 
1 x 10-6 and 1 x 10-3 M respectively. The inhibitory power of a tetra-antennary ligand 
was 1 x 106 times greater than that of a mono-antennary ligand while the total 
galactose concentration was only four times greater. 
The cluster effect is observed only with hepatocytes, not with the purified isolated 
receptor, indicating that the receptor is organized differently when in the membrane 
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(ConnoIIy et aI, 1982;Baenziger & Fiete, 1980). In contrast to the membrane-bound 
receptor, the isolated human receptor is inhibited by asialo-triantennary and 
asialo-biantennary oIigosaccharides with ICso values of 1.3 x 10-6 and 3.9 x 10-s M 
respectively (Baenziger & Maynard, 1980). 
The above-mentioned Rice et al paper (1990) supports this hypothetical difference in 
spatial arrangements in the membrane because, if soluble rat liver receptor is used, the 
glycopeptide does not bind to H2. In conclusion, HI and H2need to associate to have 
full binding properties. 
The binding of a galactose residue to an individual receptor subunit is of low affinity 
and therefore high affinity binding is the result of at least three galactose residues 
interacting simultaneously with three subunits, forming an oligomeric complex. If it 
is assumed that the ASGP-R binds three galactose residues of an oligosaccharide then 
this would explain why the difference in inhibitory concentration between tetra-
antennary and tri-antennary is not as great as that between all the other species of 
oligosaccharide. 
In addition to the galactoselN-acetylgalactosamine-binding ASGP-R, there is a range 
of animallectins with different specificities (Drickamer & Taylor, 1993). All C-type 
lectins have a similar structure but can vary in their sugar binding characteristics (e.g. 
mannosel glucoselN -acetylglucosamine/fucose versus 
galactoselN-acetylgalactosamine); these being the result of just a few changes in 
amino acid sequence (lobst & Drickamer, 1994). 
Many studies have been carried out with the aim of exploiting the ASGP-R and the 
fact that it is, for the most part, expressed exclusively by the liver. Drugs and genes 
can be specifically targeted to the liver by conjugation with high affinity ligands for 
the ASGP-R (see (Wu et aI, 2002) for review). This research again confirmed that the 
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two most important factors that govern binding to the ASGP-R are the branching 
pattern of the oligosaccharide and the distance between its terminal galactose residues. 
The ASGP-R is also suspected of being used as the entry site for Hepatitis A virus 
(Dotzauer et aI, 2000), Hepatitis B virus (Treichel et aI, 1997), Hepatitis C virus 
(Saunier et aI, 2003) and the Marburg virus (Becker et aI, 1995). The Marburg virus 
has terminal galactose residues on its surface glycoproteins and it is therefore 
suggested that it uses the ASGP-R as a point of entry into hepatocytes. Asialo-fetuin 
inhibits the attachment. Hepatitis B virus is also inhibited by asialo-fetuin (Treichel et 
aI, 1994). 
1.16. Objectives 
Replacement ofthe Epo in vivo assays with an in vitro method would result in a 
reduction in the number of animals sacrificed and a reduction in costs incurred (testing 
one Epo sample against a reference standard in the normocythaemic assay costing 
approximately £1510), and could potentially improve the level of precision. Current 
in vitro assays for Epo are all but unaffected by their level of glycosylation, which is 
why correlation is not obtained between bioactivities obtained by in vivo methods and 
by immuno- or cell-based assays (Yamaguchi et aI, 1991). One aim of this thesis was 
to test whether it was feasible to manipulate in vitro assays in such a way that 
rendered them sensitive to the factors that affect in vivo assays. To what extent would 
correlation be achieved between potencies obtained by such assays and by the mouse 
bioassays? The most important property of such an assay would be the ability to 
differentiate between sialylated Epo and desialylated Epo. Three approaches to this 
problem were pursued although all shared the common rationale of incorporating a 
mechanism for mimicking the action of the liver. 
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An additional objective was to determine how effective such a strategy might be in 
comparison with other currently available biological and physico-chemical techniques 
when used on three different Epo sample sets, each one presenting a different 
pharmaceutical situation - a neuraminidase-treated sample set, a set whose samples 
differed in terms of culture conditions and purification procedures, and a single batch 
of pharmaceutical-grade Epo separated into fractions by anion-exchange 
chromatography. An assessment could then be made of the potential for reducing the 
requirement for animal testing. 
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Chapter 2. Materials and Methods 
Water was either MilliQ grade (equivalent to double distilled H20) or, for molecular 
biology applications, "sterile", i.e. purified using the Bamstead Thermolyne 
NANOpure Diamond Life Science UV/UF ultrapure system and autocIaved 
(nucIease-, DNA- and pyrogen-free). 
All reagents were obtained from Sigma unless otherwise stated. 
2.1. Molecular Biology Techniques· 
2.1.1. Messenger RNA purification 
Messenger RNA (mRNA) was purified from mammalian cells using the QuickPrep 
mRNA Purification Kit (Amersham Biosciences, UK), following the manufacturer's 
protocol. Briefly, after guanidinium thiocyanate inactivation of endogenous RNases 
in the cell extract, mRNA was isolated by exploiting the fact that its 3'-terminal 
poly(A)tracts bind to oligo(dT)-cellulose beads. A series of high- and low- salt buffer 
washes was then followed by a final elution step. 
Total RNA was isolated from plant seeds using the plant RNeasy Plant mini-kit 
(Qiagen). The seeds were homogenised under liquid nitrogen in a pestle and mortar 
and RNA was extracted according to the manufacturer's instructions. The kit involves 
a guanidine-isothiocyanate lysis step, followed by passage through a QIAshredder 
column which homogenises and filters viscous plant lysates, and finally 
silica-gel-membrane purification. 
2.1.2. First-strand cDNA synthesis 
First-strand cDNA was produced from mRNA using reverse transcriptase reagents 
provided by Amersham Biosciences. 
A typical reaction: 
Reagent Volume (J.tl) 
Bulk First-Strand Reaction Mix 11 
(containing Murine Reverse 
Transcriptase [5 units/J.tIJ, Tris buffer at 
pH 8.3, KCI, MgCh, BSA, dNTPs) 
200 mM dithiothreitol (DTT) 1 
Primers (pd[NJ6) 1 
RNA template (prepared as described in 20 .. 
Section 2.1.1.) 
Prior to adding all reagents to a sterile thin-walled 500 J.tl PCR tube, the RNA was 
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heated at 65°C for 10 minutes, then chilled on ice in order to remove RNA secondary 
structure. Following brief mixing and centrifugation the solution was incubated at 
37°C for one hour. 
The resulting cDNA product was stored at -40°C. 
2.1.3. Polymerase chain reaction 
2.1.3.1. Design of primers 
Primers were designed according to the relevant sequences in the GenEMBL database. 
The 10 bases preceding the start codon (the Kozak sequence) were amplified in 
addition to the open reading frames because the presence of this sequence has been 
shown to optimise translation (Kozak, 1987). In some cases primers also contained a 
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restriction site to facilitate cloning, plus a few extra bases should the ends be degraded 
during the PCR process. Where appropriate, the 3' primer contained a stop codon. 
The primers used in plasmid construction were synthesised by Eurogentec 
(Southampton, UK) or VH BIO (Newcastle, UK). 
2.1.3.2. peR mix 
The Expand High Fidelity PCR System (Roche, UK) was the principal method used 
for PCR-amplification of the DNA. The kit contains an enzyme mix combining the 
high fidelity of the proof-reading Tgo DNA polymerase and the high yield of Taq 
DNA polymerase. 
For a 50 pi typical reaction: 
Reagent Volume (J.1I) Final concentration 
10 x Expand High Fidelity buffer 5 1 x 
with 15 mM MgCh 
dNTPs (1.25 mM each) 8 0.2 mM 
Forward primer (20 J.lM) 5 2J.lM 
Reverse primer (20 J.lM) 5 2J.lM 
Sterile water 25 -
Expand High Fidelity enzyme mix 1 0.07 U/J.lI 
(3.5 U/J.ll) 
Template (1 st strand cDNA or 1 
-
plasmid diluted 111000) 
All reagents except the template were placed in a sterile thin-walled 500 J.lI PCR tube 
(Scientific Speciaities, Inc, USA) and heated to 94°C in the Techne Genius PCR 
machine/thermal cycler (Techne Ltd, Cambridge, UK) for 1 minute to allow them to 
heat up. The template was then added and the PCR cycle initiated. 
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A typical peR cycle: 
Step Temperature Time N umber of cycles 
Initial denaturation 94°C 1 min 1 
Denaturation 94°C 30 secs 30 
Annealing 55°C 30 secs 
Elongation 72°C 1 minperkbp 
On completion of the cycles the temperature was held at 72°C for 10 minutes, during 
which time an increased number of 3' -A overhangs were added on to aid in 
TA-cloning. 
Piu DNA polymerase (Stratagene, UK) was occasionally used in PCR-amplification 
because, although it is less reliable in terms of yield, it has the potential for greater 
accuracy. Since Piu DNA polymerase produces blunt-ended PCR products, the latter 
have to undergo an A-tailing procedure. 
The A-tailing reaction (l0 pl): 
Reagent Amount 
PCR fragment (purified as described in 6.4 JlI 
Section 2.1.11. in order to remove 
proof-reading enzyme) 
10 x Expand High Fidelity buffer with 1 JlI 
15 mM MgCh 
dATP (1.25 mM) 1.6 JlI 
Taq DNA polymerase (5 unitslJlI, 1 
Promega, UK) 
The reaction was then incubated at 70°C for 30 minutes. 
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2.1.4. TA cloning 
PCR products (from Section 2.1.3.) were cloned into the pGEM-T "T vector" 
(Promega, UK) using T4 DNA ligase and transformed into Escherichia coli (E. coli) 
JM109 cells (see Section 2.1.5. below). See Fig. 2.1.1. for a diagram ofpGEM-T. 
pGEM-T ligation reaction mix (10 pI): 
Reagent Volume 
2x Rapid Ligation Buffer (containing 5 /-LI 
60 mM Tris-HCI [pH 7.8], 20 mM 
MgCI2, 20 mM DTT, 2 mM ATP and 
10% polyethylene glycol) 
pGEM-T Vector (50 ng) 1 /-Ll .. 
PCR product from Section 2.1.3. 2 /-Ll 
T4 DNA Ligase (3 units//-Ll) 1 /-Ll 
Sterile water 1 /-Ll 
2.1.5. Bacterial transformation 
Competent cells 
Transformations were carried out using E. coli JM 109 (Promega, UK) and SCS 11 0 
(Stratagene, UK) competent cells. 
Media 
See Appendix for Luria-Bertani (LB) medium, LBamp and LBamp/IPTG/X-Gal plate 
reCIpes. 
Transformation of bacteria 
E. coli JMI 09 competent bacteria (Promega, UK) initially underwent gentle thawing 
on ice. For transformation, 2 /-Ll ofligation product was added to 100 /-LI of the 
pGEM-T 
3000 bp 
NcoI 
SacII 
T 
T 
Spel 
NotI 
BstZl 
PstI 
SaIl 
NdeI 
SacI 
BstXI. 
Nsil 
Sp6 
Fig. 2.1.1. Diagram of the pGEM-T vector (Promega). Note the 
overhanging Ts used in TA cloning (Section 2.1.6.), the lacZ gene 
used in blue/white screening, and the multiple cloning site (useful for 
fusion protein construction (Chapter 5». 
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competent cells cells in a 14 ml Falcon tube (BD Biosciences Catalog #352059) and 
chilled on ice for 30 minutes. The cells were then heat-shocked at 42°C for 
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45 seconds and placed on ice for a further two minutes. Sterile LB medium (500 Ill) 
was added to the cells, which were incubated at 37°C for 1 hour with shaking at 
200 rpm. Then, 100 III of the transformation reaction was added to an LBamp plate or 
an LBamp plates with IPTG/X-Gal and incubated overnight at 37°C. 
E. coli SCS 110 bacteria, which are deficient in two methylases (Dam and Dcm) and 
therefore incapable of methylating plasmid DNA, were used when the restriction 
enzyme ClaI, the site of which is methylation-sensitive when preceded by a G or 
proceeded by a C base, was needed for subsequent subc10ning steps. This strain was 
transformed using the above method, but with the' following two modifications: 
to improve transformation efficiency, SCS 11 0 (100 Ill) were incubated for ten minutes 
with 1.7 III ofJ3-mercaptoethanol prior to addition of the DNA; and LB medium was 
replaced by SOC medium (see Appendix for medium recipe). 
2.1.6. Blue/white screening 
The pGEM-T vector (first referred to in Section 2.1.4.) allows blue/white screening of 
recombinants as it contains the Lac Z gene, which codes for J3-galactosidase. This 
enzyme hydrolyses 5-Bromo-4-chloro-3-indolyl-J3-D-galactopyranoside (X-Gal) to 
produce a blue colony. Isopropyl J3-D-thiogalactoside (IPTG) acts as an inducer of the 
gene. Introduction of a coding sequence into the Lac Z gene disrupts its expression, 
resulting in the production of white recombinant colonies. Cultures of cells picked 
from the white colonies were grown up and their plasmid DNA extracted (see 
description in Section 2.1.7. below). 
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2.1.7. Preparation of DNA from transformed E. coli 
A single colony containing plasmid DNA was touched with a pipette tip which was 
then dipped into a Falcon polypropylene round-bottom tube (BD Biosciences Catalog 
#352059) containing 2 ml LBamp. The cultures were incubated overnight at 37°C 
with shaking at 225 rpm, whereupon 1.5 ml of the culture was transferred to a 
microfuge tube and the contents centrifuged at 13,000 rpm for 5 minutes to pellet 
cells. The supernatant was aspirated and the pellet resuspended in 100 /-tl of solution 
PI (see Appendix for solution recipes) by vortexing. 
Solution P2 (200 /-tl) was added to the tube and the contents were mixed by inversion, 
before incubating at room temperature for 5 minutes. This solution causes lysis of 
cells and the separation of genomic DNA from plasmid DNA. 
Chilled solution P3 (150 /-tl) was added to neutralise the contents and mixed by 
inversion. 
The tube was left on ice for 5 minutes before centrifuging for 5 minutes at 13,000 rpm 
to pellet cellular debris. The supernatant was transferred to a new tube, an equal 
volume ofphenol:chloroform:isoamyl alcohol 25:24:1 mixture (Sigma, UK) was 
added and the tube was then vortexed. After centrifugation (at 13,000 rpm for 
5 minutes) the bottom organic layer was removed by pipetting and discarded. Twice 
the volume (0.8 ml) of 100% ethanol was added to the tube and the contents were 
mixed by inversion. After centrifugation (at 13,000 rpm for 10 minutes) the 
supernatant was aspirated leaving the DNA pellet. The pellet was washed in 80% 
ethanol to remove any salts left over from the buffer. The DNA was air-dried for 
10 minutes and resuspended in 50 /-11 RNAse-containing water (20 /-tg/ml) and stored 
at -40°C. The DNA was analysed for the presence of a DNA insert by digestion using 
the appropriate restriction endonuclease (Section 2.1.8.). 
Approximately 200 III of the remaining overnight culture was added to an equal 
volume of30% glycerol in LB and stored at -80°C. 
2.1.S. Restriction endonuclease digestion plasmid DNA 
Endonuclease reactions were performed using Amersham Biosciences, Promega or 
New England Biosciences (NEB) products. 
A typical restriction enzyme digestion was as/ollows (10 pI): 
Reagent Volume 
Plasmid 2 III 
IOx One-Phor-All (OPA) buffer I III 
(Amersham Biosciences, UK) or the 
appropriate IOx NEB buffer --
Restriction enzyme A (-5 units/ill) 0.25 III 
Restriction enzyme B (-5 units/ill) 0.25 III 
Sterile water 6.5 III 
The digests were incubated for two hours at the optimum temperature for enzyme 
action (usually 37°C). Then,2 1l16x DNA gel loading buffer was added to the 
digestion mixture and the DNA was resolved on a 1% agarose gel (1.5% when 
analysing fragments less than 500 bp) to confirm the digestion. 
2.1.9. Electrophoresis of DNA 
1 % agarose gels 
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A quantity (0.5 g) of electrophoresis-grade agarose (Amersham Biosciences, UK) was 
added to 50 ml of Ix TBE buffer (Sigma, UK), and the mixture heated in the 
microwave for about two minutes until the agarose had dissolved. The solution was 
cooled to about 50°C and 25 III of I mg/ml Ethidium Bromide (final concentration of 
0.5 Ilg/ml) was added. The mixture was poured into a gel tray and allowed to set. 
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Gel electrophoresis 
Electrophoresis was perfonned using a horizontal electrophoresis system (BDH, UK). 
Samples (10 JlI) were loaded onto the gel in an electrophoresis tank filled with 
Ix TBE running buffer and run against a 0.05-10 kb DNA ladder (Perfect DNA 
markers, Novagen, UK) at 8 V/cm for one hour. DNA was visualised under UV light 
using a transilluminator and the result recorded photographically. 
2.1.10. Nucleotide seguencing 
Clones with inserts were purified using the QIAquick PCR Purification Kit (Qiagen, 
UK) and the nucleotide sequence of the insert DNA was detennined by DBS 
Genomics at Durham University. The primers 5'~gtaatacgactcactataggcg-3' and 
5'-gctatttaggtgacactatag-3' were used for sequencing inserts within the pGEM-T 
vector, while primers 5' -cgactcactatagggagacc-3' and 5' -cgcttttgagagggagtactc-3' 
were used for sequencing inserts within the pIRESblast vector. Sequences were 
compared with the GenEMBL data bank entry using the Bestfit program from the 
GCG package (University of Wisconsin Genetics Computer Group sequence analysis 
software). 
2.1.11. Purification of DNA from agarose gels 
Clones verified as correct had their inserts removed by digestion with the appropriate 
restriction enzymes (Section 2.1.8.). The insert was separated from pGEM-T by 
agarose gel electrophoresis, gel extracted and finally ligated into the mammalian 
vector, pIRESblast (described below in Section 2.2.3.2.). 
A slice of gel containing the DNA fragment was excised using a sterile scalpel and the 
DNA extracted from the gel using a commercial kit (QIAquick Gel Extraction Kit, 
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Qiagen, UK) based on silica-gel membrane binding. The DNA was eluted in 30 III of 
sterile water. 
2.1.12. Dephosphorylation of plasmid DNA 
When DNA was prepared for ligation, the 5' ends of the parent plasmid were 
dephosphorylated in order to prevent religation. The 5' ends of the insert were left 
intact, so favouring their integration. Restriction digested plasmid DNA (10 Ill) was 
dephosphorylated by incubation with 3.75 units calf intestinal alkaline phosphatase 
(Amersham biosciences, UK) at 37°C for 1 hour and then heat-inactivated at 85°C for 
10 minutes. 
2.1.13. Ligation of DNA fragments into a plasmid 
Ligations were carried out in 10 III reaction volumes. 
A typicalligation reaction was as follows: 
Reagent Volume (Ill) 
Parent plasmid digested with appropriate 1 
restriction enzymes and 
phosphatase-treated (50 ng/1l1) 
Gel-extracted fragment (Section 2.1.11.) 3 
One-Phor-All (OPA) buffer (Amersham 1 
Biosciences, UK) 
Sterile H2O 3 
ATP(10mM) 1 
T4 DNA ligase (Promega, UK) diluted to 1 
an initial concentration of 0.5 UIlll 
The first four reagents were placed in a tube and heated to 65°C for 5 mmutes then 
cooled on ice in order to break the weak hydrogen bonds between compatible ends 
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and allow new ones to fonn between the plasmid and the insert. The final two 
reagents were then added and the tube left at 10°C overnight. 
Control reactions were also included in which insert DNA was replaced with sterile 
water. 
The next day, ligation reactions were transfonned into JM109 cells (Section 2.1.5.). 
2.1.14. Site-directed mutagenesis (SDM) 
Site-directed mutagenesis - a molecular biology technique which creates a mutation at 
a specified site within a plasmid DNA molecule - was carried out using the following 
approach: 
two oligonucleotide primers (of approximately 30 bp), each complementary to 
opposite strands of a plasmid containing the insert of interest, were designed which 
contained the desired mutation, and a typical reaction was set up in a thin-walled 
500 ~l PCR tube. 
Reagent Volume (~) 
Primer 1 (25 ngl~l) 5 
Primer 2(25 ngl~l) 5 
Sterile H2O 30 
PfuTurbo (2.5 U/~l, Stratagene) 1 
"' 
dNTP mix (1.25 mM) 8 
Template (5-50 ngl~l) 1 
The PCR tube was then placed in a Techne Genius thermal cycler (Techne Ltd, 
Cambridge, UK) set to run as follows: 
Segment Cycles Temperature Time 
1* 1 95°C 30 seconds 
2 12-18 95°C 30 seconds 
55°C 1 minute 
68°C 1 minute/kb of 
plasmid length 
*Plasmid template was added following this segment. 
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PfuTurbo is an extremely high fidelity DNA polymerase which permits the synthesis 
of DNA strands that anneal to form a plasmid. This plasmid is identical to the original 
except for the single desired mutation and the fact that the DNA is no longer 
methylated (plasmids are methylated by most strains of bacteria). The latter point was 
crucial to the next step, which involved incubating the reaction mixture with DpnI, a 
restriction enzyme that digests DNA at the relatively common GATC site but only if it 
is methylated. The majority of the original unmutated plasmid DNA was therefore 
cleaved whereas plasmids created by polymerase primer extension and containing the 
mutation were left intact and in a form capable of being transformed into JMl 09 
bacteria (Section 2.1.5.). 
This technique was used to make silent mutations in genes of interest in order to 
remove restriction enzyme-cleavable sites that were required for sub cloning steps. 
SDM progress was monitored by restriction digestion, the enzyme concerned being 
used to differentiate between the wild-type plasmid and successfully mutated DNA. 
See Fig. 2.1.2. for rui example of an EeaRI site having been removed by SDM and 
detected following EeaRI digestion by visualisation under UV light. 
bp 
3000 ~ 
1 2 3 4 5 6 7 
Fig. 2.1.2. Restriction endonuclease analysis of small scale preparation of 
plasmid DNA aimed at establishing whether mutation by SDM had been 
successful. 
Since, in this case, SDM was used to remove an internal EcoRI restriction 
site, digestion was performed with EcoRI restriction enzyme. 
The first six lanes contain putative clones 1 to 6, lane 7 the original 
unmutated plasmid. The conclusion was therefore that all clones had had 
their EcoRI sites successfully removed. 
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2.1.15. Endotoxin-free large-scale preparation of DNA 
When a vector construct had been created and confirmed by sequencing as being 
correct, a large-scale preparation was performed using the Endofree Plasmid Maxi Kit 
(Qiagen). This kit uses a modified alkaline lysis method (Bimboim & Doly, 1979;Ish-
Horowicz & Burke, 1981), followed by the binding of plasmid DNA to 
anion-exchange resin under low salt and pH conditions. All other RNA, proteins and 
low-molecular weight impurities are removed by a medium salt wash. Endotoxin (an 
inhibitor of transfection) is removed by filtration and incubation on ice with an 
endotoxin removal buffer. The latter prevents any endotoxin from binding to the 
resin. The plasmid DNA is eluted in a high salt buffer, concentrated and desalted by 
isopropanol precipitation, and dissolved in 0.5 mlofthe endotoxin-free buffer 
provided. 
2.1.16. Determination of DNA concentration and purity 
DNA was quantified by UV absorbance, assuming an O.D. at 260nm of 1.0 was equal 
to 50 Jlglml. Absorbance measurements were taken using a quartz cuvette (Scientific 
Supplies Co.) with a 1 cm path length in a Philips PU8720 UVNIS 
spectrophotometer. 
The A260lA280 nm ratio was taken as an index of DNA purity, i.e. the extent to 
which DNA was contaminated with protein. Only DNA with a ratio> 1.8 was used in 
transfections. 
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2.2. Cell culture technigues 
2.2.1. The Epo-dependent erythroleukaemic AS-E2 cell line 
The Epo-dependent erythroleukaemic AS-E2 cell line (Miyazaki et aI, 1997) was 
kindly donated by Drs Tomonaga and Imai (Nagasaki University, Nagasaki, Japan). 
2.2.2. Maintenance of cell lines 
2.2.2.1. Tissue culture reagents 
Cells were cultured under aseptic operating conditions and in sterile growth media. 
The media used in these studies provide the cells with optimum growth conditions for 
extracellular survival. 
Iscove's Modified Dulbecco's Medium (lMDM, Sigma, UK) was supplemented with 
Epo, foetal calf serum (FCS), glutamine and antibiotics. The FCS provides growth 
factors, while antibiotics minimise the risk of bacterial contamination. 
Medium used to culture AS-E2 cells, 200 ml: 
Reagent Volume (ml) Final concentration 
IMDM 154ml -
Epo (20,000 IU/ml) 20 Jll 2 IU/ml 
FCS 40ml 20% 
Penicillin (10,000 U/m!) 2ml 100 U/ml 
Streptomycin (10 mg/ml) 2ml 100 Jlg/ml 
Glutamine(200 mM) 2ml 2mM 
.. 
The cells were passaged every 3-4 days and seeded at an ImtIal densIty of 
5 X 104 cells/ml. 
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2.2.2.2. Maintenance and culture of cell lines 
Cell cultures were maintained in tissue culture incubators at 37°C in an atmosphere of 
5% CO2/95% air. The growth medium was replaced every 3-4 days. In the case of 
the AS-E2 cell line, cells were centrifuged, the supernatant poured off and the pellet 
resuspended in approximately 2 ml of fresh medium. A sample (20 JlI) was taken for 
cell counting, using a Neubauer haemocytometer. 
2.2.2.3. Storage and recovery of cells 
Cells were suspended in cryopreservant, full medium supplemented with 
dimethylsulphoxide (DMSO, Sigma, UK), at a concentration of 10% (v/v) and 
pipetted into 2 ml cryotubes. The tubes were placed in a polystyrene cell freezing box 
and left overnight in a -70°C freezer. The polystyrene acts as an insulator, slowing 
down the freezing process and preventing any extreme shock to the cells. Lastly, the 
cryotubes were transferred into liquid nitrogen (-196°C) for long-term storage. Cells 
were retrieved for culture by placing a cryotube into a water bath at 37°C to rapidly 
thaw the cells. In order to remove DMSO, the contents of the cryotube were added to 
10 ml of full medium and centrifuged at 300 g; the supernatant was then removed and 
the cell pellet resuspended in 12.5 ml of fresh full medium. This cell suspension was 
then added to a 25 ml flask and placed in the incubator. 
2.2.3. Transfections 
The ability of a range of transfection reagents to transfect the Epo-dependent cell line 
AS-E2 was screened using a luciferase-based reporter plasmid (pGL3, Promega) and 
assayed for luciferase activity (by Promega's Luciferase Assay System) in a Turner 
luminometer. GeneJuice transfection reagent (Novagen) consistently produced the 
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highest readings and so was selected for use during this study. GeneJuice consists of a 
non-toxic cellular protein and a small quantity of a novel polyamine. 
2.2.3:1. Method for transfecting AS-E2 cells 
AS-E2 cells were seeded at 1 x 105 cells/ml the day before transfection. On the day of 
transfection they were seeded at 0.2 x 106 cells/ml as 3 ml per well of 6-well plates 
(Falcon, BD Biosciences Catalog #353046). The cells of each well were then 
transfected with 200 JlI IMDM medium, 6 JlI Genejuice and 2 JlI plasmid DNA at a 
concentration of I Jlg/Jll. 
2.2.3.2. Vector used for obtaining stable transfections - pIRESblast 
To obtain stably transfected cells that overexpress the protein of interest, cells were 
transfected with the pIRESblast vector containing the relevant gene. 
The pIRESblast vector was created by excising the neomycin gene from pIRESneo as 
a XmaI/XhoI fragment and replacing it with a blasticidin resistance cassette, which 
was derived from pcDNA 6.2-DEST Gateway (lnvitrogen). 
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The blasticidin-resistance cassette was peR-amplified with primers incorporating the 
appropriate restriction ends: 
Name Function Sequence Restriction Site 
BlastXmaI-5' Forward primer for 5' -gacgatcccgggc -XmaI underlined 
amplifying the blasticidin gacaaggtgaggaact 
resistance gene and the aacc-3' 
SV40 early 
polyadenylation signal 
BlastXhoI-3' Reverse primer for 5' -gacgatctcgagc -XhoI underlined 
amplifying the blasticidin agacatgataagatac 
resistance gene and the attgatgagt-3 ' 
SV40 early 
polyadenylation signal 
The pIRESblast vector contains an Internal Ribosome Entry Site (IRES) sequence 
which permits the translation of two open reading frames from one mRNA (see 
Fig. 2.2.1. for a map of the vector)." 
2.2.3.3. Blasticidin selection 
Two days after transfection, and allowing time for expression of the 
blasticidin-resistance gene, the cells were reseeded into flasks at a concentration of 
5 x 104 cells/ml with blasticidin (10 Ilg/ml). For approximately two weeks the cells 
were passaged as normal, every 3-4 days, with reseeding at 5 x 104 cells/ml but 
continuing with blasticidin pressure. During this period, however, blasticidin-induced 
cell-death meant a reduction in cell numbers, the latter falling to 500,000 cells (in 
10 ml of medium). Cells then began to grow back and soon reverted to their original 
doubling time of approximately two days. Similarly treated, but untransfected, cells 
did not survive beyond day 7. 
plRESblast 
4851 bp 
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MCS 
Clal- 909 
EcoRV -912 
Notl- 919 
EcoRl- 934 
BamHI- 943 
BstXJ - 963 
Fig. 2.2.1. Map of pIRESblast vector used in mammalian transfections. The 
DNA sequence is inserted into the multiple cloning site (MCS). The vector 
contains the blasticidin-selectable marker (Blast R), a cytomegalovirus 
(CMV) enhancer-promoter for high-level expression and an ampicillin 
resistance gene that allows selection and maintenance in E. coli. 
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In some cases cells did not grow back and so, when the cell number reached -50,000, 
they were added (as a 1 ml suspension) to 8 ml ofClonacell (StemCell Technologies, 
UK) and 1 ml of IMDM containing 10x glutamine, 10x antibiotics, 10x Epo and 
10x blasticidin to give final 1 x concentrations. Clonacell is a methylcellulose-based 
semi-solid medium which allows suspension cells to grow as discrete colonies that can 
then be individually picked by pipette. The above mixture was syringed into 10 ml 
cell culture plates and placed in a box with a loose-fitting lid containing a lidless cell 
culture plate filled with sterile water to maintain humidity. The box was incubated for 
approximately two weeks, by which point individual cell colonies could be seen, 
picked in 20 IJ.I volumes and grown up in 96-well plates (200 IJ.I blasticidin-
containing full medium per well). 
2.2.3.4. peR-amplification from cell extract 
PCR-amplification was used to determine whether transfected blasticidin-resistant cell 
lines contained recombinant DNA. 
Mammalian cells were centrifuged, washed once with PBS (see Appendix), 
re-centrifuged and suspended in K buffer (0.5% Tween 20 [v/v], 100 IJ.glml proteinase 
K, from Sigma, in 1 x Expand High Fidelity buffer) at a final concentration of 5000 
cells/lJ.l. The suspension was then heated at 56°C for 45 minutes. The resulting cell 
extract (2 1J.1) was used in a 50 IJ.I volume PCR reaction. 
PCR-amplification of human f3-actin (GenEMBL Accession No. X00351) with 
actin-5' (TGACGGGGTCACCCACACTGTGCCCATCTA) and actin-3' 
(CTAGAAGCATTTGCGGTGGACGATGGAGGG) primers was used as a positive 
control. 
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2.2.4. AS-E2 Epo hioassays 
Epo-induced proliferation in AS-E2 cells was measured using alamarBlue (Serotec 
Ltd, UK). Before commitment to bioassay the AS-E2 cells were washed three times 
in IMDM and maintained as stock cultures for 72 hrs in Epo-free IMDM containing 
5% FCS. The AS-E2 cells were suspended in IMDM at a density of 
2.5 x 106 cells/ml. The cell suspension (100 /-lllwell) was transferred to a 96-well 
microtitre plate (Falcon, Catalogue No. 353072). Epo intended for testing was diluted 
in assay medium consisting ofIMDM, 200 units/ml penicillin and 200 /-lglml 
streptomycin and then added to the wells as an additional 100 /-ll. Epo-free assay 
medium was used in negative control wells. Concentrations were expressed as final 
concentrations in the wells (nM). The assays were done in triplicate, using serial 
twofold dilutions. Only the inner 60 wells were used, owing to the outer wells' greater 
susceptibility to so-called "edge effects", widely thought to be caused by the outer 
wells being exposed to more rapid variations in temperature and pH (Meager, 2002). 
The cells were incubated for one week under the conditions described above. Their 
reducing activity was assayed by adding 20 /-ll of alamarBlue solution, followed by a 
further 24-hour incubation period. The bioassay responses of the 96 wells were 
quantified with a SpectraMax 340PC or an E-max precision microplate reader (both 
from Molecular Devices Corporation, Sunnyvale, California, US) measuring optical 
densities at 570 and 600 nm. The values were calculated using SOFTmax (Molecular 
Devices Corporation) software. 
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2.2.4.1. Statistical analysis 
The results were expressed as mean and standard error of the mean (s.e.m). Median 
effective concentration (ECso) values (in other words the concentration required to 
induce a 50% effect) were calculated by non-linear regression and, using GraphPad 
Prism for Windows, version 4.00 (GraphPad Software, San Diego, California, USA), 
were assigned 95% confidence intervals (probability (P) values less than 0.05 were 
regarded as statistically significant). Comparisons between sample dose-response 
curves were based on comparison of the estimated ECso values. For added rigour, 
tight clusters of results were also analysed, using either the in-house WRANL 
program featuring iterative weighted regression analysis oflogistically transformed 
responses on log dose (Gaines & Tydeman, 1982) or RANDOM which analyses only 
the steepest part of the graph. COMPOT was a program used to calculate combined 
estimate of potencies. Pearson correlations between results were performed using 
Minitab. R values greater than 0.7 were considered as positively correlated and R 
values lower than -0.7 were considered as negatively correlated, these being 
commonly used thresholds for strong statistical similarity. 
2.3. Protein Analysis 
2.3.1. Preparation of celllysates for Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) analysis 
Cells from 50 ml of culture were centrifuged and resuspended in lysis buffer (-100 /-ll 
- see Appendix for buffer recipe). 
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2.3.2. Measurement of protein content and preparation of samples for 
electrophoresis 
Total protein was detennined using the bicinchoninic acid (BCA) assay (Pierce, 
Cheshire, UK), which is based on measuring Cu + ion concentration (Smith et ai, 
1985). Samples were mixed with 6x SDS loading buffer (see Appendix) in the ratio 
5:1, incubated for 5 min at 95°C and resolved by SDS-PAGE (Section 2.3.3.). 
2.3.3. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (adapted from 
Laemmli,1970) 
Recipe/or the preparation o/SDS-PAGE gels: 
Reagents Separating gel 11 % Stacking gel 5% 
30% (w/v) Acrylamide: 4.5 ml 1.0ml 
0.8% (w/v) Bis-Acrylamide 
(National Diagnostics, UK) 
Tris-HCI pH 8.8 (1.85 M) 2.8ml -
Tris-HCI pH6.8 (1.25 M) - 0.6ml 
MilliQ water 5.0ml 4.3 ml 
10% SDS 140 JlI 60 Jll 
N,N,N',N'- 20 JlI 10 JlI 
Tetramethylethylenediamine 
(TEMED) 
10% ammonium 85 JlI 30 JlI 
persulphate 
The electrophoresIs apparatus was set up III accordance wIth the manufacturer's 
specifications (Mini-Protean II, Bio-Rad, UK). SDS running buffer (800 ml) was 
added to the tank (see Appendix for recipe). 
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Protein samples (20 Ill) were loaded against 10 III of protein ladder (BenchMark 
Pre-Stained Protein Ladder, Invitrogen, UK) and the samples run at 25 mA per gel for 
1.5 hours. 
2.3.4. Protein transfer 
Before transfer, a polyvinylidene fluoride (PVDF) membrane (Immobilon-P, 
Millipore, UK) was soaked in 100% methanol for 1 minute, rinsed with water and 
immersed in blot transfer buffer (see Appendix for recipe). 
The transfer sandwich was set up in the following order: the anode plate, four pieces 
of blotting paper cut to the size of the SDS-PAGE gel, the PVDF membrane, the 
SDS-PAGE gel, four more pieces of blotting paper, and finally the cathode plate. The 
current was set at 200 mA for 2 hours adapted from (adapted from Towbin et ai, 
1979). 
2.3.5. Western blotting 
Following transfer, membranes were blocked with 5% (w/v) milk powder/O.l % (v/v) 
Tween-20 in phosphate-buffered saline (PBS-milk) for 1 hour at room temperature 
with gentle agitation (recipe for PBS same as that used in Section 2.2.3.4). 
Membranes were incubated overnight at 4°C with an antibody (111000 dilution in 
PBS-milk) directed against the protein of interest. After antibody binding, membranes 
were further washed in PBS containing 0.1 % Tween-20 (PBS-Tween) for 
3 x 30 minutes with gentle agitation. Membranes were then incubated for 1 hour at 
room temperature with a secondary antibody (111000 dilution PBS-milk) that binds 
specifically to the bound primary antibody. Membranes were washed for 
3 x 30 minutes in PBS-Tween with gentle agitation. The secondary antibody is 
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conjugated to alkaline phosphatase. Specific protein bands can then be detected using 
the colorimetric alkaline phosphatase substrate 5-bromo-4-chloro-3 indolyl 
phosphate/nitro blue tetrazolium (BCIPINBT, Sigma, UK). 
2.3.6. Isoelectric focusing 
Isoelectric focusing (IEF) was performed by polyacrylamide slab gel electrophoresis 
on a Bio-Rad Protean 2 16 cm slab cell. 
Recipe/or the preparation 0/ an IEF gels: 
Reagent Volume (to make one gel) Final 
concentration 
72.5% (w/v) Acrylamide: 7ml 10.0% (w/v) 
2.5% (w/v) Bis-Acrylamide Acrylamide; 
.. 
(Bio-Rad, UK) 0.34% (w/v) 
Bis-
Acrylamide 
Sucrose (60% [w/v], 12.5 ml 14.8% (w/v) 
Sigma, UK) 
MilliQ water 28ml -
For pH 2.5-9.0 For pH 2.5-7.0 
Ampholines pH 3-10 (all 0.6ml -
ampholines from 
Sigma, UK) 2.5% 
Ampholines pH 2.5-5 0.22 ml 0.625 
Ampholines pH 5-7 0.22 ml 0.625 
Ampholines pH 7-9 0.22 ml -
Riboflavin (0.0004% [w/v], 2ml 0.000016% 
Sigma, UK) 
N,N,N',N'- 14 ~l 0.00028% 
Tetramethylethylenediamine 
(TEMED, Bio-Rad, UK) 
The anode buffer and cathode buffer consisted of 10 mM orthophosphoric acid and 
20 mM sodium hydroxide respectively. 
Sucrose was added to the Epo samples to reach a final concentration of 20% and 
10 !J.g loaded per well. Isoelectric focusing markers from Serva (pH 3-10) and from 
Amersham Biosciences (pH 2.5-6.5) were used to enable determination of the 
isoelectric point (pI) of bands. Gels were run overnight at a constant 340 V and, the 
following morning, either silver stained or transferred to membrane. 
2.3.7. Silver staining 
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Incubations were carried out on an orbital shaker. Solutions were drained off between 
each step. The proteins in the gel from Section 2.3.6. were first precipitated by 
incubation in a 10% (w/v in MilliQ water) solution of trichloroacetic acid. Solution A 
(200 ml, see appendix for recipe) was added to the gel for five minutes, drained off 
and the remaining 250 ml was then added to the gel for two hours to fix the gel. Four 
changes of MilliQ water (2 x 200 ml at 60°C and 2 x 200 ml at room temperature) 
were then added for 15 minutes at a time to wash out the fixative. A 32 !J.M solution 
of the reducing agent dithiothreitol (developer) was added for 30 minutes. Silver 
nitrate solution (0.1 % w/v in MilliQ water) was then added for 30 minutes. Solution 
B (120 ml, see Appendix for recipe) was added until the liquid started to turn yellow, 
drained, and another 120 ml of Solution B added for 30 seconds, drained, and the 
remaining 260 ml of Solution B added and shaken until the staining of the bands 
developed. The staining process was terminated by the addition of citric acid solution 
(6.05 gin 12.5 ml MilliQ water). After 15 minutes, the gel was then washed several 
times with MilliQ water. 
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2.3.8. Protein transfer (specific to IEF gels) 
Gels were transferred onto a PVDF membrane (Immobilon-P, MiIIipore, UK) in 0.7% 
acetic acid blotting solution for 3 hours at a constant current of 200 mA with the 
gel/membrane assembled in reverse order so that the membrane was on the cathode 
side of the gel. This protocol is recommended for the transfer of proteins with a high 
pH. The membrane was then processed as in Section 2.3.5. Once colour had been 
developed using BCIPINBT, the blot was read by densitometer as described in 
Section 2.3.9. below. 
2.3.9. Densitometric analysis 
Gels and blots were scanned by densitometer (Molecular Dynamics Personal 
Densitometer SI). Densitometric analysis of the bands was performed using 
ImageQuant software (Molecular Dynamics ImageQuant, Sunnyvale, California, 
USA). The amount of each Epo isoform was expressed as a percentage of the total 
staining intensity of all bands. The mean pI value of a sample was calculated using 
the following equation: 
Mean pI value = I (PI; {)£; ) 
where pIi is the pI of the ith band and Xi is the amount of the ith band (:Exi=100%). 
2.3.10. Desialylation ofEpo 
A range of desialylated Epo samples was produced that could be tested during the 
course of this project. Erythropoietin was dissolved in buffer A (150 mM NaCl, 
50 mM sodium acetate, 1 mM CaCh, pH to 5.5 with HCl) to give a final concentration 
of 300 /-lglmI. Neuraminidase conjugated to agarose gel (314 /-ll of a 1: 1 mixture of 
gellbuffer A, Calbiochem) was added to 6 ml of the above Epo solution, then mixed 
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by slow vertical rotation (12 rpm) at 37°C. Equal volume aliquots (570 Jll) were 
removed at t=O, 5, 10, 20, 40, 80, 160, 480, 960 and 1800 min, centrifuged to remove 
the neuraminidase-agarose and stored at -40°C. 
2.3.11. Ion-exchange high performance liquid chromatography (HPLC) 
Preparative ion-exchange HPLC was perfonned using a Gilson HPLC system. Epo 
(Amgen, lot 5141) was diluted tenfold from an original concentration of3.19 mg/ml 
in 0.01 M NaH2P04, pH 7.0. This solution (5 ml) was loaded onto a column (MonoQ, 
Pharmacia) at 3 ml/min in Buffer A (0.01 M sodium phosphate pH7.0, 
0.025 M NaCl). After three minutes, this process was repeated a second time, 
whereupon the run was started at a flow rate 0[2 ml/min equilibrated in Buffer A, 
following the absorbance ofthe eluate at 276 nm. 
The following ramp was used: 
Time/min %A (O.OIM sodium phosphate %B (O.OIM sodium phosphate 
pH7.0, O.025M NaCI) pH7.0, IM NaCI) 
0 100 0 
5 100 0 
45 80 20 
46 100 0 
60 100 0 
Ten x 2-minute fractIOns (4 ml/fractIOn) were collected, followed by 0.4 mm fractIOns 
(0.8 ml/fraction). 
2.3.12. Enzyme-Ii~ked immunosorbent assay (ELISA) 
Epo concentrations were detennined using an anti-Epo ELISA (generously donated by 
B. Rafferty, Division of Immunobiology and Endocrinology, NIBSC). 
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Nunc MaxiSorp ELISA plates (Nunc, Roskilde, Denmark) were coated with rabbit 
anti-Epo antibody (200 Jll per well, 5 Jlglml in PBS) and incubated overnight at 4°C. 
The following day plates were washed three times with wash dilution buffer (WDB, 
see Appendix for recipe). 
Serial dilutions of samples for testing and a standard (2 x 10-10 glml as the top dose) 
made up in WDB were added as 100 Jll. Biotinylated goat anti-Epo antibody (100 Jll, 
7 Jlglml, B. Rafferty), diluted in WDB with 1 % goat serum, was also added to the 
wells. The plates were incubated for four hours with shaking at room temperature, 
then washed three times with WDB. Horse Radish Peroxidase-conjugated Avidin in 
WDB (200 Jll, 0.025% [v/v], DAKO) was then added for 15 minutes and washed three 
times with WDB. O-Phenylenediamine dihydrochloride (OPD, Sigma), a horse-radish 
peroxidase substrate (0.02% [w/vD and hydrogen peroxide (H20 2, 0.04% [v/vD were 
added to substrate buffer (see Appendix) and 200 Jll added to the wells. 
Sulphuric acid (H2S04, 100 Jll, 1 M) was added to stop the chromogenic reaction. 
The absorbance was read at 490 nm on the SpectraMax 340PC (Molecular Devices 
Corporation, Sunnyvale, California, US). 
Relative concentrations were determined using the in-house program WRANL 
(Iterative weighted regression analysis oflogistically transformed responses on log 
dose (Rybicki & von Wechmar, 1982). 
2.3.13. Fluorescence microscopy 
Coverslips were coated with poly-L-lysine (Sigma, UK) at room temperature for 15 
minutes then left to dry. Cells (2 x 106) in a volume of 200 Jll were placed on the 
coverslip and allowed to adhere for one hour at 37°C. Excess cells were blotted off 
and the remaining cells fixed by the addition of 4% (w/v) formaldehyde in PBS for 30 
minutes at room temperature. The cells were washed three times with PBS. 
Alpha-I-acid glycoprotein, desialylated for 48 hours as in Section 2.3.10., and 
conjugated to Alexa Fluor 488 (Molecular Probes, UK) according to the 
manufacturer's instructions, was added to the cells in a 200 III volume (8 Ilglml in 
PBS) and incubated for 20 minutes at room temperature. Coverslips were washed 
three times with PBS. 
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To stain the actin cytoskeleton, a solution of a fluorescence-conjugated actin-binding 
toxin, Phalloidin-594 (Molecular Probes, UK), was made up in PBS (10 III plus 
170 Ill) from a 200 unit/ml (dissolved in methanol) stock, added to the coverslip and 
incubated for 40 minutes at 37°C. Salts were removed by three washes with MilliQ 
water, whereupon the nuclei of the cells were stained for 30-40 seconds with Hoechst 
33342 (Molecular Probes, UK), a dye which binds adenine-thymidine base pairs. 
After coverslips were rinsed twice with MilliQ water, cells were permanently mounted 
in Vectashield mounting medium (Vector laboratories, UK). 
Confocallaser scanning microscopy (CLSM) was performed by Drs L. Berry and 
R. Fleck ofNIBSC with a Leica SP2 AOBS confocallaser scan head mounted on an 
upright microscope (DM RE-7 Leica) set up for dual channel fluorescence using 
fluorescein and Alexa594 filter settings (laser wavelength 488 nm and 543 nm). 
Images were taken using a 20x lens (NA 0.70) or an oil-immersion objective (HCX 
PL Apo ABL NA 1.4-0.6) and separated with spectral filtering (user optimised) for 
each fluorophore and collected by sequential scanning exciting each fluorophore 
individually. Images were analysed and exported using the Leica 3D software 
package. 
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2.3.14. Glycoanalysis (carried out by Dr Yuen, NIBS C) 
N-Glycans were first released from Epo by peptide:N-glycosidase P and labelled with 
the fluorescent label, 4-aminobenzoic acid (Yuen et aI, 2002). The labelled N-Glycans 
were then resolved by normal-phase HPLC and plotted on a graph. Identification of 
the fractionated derivatised oligosaccharides within each peak was determined by 
Matrix-assisted laser desorption ionization (MALDI) mass spectrometry using a 
MALDI mass spectrometer (Micromass TofSpec-2E, MaccIesfield, UK). The 
percentages of each oligosaccharide identified within a fraction were calculated by 
measuring the area under the relevant peak. 
2.4. In vivo bioassays: the post-hypoxic polycythaemic and 
normocythaemic mouse assays for Epo 
In line with Institute policy, all animal handling was carried out by professional 
animal technicians in Biological Support Services, NIBSC, in particular by Peter 
Gerson and Pauline Lloyd. All in vivo experiments were performed according to UK 
Home Office regulations and were approved by the Local Ethics Committee. 
The post-hypoxic polycythaemic and the normocythaemic mouse assays for Epo are 
the only two assays currently recognised by the European Pharmacopoeia as being 
capable of measuring the in vivo biological activity ofEpo. 
2.4.1. The post-hypoxic polycythaemic mouse assay for Epo 
During the course of this assay, mice are rendered polycythaemic by exposure to 
reduced atmospheric pressure. Endogenous production of Epo is reduced, making 
them sensitive to the hormone. The biological activity of Epo is then estimated by 
measuring the incorporation of 59Pe into circulating red blood cells. 
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Female CBNCa mice (16-23 g, purchased from Harlan UK Limited) were placed in a 
hypoxic chamber at 0.6 atmospheres on Day O. On Day 3, the atmospheric pressure 
was reduced to 0.4 atmospheres. On Day 14, the mice were returned to normal 
atmospheric conditions. On Day 14+3, sequential dilutions ofthe Epo samples 
intended for testing and the standard were made up in Albumin-buffered saline 
solution pH7.2 (ABS - see Appendix for buffer composition) at concentrations of 
approximately 600, 300 and 150 mIU/ml. Doses (0.2 ml) were injected 
subcutaneously into the mice. Blanks consisted of ABS alone. Six mice were used 
per treatment group. On Day 14+5, 0.2 ml of 59Fe (1 J..lCilml) in citrate buffer (see 
Appendix) was injected intraperitoneally. On Day 14+7, mice were injected 
intraperitoneally with 0.3 ml of the anaesthetic Avertin (10 g of2,2,2 tribromoethanol 
in 10 mls 2 methyl 2 butanol, BDH). A blood sample was taken from the orbital sinus 
of each mouse into a capillary tube which was then sealed with Cristaseal (Hawksley 
& Sons Ltd, UK) and centrifuged for five minutes, enabling measurement of the 
percentage of red blood cells in the total blood volume (the haematocrit or packed cell 
volume). Blood samples (0.5 ml) were taken by heart puncture, then measured by 
gamma counter (LKB 1282). 
The response was calculated for each mouse as percentage of dose of 59Fe 
incorporated into the total blood volume of the mouse (assumed to be 7.5% of body 
weight). 
Response= 59Fe in blood sample (cpm) x body weight (g) x 7.5 
Volume of blood sample (ml) x 59Fe dose (cpm) 
2.4.2. The normocythaemic mouse assay for Epo 
Female Balb/c mice (17-21 g) were purchased from Harlan VK Limited. On Day 1, 
sequential dilutions of the Epo samples intended for testing and the standard were 
prepared in Albumin-buffered saline solution pH7.2 (ABS) at concentrations of 
approximately 50, 100 and 200 IV/m!. Doses (0.2 ml) were injected subcutaneously 
into each mouse. Blanks consisted of ABS alone. Six mice were used per treatment 
group. On Day 5, all the mice were anaesthetised by intraperitoneal injection with 
0.3 ml Avertin (BDH). Blood (approximately 20 J.ll) was taken up from the orbital 
sinus of each mouse and placed in a heparinised tube. Reticulocyte concentration -
determined by adding 5 J.lI of the blood samples to 1 ml ofRetiCount (a fluorescent 
dye that binds the RNA of immature red blood cells, Becton Dickinson) and 
incubating for at least 30 minutes in the dark - was then analysed by FACScan 
(F ACScalibur, Becton Dickinson). 
2.4.2.1. Statistical analysis of in vivo results 
All bioassay estimates were expressed in terms of the Second International Standard 
for Erythropoietin, NIBSC Code: 88/574 (Storring & Gaines Das, 1992). 
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After the log dose-log response data were analysed as paired parallel-line assays, an 
analysis of variance was performed for each assay. Statistical weights were calculated 
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as the reciprocal of the variance of the log potencies. Estimates of log potency were 
examined for heterogeneity using a "I: test. Homogeneous estimates (P > 0.05) were 
combined as weighted geometric means, and heterogeneous estimates were combined 
as unweighted geometric means with fiducial limits based on the variance of the 
logarithms of the combined estimates. 
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Chapter 3. A sialylation-sensitive cell-based in vitro bioassay 
for erythropoietin; incorporation of the galactose-binding 
Erythrina crista-galli lectin. 
Summary and overview 
This chapter describes the development of a sialylation-sensitive in vitro assay by 
incorporation of the galactose-binding properties of a plant-derived lectin into a 
cell-based Epo bioassay. It features the following sequence of studies: 
(i) Development of an in vitro bioassay protocol incorporating a solid-phase lectin 
binding step which differentiates between sialylated and desialylated Epo 
(Section 3.2.1.); 
(ii) Validation studies on three separate sample sets, which are expected to exhibit a 
range ofbioactivities: 
-sample set 1: neuraminidase desialylated Epo preparations (Section 3.3.1.) 
-sample set 2: Epo preparations generated through different production and 
purification methods and varying in biological activity (Section 3.3.2.). 
-sample set 3: pharmaceutical Epo separated into anion-exchange subfractions, 
relatively enriched with differentially charged isoforms (Section 3.3.3.); 
(iv) Comparisons of in vitro results with in vivo bioactivity measurements (Sections 
3.3.1.8.,3.3.2.4. and 3.3.3.6. (includes correlation studies»; 
(v) Correlation studies comparing in vitro and in vivo results with physico-chemical 
analysis by glycan mapping and IEF (Section 3.3.3.6.); 
(vi) Analysis and interpretation of results (Section 3.4.). 
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3.1. Introduction and aims of the study 
Lectins are non-enzymatic proteins that bind to carbohydrates non-covalently. Widely 
distributed in plants, animals, micro-organisms and bacteria, they are in many cases 
unrelated structurally, although some common structures exist that have arisen by 
convergent evolution (Loris, 2002;Sharon, 1993). Animallectins include: C-type 
lectins (involved in mediating adhesion, glycoprotein clearance and pathogen 
neutralization), one of which is the ASGPR; galectins (crosslink sugars in the 
extracellular matrix); I-type lectins (immunoglobulin-related sialic acid-binding 
proteins) and P-type lectins (which bind to mannose 6-phosphate and are involved in 
protein sorting) (Dodd & Drickamer, 2001). 
Plants also produce lectins with a wide range of carbohydrate-binding specificities, 
possibly due to sequence hypervariability in the region responsible for sugar binding 
(Sharon & Lis, 1990). Although the function of plant lectins is not fully known, 
investigators are keen to exploit their wide range of abilities in terms of binding to 
different sugars. Table 3.1.1. lists some commonly used lectins and their binding 
specificities. 
As explained in the introduction, correct glycosylation, including terminal sialylation, 
is essential for the in vivo activity of Epo but has little bearing on its in vitro activity 
(Tsuda et ai, 1990). The work described in this chapter was aimed at developing a 
sialylation-sensitive cell-based assay for Epo and investigating how effective it was at 
assessing potency compared to other in vitro assays, physico-chemical tests and the 
gold standard of in vivo assays. One step of the cell-based assay developed exploited 
the similarity in binding characteristics between ASGP-R and certain 
galactose-binding plant lectins. The liver's ASGP-R binds glycoproteins containing 
exposed galactose residues thus removing them from the circulation and preventing 
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Lectin Plant species Sugar Ligand 
abbreviation from which the 
lectin is derived 
ConA Canavalis Mannose/Glucose 
ensiformis 
RCA Ricinus communis Galactose 
" 
ECL Erythrina crista- Galactose 
galli 
DBA Dolichus biflorus N -acetylgalactosamine 
SNA-l Sambuccus nigra Sialic acid 
Table 3.1.1. Commonly used lectins, the plant species from which they are 
derived and their binding specificities (Storring et at (1996». 
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them from exerting an effect on their target cells. The action of the liver receptor was, 
in this context, mimicked most successfully by means of Erythrina crista-galli lectin 
(ECL). See Fig. 3.1.1. for an outline ofthe assay protocol. In essence, a solution of 
Epo of known concentration was incubated with agarose-conjugated ECL, allowing 
the lectin to bind Epo containing terminal galactose residues. The sample was then 
centrifuged, causing complexes comprised of agarose-conjugated ECL bound to such 
Epo molecules to be pulled down. The supematant was then used in an 
Epo-dependent AS-E2 cell bioassay. Epo solutions containing a higher proportion of 
terminal galactose residues would theoretically be depleted of more Epo and would 
therefore stimulate a reduced proliferation response in the Epo-dependent assay. 
Three different types of Epo were tested using the assay developed, each representing 
one of the different forms of Epo that might require assessment in terms ofthe quality 
of Epo as a medicinal product: experimentally desialylated Epo, a range of Epo 
samples generated by different production and purification procedures, and a batch of 
pharmaceutical grade Epo separated into fractions by anion-exchange HPLC. These 
three Epo sample sets were also tested using the unmodified Epo-dependent cell-based 
and in vivo bioassays. Physico-chemical analysis was carried out to allow further 
investigation of the relationship between glycosylation, in particular, sialylation and 
galactose exposure, and in vivo activity. 
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-Fig. 3.1.1. (Facing page) Schematic representation of the rationale behind the 
AS-E2IECL bioassay protocol; (a) a solution of Epo of known concentration is 
incubated with agarose-conjugated ECL (Vector Laboratories) for 6 hours at 
4°C, allowing the lectin to bind any Epo terminal galactose residues, (b) the 
sample is then centrifuged, causing such complexes to be pulled down, and (c) 
the supematant is used in an Epo-dependent AS-E2 cell bioassay. 
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3.2. Experimental procedures 
3.2.1. Modified AS-E2 Epo hioassay incorporating the use of agarose-conjugated 
Erythrina crista-galli lectin (AS-E2/EeL bioassay) 
The bioassay was performed as described in Section 2.2.4., but with the following 
change: Epo solutions (23.5 - 33 picomoles in lm! IMDM, 1 % bovine serum albumin, 
Sigma) were incubated with 100~1 (l:llectinlIMDM) agarose-conjugated ECL (a 
galactose-specific lectin, Vector Laboratories) for six hours at 4°C with slow vertical 
rotation (12 rpm). The samples were then centrifuged at 200 g for two minutes and 
the supematants removed and used in serial dilutions. 
The above protocol was also carried out in essentially the same way except that 
agarose-conjugated ECL was replaced by agarose-conjugated Ricinus communis 
agglutinin (RCA120) or agarose on its own (from Vector Laboratories and Sigma 
respectively). 
An additional assay was carried out in which the agarose-conjugated ECL incubation 
step was performed in the presence of galactose-eluting concentrations oflactose 
(200 mM). 
3.2.2. Plate plan 
Fig. 3.2.1. shows a typical plate plan used in the 96-well bioassays. 
Fig. 3.2.1. Plate plan for cell-based Epo bioassays. Each colour represents a 
different sample being tested. The top dose (1) corresponds to 0.66 nM. 
Grey outer wells contain medium only. 
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3.2.3. In vivo mouse assay for Epo 
The in vivo post-hypoxic polycythaemic and normocythaemic mouse assays for Epo 
were carried out (Sections 2.4.1. and 2.4.2. respectively) for the purposes of 
comparison with the in vitro assays developed in the course of this project. 
3.2.4. Glycoanalysis 
81 
Glycoanalysis was carried out on the anion-fractionated Epo samples of Section 3.3.3. 
by Dr Yuen of NI BSC, as described in Section 2.3.14. 
3.3. Results 
3.3.1. Sample set 1: neuraminidase-desialylated Epo 
3.3.1.1. Desialylation of Epo 
A range of increasingly desialylated Epo samples was generated for use in comparing 
in vivo and in vitro assay results. This was achieved by neuraminidase digestion as 
described in Section 2.3.10. Removal of negatively charged sialic acids increases the 
pI of a protein, allowing digestion to be followed by IEF (in this case, migration shifts 
towards the cathode). The samples were run on an IEF gel (ampholines pH3-10:2.5-
5:5-7:7-9=1 :1:1 :1) that was then transferred to a PVDF membrane and 
Western-blotted with an anti-Epo antibody (generously donated by B. Rafferty, 
NIBSC) as described in Sections 2.3.5.,2.3.6 and 2.3.8. Fig. 3.3.1 a shows an increase 
in the pI of the Epo bands corresponding to the duration of incubation with 
neuraminidase. Protein transfer and Western blotting were employed in preference to 
chemical staining with silver or Coomassie blue since attempts at the latter revealed 
that the more desialylated proteins - i.e. those with a higher pI - did not stain, either 
Fig. 3.3.1. (Facing page) (a) Epo treated with neuraminidase for 
increasing lengths of time subjected to isoelectric focusing gel 
electrophoresis followed by western blot (following protocol in 
Sections 2.3.6. and 2.3.8.) with anti-Epo antibody. Samples 
marked * were selected for further study. (b) The mean pI values 
of the selected samples were calculated as described in Section 
2.3.9. 
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t=O min 4.21 
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t=480 min 5.83 
t=1800 min 6.65 
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because they are unable to stain to the same extent as less desialylated Epo or because 
they are washed away during the staining procedure. A sugar chain at an N-
glycosylation site can contain up to four sialic acids, while at an O-glycosylation site 
it can have no more than two (see diagram in Fig. 1.3. in Chapter 1). Thus Epo has a 
theoretical maximum of 14 sialic acid residues per molecule. As expected, 15 bands 
are visible on the isoelectric focusing gel in Fig. 3.3.la. (14 bands corresponding to 
Epo with 1 to 14 sialic acid charges and one band with no charges conferred by sialic 
acid). Samples incubated with neuraminidase for 0 minutes (Epo sample t=O min), 
20 minutes (Epo sample t=20 min), 480 minutes (Epo sample t=480 min) and 
1800 minutes (Epo sample t= 1800 min) were chosen for use in bioassays as they 
represented a broad range of sialylation levels ... While it still contained significant 
amounts of intact Epo, the t=20 min sample also contained bands between pI 5.3 and 6 
(possibly corresponding to as many as 5-8 desialylations per molecule). The 
t=480 min sample exhibited more extensive desialylation, with the presence of some 
bands corresponding to the lower pI bands in intact Epo, but with the majority of 
forms displaying anything between 6 and 12 desialylation events per molecule. The 
t= 1800 min sample appeared to be on the verge of complete desialylation. Each 
sample was assigned a mean pI (Fig. 3.3.1 b) by the method described in Section 2.3.9. 
Mean pI provides a quantitative measure of isoform distribution and was employed 
here for comparison purposes as it has been reported to be a better predictor of 
follicle-stimulating hormone (FSH) activity than calculating the proportion of 
isoforms bands with a pI ofless than 5 (Mulders et ai, 1999». Epo sample t=O min, 
untreated with neuraminidase, had the lowest mean pI (4.21). The mean pI of the 
samples increased the longer they were incubated in neuraminidase. A 30-hour 
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incubation in neuraminidase resulted in the sample (t=1800 min) having a mean pI of 
6.65. 
3.3.1.2. In vivo post-hypoxic polycythaemic mouse assay 
The post-hypoxic polycythaemic mouse assay was carried out on samples t=O min, 
20 min, 480 min and 1800 min (Table 3.3.1.) to ascertain the extent to which 
desialylation had affected in vivo biological activity. The more sensitive 
polycythaemic assay was chosen for measuring the biological activity of the four 
samples, the prediction being that the activity of the more extensively desialylated 
samples would be too low to allow detection by means of the normocythaemic assay. 
Sample t=O min was the most biologically active, having an Epo bioactivity of 
139,375 IU/mg. An increase in length oftreatment with neuraminidase was 
associated with a progressive decrease in biological activity. The Epo sample treated 
for the longest period, t= 1800 min, exhibited a biological activity of 2,731 IU/mg. 
This was more than a 50-fold decrease in activity compared with untreated Epo. 
There is clearly not a linear relationship, however. The loss of activity exceeded 97% 
after 480 minutes, having reached 73% after 20 minutes, by which time it was very 
difficult to see any significant desialylation by means of an IEF blot. 
3.3.1.3. Unmodified AS-E2 bioassay 
AS-E2 is an erythropoietin-dependent human leukemia cell line derived from a patient 
with acute myeloid leukemia. It expresses a low affinity Epo-R and resembles late 
BFU-E or CFU-E in that it is responsive to Epo but not IL-3, GM-CSF or stem cell 
factor (Miyazaki et aI, 1997). 
Table. 3.3.1. Estimates of the specific activities of the 
untreated and neuraminidase-treated Epo samples, based on in 
vivo post-hypoxic polycythaemic mouse assay in terms of the 
Second International Standard for Erythropoietin. The figures 
of the table are plotted in the graph below. 
Epo sample 
t=O min 
t=20 min 
t=480 min 
t=1800 min 
300000 
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5.83 
6.65 
t=O min 
Epo bioactivity 95 % Confidence 
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139,375 104,300-205,684 
.' 
37,275 21,121-56,522 
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The cell-based bioassay used in this project used alamarBlue, a colorimetric reagent 
which is blue in its oxidized form (resazurin) but which turns pink when reduced, 
becoming resorufin. Reduction is brought about by the metabolic activity of the cells 
undergoing measurement as part of the assay. 
In vitro biological activity of Epo before and after desialylation was determined in the 
unmodified AS-E2 cell bioassay (see Fig. 3.3.2a). Epo that had not been treated with 
neuraminidase stimulated a dose-dependent proliferation between 0.03nM and 
0.26nM (ECso= 0.0614nM). Epo subjected to 20 minute, 480 minute or 1800 minute 
neuraminidase treatment showed very similar dose-responses. There was no 
noticeable change in the slope of the curve or in the maximum proliferation. The ECso 
results varied little, all being in the range 0.05833-0.06413nM (Fig. 3.3.2b). The 95% 
confidence intervals for the estimated ECso values showed no statistically significant 
differences between any of the samples. 
3.3.1.4. AS-E2/EeL bioassay 
In vitro biological activity ofEpo before and after desialylation was then tested in the 
modified AS-E2/ECL bioassay (Fig. 3.3.3a) and ECso values calculated (Fig. 3.3.3b). 
Epo concentrations were no longer known following the lectin-mediated depletion of 
Epo containing galactose-exposed sugars. Accordingly, units along the x-axis of 
Fig. 3.3.3.a represent the concentrations prior to treatment with ECL. Untreated Epo 
(t=O min) stimulated proliferation in a dose-dependent manner until maximum 
proliferation was reached at approximately 0.25nM Epo (ECso= 0.04563 nM). The 
neuraminidase-treated Epo samples, however, differed from the t=O min sample to 
varying degrees. Sample t=20 min reached maximum proliferation at approximately 
the same concentration but half-maximal response was attained at a slightly higher 
Fig. 3.3.2:-(Facing page) Proliferative response of AS-E2 
cells to untreated and neuraminidase-treated Epo. 
(a) Sample t=O min (_), t=20 min (A), t=480 min (e) and 
t=1800 min (0). Data represent mean +/- s.e.m. of 
triplicated samples. 
(b) ECso values and 95% confidence intervals were 
calculated for the dose-response curves. 
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t=20 min (A) 0.05833 0.05446 - 0.06248 
t=480 min (.) 0.06413 0.06094 - 0.06747 
t=1800 min (0) 0.06140 0.05863 - 0.06431 
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Fig. 3.3.3. (Facing page) Proliferative response of AS-E2 cells 
to untreated and neuraminidase-treated Epo subsequent to 
incubation with agarose-conjugated Erythrina crista-galli 
lectin (ECL). (a) Sample t=O min (_), t=20 min C.6.), t=480 
min (e) and t=1800 min (0). Units along the x-axis represent 
Epo concentrations prior to treatment with ECL. Data 
represent mean +/- s.e.m. of triplicated samples. 
(b) ECso values and 95% confidence intervals were calculated 
for the dose-response curves. 
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-
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Epo concentration (ECso= 0.06405nM). Judging from the confidence intervals 
(Fig. 3.3.3b), this did not differ significantly from the t=O min sample, however. By 
contrast, samples t=480 min and 1800 min differed significantly from the untreated 
sample - the onset of their proliferation being delayed until the concentration had 
reached at least 0.06nM Epo (at the same concentration, samples t=O min and 
t=20 min were at 75% and 50% maximal proliferation respectively), with maximal 
proliferation being recorded at approximately 2nM Epo. The ECso was 0.377nM Epo 
for sample t=480 min and 0.5136nM Epo for sample t= 1800 min (the latter indicating 
a roughly ten-fold decrease in activity compared with untreated Epo). On the basis of 
the 95% confidence intervals (Fig. 3.3.3b), it is clear that these differ significantly 
from the t=O min and t=20 min samples, and from each other. 
In order to see whether statistical significance could be obtained between samples 
t=O min and t=20 min, the assay was repeated with just these two samples and a 
dose-response curve with a larger number oflower Epo concentrations (Fig. 3.3.4a). 
Fig. 3.3.4b shows ECso values for t=O min and t=20 min of 0.02878 and 0.04531 nM 
respectively. The non-overlapping confidence intervals indicate those results to be 
statistically significant at the 5% significance level. 
3.3.1.5. AS-E2/RCAl2o assay 
The same experiment was performed as in Section 3.3.1.4., except that 
agarose-conjugated ECL was replaced by agarose-conjugated Ricinus communis 
agglutinin (RCA120) and the results plotted in Fig. 3.3.5 .. Although the results were 
generally comparable with those obtained as described above, cell death was observed 
at higher concentrations of Epo, presumably as a result of contamination by the 
RCA120 toxin. 
Fig. 3.3.4. (Facing page) Proliferative response of AS-E2 
cells to untreated and 20 minute-neuraminidase-treated Epo 
subsequent to incubation with agarose-conjugated ECL; 
differentiation between samples t==O min and t=20 min. 
(a) Sample t=O min (_) and t=20 min (A). Units along the x-
axis represent the concentrations prior to treatment with 
ECL. Data represent mean +/- s.e.m. of triplicated samples 
(where an error bar is not shown, it lies within the 
dimensions of the symbol). 
(b) ECso values and 95% confidence intervals were 
calculated for the dose-response curves. Data are 
representative of two independent experiments. 
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Fig. 3.3.5. Proliferative response of AS-E2 cells to untreated and 
neuraminidase-treated Epo subsequent to incubation with agarose-
conjugated RCA I20; replacement of agarose-conjugated ECL with 
agarose-conjugated Ricinus communis agglutinin (RCAI20). 
(a) Sample t=O min (_), t=20 min (.), t=480 min (e) and t=1800 min (0). 
Units along the x-axis represent the concentrations prior to treatment with 
RCA120• Data represent mean +/- s.e.m. of triplicated samples. 
(b) EC50 values an_d 95% confidence intervals were calculated for the dose-
response curves. 
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3.3.1.6. Depletion of Epo was lectin-dependent 
To confirm that the depletion of Epo in these assays was not due to adhesion to 
agarose or degradation during the six-hour incubation, the four Epo samples were 
incubated with agarose alone and then tested in the AS-E2 bioassay. Fig. 3.3.6. shows 
that the four Epo samples incubated for six hours with agarose alone did not exhibit 
the same trend as when they were incubated with lectin-bound agarose, in that Epo 
treated with neuraminidase for eight hours or more (t=480 min and t=1800 min) did 
not give a lower proliferative response. 
The most extensively desialylated Epo sample (t= 1800 min) incubated with 
agarose-conjugated ECL in the presence or absence ofIactose at an eluting 
concentration of200 mM was assayed using AS-E2 cells (Fig. 3.3.7.). Epo sample 
t=1800 min incubated in the absence ofIactose had an ECso value of 0.65 nM, similar 
to that obtained in Fig. 3.3.3. for the same sample and type of assay (i.e. AS-E2/ECL 
assay), whereas the same t=1800 min sample incubated with ECL in the presence of 
lactose had a much lower ECso value in the region of 0.1 nM, similar to the ECso value 
obtained in the unmodified AS-E2 (Fig. 3.3.2.). Lactose contains galactose and 
therefore is recommended for eluting ligands from ECL. This experiment 
demonstrates that the sugar specific for inhibiting binding to ECL abolishes the effect 
of depleting desiaIylated Epo described in Section 3.3.1.4. 
3.3.1.7. Lectin free in solution does not result in depletion of Epo 
ECL (0.375mg/ml - corresponding to 2.5x the concentration ofECL used in the 
agarose-conjugated form of the assays) was added free in solution to the AS-E2 
bioassays measuring the potency of the t=0 min and t= 1800 min Epo samples. This 
was done to see whether it was possible to distinguish between intact and desialylated 
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Fig. 3.3.6. Proliferative response of AS-E2 cells to untreated and 
neuraminidase-treated Epo subsequent to incubation with agarose alone. 
Sample t=O min (_), t=20 min (A), t=480 min (e) and t=1800 min (0). 
Units along the x-axis represent the concentrations prior to tr~atment 
with agarose. Data represent mean +/- s.e.m. of triplicated samples 
(where an error bar is not shown, it lies within the dimensions of the 
symbol). 
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Fig. 3.3.7. Proliferative response of AS-E2 cells to neuraminidase-
treated Epo (sample t=1800 min) subsequent to incubation with 
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agarose-conjugated ECL with (_) or without (0) the presence oflactose 
(200 mM). Units along the x-axis represent the concentrations prior to 
treatment with ECL. Data represent mean +/- s.e.m. of triplicated 
samples (where an error bar is not shown, it lies within the dimensions 
of the symbol). 
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Epo without any need for pre-incubation with the agarose-bound form of the lectin. 
Fig. 3.3.8. shows that the free ECL did not reduce the proliferation of AS-E2 cells 
stimulated with the t=1800 min Epo sample. In the unmodified AS-E2 bioassay, Epo 
sample t=1800 min is 1.067 times as active as t=O min. When ECL is added free to 
the medium of the assay at a concentration of 0.37 5 mg/ml , Epo sample t= 1800 min 
still has a higher potency than t=O min (1.33 times as potent). ECL free in solution 
did not competitively inhibit Epo containing a higher proportion of terminal galactose 
residues from binding the Epo receptor and stimulating proliferation. 
3.3.1.8. Comparison of the AS-E2, AS-E2/ECL and the in vivo mouse bioassays 
The percentage activity of the desialylated samples was calculated relative to 
untreated Epo (t=O min) for each of the three types of assay (Fig. 3.3.9a). The results 
were plotted against their mean pI values (Fig. 3.3.9b). 
The pI of intact Epo (Epo sample t=O min, pI=4.21) was only 0.3 pI units lower than 
slightly desialylated Epo (Epo sample t=20 min, pI=4.51) indicating a slightly higher 
level of sialylation, but this corresponded to a 73% drop in activity. Epo samples 
t=480 min and t=1800 min were desialylated to a greater extent (indicated by mean pI 
values of 5.83 and 6.65 respectively) and had lost nearly all potency, being well below 
5% initial starting activity. 
Samples tested in the unmodified AS-E2 bioassay displayed the same level of activity 
relative to that of untreated Epo (approximately 100%), irrespective of sialylation 
level. 
In the AS-E2/ECL bioassay, the slightly desialylated Epo sample t=20 min exhibited 
approximately 70% of the activity level ofEpo untreated with neuraminidase, whereas 
the two extensively desialylated Epo samples (t=480 min and t=1800 min) 
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Fig. 3.3.8. Effect of Erythrina crista-galli lectin free in solution. 
(a) Cells were grown in normal assay medium supplemented with sample t=O min Epo 
(-) and sample t=1800 min Epo (0). 
(b) ECL (at a concentration of 0.375 mg/ml) was included in the assay medium. Sample 
t=O min (_) and t=1800 min (0). Data represent mean +/- s.e.m. of triplicated 
samples. 
Eposample Best-fit ECso values (nM) Best-fit ECso values (nM) 
for normal assay for assay in which free EeL 
was included in the medium 
t=O min (_) 0.09715 0.1307 
(95% confidence intervals= (95% confidence intervals= 
0.07812 - 0.1208) 0.05989 - 0.2854) 
t=1800 min (0) 0.09101 0.09815 
, 
(95% confidence intervals = (95% confidence intervals= 
0.07312 - 0.1133) 0.06618 - 0.1456) 
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Fig. 3.3.9. Comparison of in vivo, AS-E2 and AS-E2IECL bioassays. 
Ca) Percentage activity of desialylated samples relative to untreated Epo for 
each of the three assays. 
Cb) CFacing page) Relative percentage activity plotted against mean pI value. 
In vivo bioassay C-), AS-E2 bioassay Ce), AS-E2IECL bioassay C"'). 
(a) 
Epo Mean pI In vivo % AS-E2 % AS-E2! 
sample value activity activity ECL% 
activity 
t=Omin 4.21 100 100 100 
t=20 min 4.51 26.74 100.7 71.23 
t=480 min 5.83 2.85 91.6 12.10 
t=1800 6.65 1.96 95.7 8.89 
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were found to be only about 10% as active. Results obtained using the AS-E2/ECL 
bioassay were similar to those obtained with the in vivo bioassay (Pearson correlation 
R=0.905, P=0.095). In essence, lower levels of sialylation, as indicated by lower 
mean pI values, correlated with a decrease in activity, albeit with less sensitivity 
(particularly in the slightly desialylated range). 
3.3.2. Sample set 2: Range of pharmaceutical Epo preparations generated by 
different production and purification procedures 
3.3.2.1. Background information 
In addition to the experimentally desialylated Epo samples, a second set of samples 
comprising a range of pharmaceutical Epo preparations was tested using the 
AS-E2/ECL bioassay. The pharmaceutical Epo preparations, which were kindly 
donated by Dr Yuen, NIBSC, and described in reference (Yuen et ai, 2003), were 
produced by Chinese Hamster Ovary (CHO) cells but were cultured and purified 
differently in order to effect a variation in their glycan structures. Pharamceutical Epo 
preparations Gr andL2 were made in roller bottles with Dulbecco's-modified Eagle's 
medium (DMEM) as the culture medium, while pharmaceutical Epo preparations 
M2G and SpB were made in a hollow fibre bioreactor with DMEMlNutrient Mixture 
F12 Ham's medium containing 5% FCS (v/v). Purification was the same for all the 
samples except that sample SpB was passed over a cation-exchange chromatography 
column so as to concentrate more basic Epo molecules. 
Glycan mapping has previously been carried out on the Epo preparations of sample set 
2 and their in vivo potencies measured to enable the relationships between 
carbohydrate structure and biological activity to be studied (Yuen et ai, 2003). A 
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direct correlation was observed between tetra-sialylated tetra-antennary structure 
content and in vivo biological activity (Pearson correlation R= 0.974, P< 0.0005), with 
sample SpB having the lowest proportion oftetra-sialylated tetra-antennary sugars and 
the lowest in vivo activity (yet the highest in vitro activity). No relationship was 
found between in vivo potency and the proportion of the trisialylated 
tri-antennary-enriched Epo, however (Pearson correlation R= -0.505, P> 0.05). 
Fig. 3.3.10. is the IEF gel from reference (Yuen et ai, 2003) which was kindly loaned, 
for densitometric analysis purposes, to calculate the mean pI values listed in Table 
3.3.2. The values range from 4.962 for the most basic SpB sample to 4.127 for the 
most acidic L2 sample (the order of increase in acidity being SpB<M2G<Gr<L2). 
The Yuen et al reference (2003) provided post-hypoxic polycythaemic mouse assay 
results and these are reproduced here by kind permission (Table. 3.3.3.). Potencies 
ranged from 28,300 IV/mg for SpB the least active pharmaceutical Epo preparation (it 
was also the least acidic ifmean pI value is used as a guide), to 94,600 IV/mg for L2, 
the most biologically active and acidic sample. Biological activity was very closely 
related to mean pI value (Pearson correlation R=-0.976, P=<0.05), with the order in 
which samples increased in activity mirroring exactly the order in which their mean pI 
values decreased. 
3.3.2.2. Unmodified AS-E2 bioassay 
When tested in the unmodified AS-E2 assay (Section 2.2.4.), the four pharmaceutical 
Epo preparations gave very similar potencies in terms of ECso values, which were all 
in the range 0.06287-0.07158 nM (see Fig. 3.3.11.). 
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Fig. 3.3.10. (Facing page) Isoelectric focusing of the four 
pharmaceutical Epo preparations detected by Western blotting: Or, 
SpB, M20 and L2 (kindly donated for the purposes of densitometric 
analysis and reproduced here with permission from Yuen et al (2003)). 
Table 3.3.2. Calculation of the mean pI values of the four 
pharmaceutical Epo preparations (see Section 2.3.9. for procedure 
followed). 
Pharmaceutical Epo Mean pI value 
preparation 
Gr 4.28 
SpB 4.96 
L2 4.13 
M2G 4.40 
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pI marker 
5.85 --+ 
5.20 --+ 
pH 
4.55 --+ 
4.15 --+ 
3.50 --+ 
Gr Sp8 L2 M2G 
Table. 3.3.3. Estimates of the specific activities of the four 
pharmaceutical Epo preparations, based on in vivo post-
hypoxic polycythaemic mouse assay in terms of the Second 
International Standard for Erythropoietin. The figures of the 
table are plotted in the graph below. 
Epo sample Mean pI Epo 95 % Confidence 
Or 
SpB 
L2 
M20 
120000 
en § 100000 
,~ 80000 
> 
'';::: (,) 60000 
ca 
o 
,2: 
> 
r:: 
-
value 
4.28 
4.96 
4.13 
4.40 
bioactivity Intervals (IV/mg) 
(IU/mg) 
84,000 65,700 - 107,000 
28,300 22,200 - 36,000 
94,600 70,500 -: 127,000 
60,800 49,900 -74,200 
O~~--~--r-~--~-'--~--r-~~ 
4.0 -4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 5.0 
Mean pi value 
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Fig. 3:3.11. (Facing page) Proliferative response of 
AS-E2 cells to the four pharmaceutical Epo 
preparations. 
(a) Sample Gr (_), SpB (. .. ), L2 (e) and M2G (0). 
Data represent mean +/- s.e.m. of triplicated 
samples. 
(b) EC50 values and 95% confidence intervals were 
calculated for the dose-response curves. 
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(a) 1.8 
1.6 
1.4 
E 
c 1.2 
0 
0 ~ 1.0 
0 ,.... 
It) 0.8 
u; 
~ 0.6 
0.4 
0.2 
0.0 
0.0 0.1 0.2 0.3 0.4 
Epo concentration (nM) 
(b) Epo sample Best-fit ECso value 95 % Confidence 
(nM) interval(nM) 
Gr(.) 0.07158 0.06639 - 0.07717 
SpB (A) 0.06769 0.06156 - 0.07444 
L2 (e) 0.06287 0.05904 - 0.06695 
M2G (0) 0.07093 0.06555 - 0.07675 
-
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3.3.2.3. AS-E2/ECL bioassay 
The AS-E2/ECL bioassay, in contrast, differentiated between the four samples, in that 
their ECso-indicated potencies rose in the following order: SpB<M2G<Gr<L2 (see 
Fig. 3.3.12.). The differences between any two pairs of samples were statistically 
significant at the 5% level (P<0.05), their ECso values ranging from 0.07998 for L2 
(indicating the highest level of activity) to 0.1254 for SpB (indicating the lowest level 
of activity). This was verified further by statistical analysis using RANDOM, an 
in-house program which calculates relative potencies. The ECso values of samples L2 
and Gr were very close, however, and did not differ more markedly from each other 
than in the unmodified AS-E2 bioassay. 
3.3.2.4. Comparison of the AS-E2, AS-E2/ECL, in vivo mouse and IEF assay 
Post-hypoxic polycythaemic mouse assay results (Table. 3.3.3.) followed the same 
pattern of increasing biological activity as was obtained in the AS-E2/ECL assay (i.e. 
SpB<M2G<Gr<L2). Mean pI values, on the other hand, decreased, presumably 
indicating an increase in the proportion of sialic acids (see Table. 3.3.2.). Potencies 
relative to L2 assigned by in vivo assay, unmodified AS-E2 assay and AS-E2/ECL 
bioassay are set out in Fig. 3.3.l3a. and plotted against mean pI values in Fig. 3.3.l3b. 
In vivo activity and AS-E2/ECL activity directly correlate (Pearson correlation 
R=0.914, P=0.086), both decreasing as the mean pI values increase. In contrast, 
AS-E2 activity remains near the 100% level, regardless of mean pI value. As was 
observed in the case of the artificially desialylated Epo samples in Section 3.3.1., the 
AS-E2/ECL bioassay was ultimately not as sensitive as the in vivo assay, with sample 
SpB reaching around 58% of the activity ofL2, compared with 30% for the mouse 
assay. Somewhat surprisingly, Gr activity appeared to be lower relative to L2 when 
Fig. 3.3.12. (Facing page) Proliferative response of AS-E2 cells to the four 
pharmaceutical Epo preparations subsequent to incubation with agarose-
conjugated ECL. 
(a) Sample Gr (_), SpB (A.), L2 (e) and M2G (0). Units along the x-axis 
represent the concentrations prior to treatment with agarose. Data represent 
mean +/- s.e.m. of triplicated samples (where an error bar is not shown, it 
lies within the dimensions of the symbol). 
(b) ECso values and 95% confidence intervals were calculated for the dose-
response curves. Data are representative of three independent experiments. 
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0.7 
Epo sample Best-fit ECso value 95 % Confidence interval 
(nM) (nM) 
Gr(.) 0.09001 0.08579 - 0.09445 
SpB (A) 0.1254 0.1193 - 0.1318 
L2 (e) 0.07998 0.07582 - 0.08436 
M2G (0) 0.1140 0.1094 - 0.1188 
-
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Fig. 3.3.13. Comparison of in vivo, AS-E2 and AS-E2IECL bioassays for the 
four pharmaceutical Epo preparations. 
Ca) Relative percentage activity for the three types of assay, taking L2 as the 
reference sample. 
(b) CFacing page) Relative percentage activity plotted against mean pI value. 
In vivo bioassay C-), AS-E2IECL bioassay Ce), AS-E2 bioassay CA). 
(a) 
Epo Mean pI In vivo AS-E2 AS-
sample value activity % activity % E2IECL 
activity % 
L2 4.127 100 100 100 
SpB 4.962 30.0 97.2 57.9 
M20 4.401 64.3 92.9 66.6 
Or 4.281 88.8 86.0 78.9 
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detected by the AS-E2/ECL assay compared to when tested in the in vivo assay. This 
can, however, be explained by the fact that Or was also less active in the unmodified 
AS-E2 assay. 
3.3.3. Sample set 3: pharmaceutical Epo fractionated by anion-exchange HPLC 
3.3.3.1. Background on the anion-exchange fractionated samples 
To generate, from a single batch of Epo, a range of samples with varying ratios of 
acidic to basic isoforms, pharmaceutical-grade Epo (kindly donated by Amgen, USA) 
was fractionated by semi-preparative anion-exchange HPLC using a MonoQ column 
(as described in Section 2.3.11.). Fig. 3.3.14. shows a plot of the elution profile 
(0.025-1 M NaCI gradient). The preparative scale ion-exchange chromatography of 
Epo used in these studies produced an elution pattern corresponding to that ofthe 
known isoform distribution by IEF, although without baseline resolution. Fractions 
eluted from the column were then tested by various means; isoelectric focusing gel 
electrophoresis, glycoanalysis, two in vivo methods, and the AS-E2 and AS-E2/ECL 
in vitro bioassays. 
3.3.3.2. Isoelectric focusing 
Fractions (0.8 ml) were collected as they eluted from the MonoQ column and run on a 
pH 2.5-7 IEF gradient (Section 2.3.6.). The IEF gel of Fig. 3.3.15. shows fractions 21 
to 42 - corresponding to minutes 24.4 to 32.8 min on the plot of the elution profile 
(Fig. 3.3 .14.) - with successive fractions having been pooled. Fractions 21 to 24, 27 to 
30, 33 to 36, and 39 to 42 were further pooled and designated as Epo Fractions A, B, 
C and D respectively. 
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Fig. 3.3.14. HPLC UV trace of pharmaceutical-grade Epo (Amgen) eluted from an 
anionic exchange column (MonoQ). The turquoise slope represents the ramp set to 
run from 0% to 20% IM NaCl. The dark blue curve tracks the absorbance of the 
eluate at 276 nm as a percentage of maximum. See Section 2.3.11. for further details. 
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Fig. 3.3.15. (Facing page) Isoelectric focusing gel of ion-exchange HPLC-
separated fractions of a batch of pharmaceutical-grade Epo (Amgen). 
Table 3.3.4. Table of mean pI values and pI values of the strongest 
band of the ion-exchange HPLC-separated Epo Fractions on the 
facing page. 
Fraction Mean pI value pI of strongest 
band 
A 3.30 3.32 
B 3.18 3.18 
C 3.13 3.12 
D 3.06 3.03 
L 2.8 pH 
cathode 
~ 
Cl) 
~I 
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Key: 
A, B, C and D= samples submitted for Glycan mapping and in vivo and in vitro testing 
x/y (e.g. 21122)= fractions x and y pooled (0.8 ml fractions collected). 
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Epo Fraction A was enriched in Epo with a pI value of3.32Fraction Bin Epo with a 
pI value of3.18, Fraction C in Epo with a pI value of3.12 and Fraction D in Epo with 
a pI value of3.03, although they did not contain populations composed solely of these 
Epo isoforms, as evidenced by additional fainter bands and slight differences in their 
mean pI values (3.30, 3.18, 3.13 and 3.06 respectively, see Table 3.3.4.). With 
recHuEpo reported to consist ofisoforms ranging from 3.5-4.5 pI units (Schlags et aI, 
2002), these values may all be regarded as relatively low. Ifit is accepted that Epo's 
negative charges are most likely conferred by sialic acids, this is consistent with later 
eluted fractions having a more acidic mean pI. 
These data show that commercially produced Epo can be separated by anion exchange 
chromatography into subfractions that are enriched for particular isoforms of the 
polypeptide. 
3.3.3.3. In vivo mouse assays for Epo 
Epo Fractions A-D were tested in vivo by the post-hypoxic polycythaemic and 
normocythaemic mouse assays (Sections 2.4.1. and 2.4.2. respectively). Epo 
Fractions that were retained longer on the positively charged MonoQ column were 
expected to be more negatively charged, presumably due to a greater sialic acid 
content, and were indeed found to have a lower mean pI value. Biological potencies 
increase with higher levels of sialylation and it was therefore expected that in vivo 
activities would increase in the order A <B<C<D as the corresponding mean pI values 
decreased. Polycythaemic and normocythaemic results are depicted in a table and a 
graph in Fig. 3.3.16. and Fig. 3.3.17 respectively. Biological activities obtained in the 
polycythaemic assay were in the order B<A<D<C. This order did not match the order 
expected, showing no resemblance to the order in which Epo Fractions were eluted 
Fig. 3.3.16. (Facing page) (a) Table containing estimates of the 
specific activities of the four ion-exchange fractionated Epo 
samples by in vivo post-hypoxic polycythaemic mouse assay, 
in terms of the Second International Standard for 
Erythropoietin. (b) Graph of the in vivo potencies (induding 
95% confidence intervals) ofEpo Fractions A, B, C and D (A-
D corresponding to the order in which the samples came off 
the anionic exchange column, A first), plotted against mean pI 
value. 
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Epo 
Fraction 
(a) 
Starting 
material 
A 
B 
C 
D 
(b) 400000 
Cl 
E 
........ 
::> 
~ 300000 
.-> 
.-
.... (.) 
ca 
g 200000 
.-
> 
c: 
-
Mean pI Epo 95 % Confidence 
value bioactivity Intervals (IU/mg) 
(IU/mg) 
- 161,001 128,053-202,432 
3.30 184,774 137,689-247,965 
3.18 162,039 134,382-195,389 
3.13 229,848 157,688-335,127 
3.06 196,743 .. 164,055-235,950 
100000-A--....----,..---......------. 
3.3 3.2 3.1 3.0 
Mean pi value 
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Fig. 3.3.17. (Facing page) (a) Table containing estimates ofthe 
specific activities of the four ion exchange fractionated Epo 
samples by in vivo normocythaemic mouse assay, in terms of 
the Second International Standard for Erythropoietin. (b) 
Graph of the in vivo potencies (including 95% confidence 
intervals) of Epo Fractions A, B, C and D (A-D corresponding 
to the order in which the samples came off the anionic 
exchange column, A first), plotted against mean pI value. 
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from the column and the order in mean pI values. Activities evaluated by the 
normocythaemic assay matched the expected order more closely, being in the order 
A=B<C<D. This is the trend one might have expected on the basis oftime of fraction 
elution or mean pI alone, the reasoning being that fractions which come off the 
column later - due to a higher negative charge, indicating a greater level of sialylation 
and consequently a more acidic mean pI - are the most active. Although the two 
fractions eluted first (Fractions A and B) were extremely close in terms of activity, it 
was Fraction B that recorded a slightly lower figure and not the other way round. The 
results of the polycythaemic Epo assay did not follow the expected trend but it must 
be taken into account that both the normocythaemic and polycythaemic assay results, 
despite being the combined estimates of two potencies of independent experiments, 
could not be distinguished with statistical significance since the 95% confidence 
intervals were so wide. It is worth noting, that, as mentioned in Section 1.10, of the 
two in vivo assays, the normocythaemic assay, which gave results which more closely 
followed the expected trend, is considered the more robust in terms of precision and 
accuracy. 
Recorded in vivo activity was higher for each of the four Epo fractions than it was for 
the starting material. The possibility remains that, while the concentration was in each 
case determined by ELISA (Section 2.3.12), the absolute concentration differed from 
that of the starting material. 
3.3.3.4. Glycoanalysis 
Glycoprotein sugars can be analysed by a variety of methods, each of which provides 
a different level of information: 
1. Monosaccharide analysis; 
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2. Glycan analysis - enzyme or chemical release ofN-IO-glycans and analysis by 
various types ofHPLC, followed by identification by mass spectrometry or 
enzyme microsequencing using exo-glycosidases; 
3. Glycopeptide analysis - identification of the site of glycosylation by amino 
acid analysis. 
Technique 2 was used to analyse the sugars liberated from Epo Fractions A-D. 
Fig. 3.3.1S. shows the graphs ofthe derivatised oligosaccharides from each Epo 
Fraction (A-D) as they eluted from a normal-phase (Amide-SO) HPLC column. Mass 
spectrometry was used to identify which sugars were contained within each peak. 
Relative amounts of oligosaccharide in each fraction were quantified by measuring the 
areas under the peaks and expressed as percentage of the total glycans (see 
Table 3.3.5.). A second table (Table 3.3.6) was drawn up containing the moles of 
exposed galactose residues, sialic acids and extra N-acetyllactosamine 
(Gal~ I ~4GlcNAc~ 1 ~3) repeats per mole of glycan found within each fraction. 
This was calculated using the following formula; 
L (% glycan structure)(the number of re si dues conferred by glycan structure in question) 
100 
Proportions oftetra-sialylated tetra-antennary (including or excluding extra 
N-acetyllactosamines), tri-antennary and bi-antennary sugars were also included in 
Table 3.3.6. 
The fractions all contained high levels (about 63-67%) oftetra-antennary 
carbohydrates, around half of which (47-60%) were poly-Iactosaminylated. Just 
under half (34-42%) of the tetra-antennary carbohydrates were fully sialylated and 
there was a tendency for tetra-antennary content (irrespective of tetrasialylation or 
5.0 
25 
o 
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Minutes 
Fig. 3.3.18. Glycan profiles of the ion-exchange HPLC-separated 
Epo Fractions A to D carried out by Dr Yuen (NIBSC), as 
described in Section 2.3.14. 
Please note: sample SpB referred to in Section 3.3.2. was included 
for comparison purposes. 
A 
SpB 
Table 3.3.5. (Facing page) Table of 
percentages of each type of carbohydrate in 
Epo Fractions A to D, calculated by 
measuring the area below each peak in Fig. 
3.3.18. 
The number of sialic acids, exposed 
galactose residues and N -acetyllactosamines 
conferred by each carbohydrate structure are 
also included. 
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I N-gIycan Proposed structure Galactose Sialic 
fraction (number of exposed galactose residues) Residues Acids 
[number ofN-acetyllactosaminesJ Exposed 
1 ? 
2 Monosialylated bi-antennary. 1 1 
3 7 
4 Disialylated bi-antennary 0 2 
5 ? 
6 ? 
7 Disialylated tri-antennary 
1 2 
8 
9 Trisialylated tri-antennary 0 3 
10 Disialylated tetra-antennary 2 2 
11 Disialylated tetra-antennary + N-acetyllactosamine + 2 0 2 N-acetylglucosamine 
12 Trisialylated tetra-antennary 1 3 
13 Trisialylated tetra-antennary & unidentified tetrasialylated 
tetra-antennary structure 
14 Tetrasialylated tetra-antennary 0 4 
15 Trisialylated tetra-antennary + N-acetyllactosamine 1 3 
16 Trisialylated tetra-antennary + N-acetyllactosamine 1 3 
17 Tetrasialylated tetra-antennary + N-acetyllactosamine 0 4 
18 Mix oftetrasialylated tetra-antennary + 
N-acetyllactosamine & trisialylated tetra-antennary + 2 
N-acetyllactosamine 
19 Tetrasialylated tetra-antennary + 2 N-acetyllactosamine 0 4 
20 7 
Extra Fraction Fraction 
N-acetyl A B 
lactosamines % total % total 
0.8 0.9 
0 1.8 1.4 
0.9 2.1 
0 2.3 5.2 
6.7 7.4 
3.3 3.4 
7.3 3.1 
0 
3.9 4.1 
0 8.2 8.1 
0 6.7 6.9 
, 1 5.8 6.5 
0 9.3 9.6 
6.0 5.1 
0 9.6 12.3 
1 7.2 6.4 
1 2.8 2.0 
1 7.6 7.7 
4.0 3.0 
2 4.6 3.5 
0.7 0.4 
Fraction 
C 
% total 
1.4 
2.0 
1.4 
4.5 
7.4 
2.8 
3.5 
3.8 
6.9 
7.4 
8.1 
8.8 
4.7 
17.0 
5.4 
1.9 
8.0 
2.3 
2.8 
0.2 
Fraction 
D 
% total 
1.1 
2.8 
1.6 
4.7 
6.6 
3.3 
4.5 
4.0 
6.6 
7.1 
8.3 
8.3 
4.3 
18.5 
4.9 
2.4 
6.1 
2.4 
2.0 
0.4 
...... 
I\) 
ex> 
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Table 3.3.6. (Facing page) Table of the proportions of each type of 
saccharide or oligosaccharide structure in Epo Fractions A to D. 
-
Oligosaccharide structures (in percentages) were calculated by 
adding up the relevant N-glycan fractions. Saccharide proportions 
(in terms of moles per mole of glycan) were calculated by 
multiplying the percentage of each N-glyan fraction (Table 3.3.5.) by 
the number of exposed galactose residues, sialic acids or extra 
N-acetyllactosamine moieties conferred by the N-glycan fraction's 
structure (as laid out in Table 3.3.5.), taking the sum for all N-glycan 
fractions and dividing by 100 (see Section 3.3.3.4. for equation). 
Mean pI units are provided also (repeated from Table 3.3.4). 
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Proposed structure Epo Epo Epo Epo 
Fraction A Fraction B Fraction C Fraction D 
Tetrasialylated tetra-
antennary 21.8 % 23.5 % 27.8 % 26.6% (including extra N-
acetyllactosamines) 
Tetrasialylated tetra-
antennary 9.6% 12.3 % 17.0% 18.5 % (excluding extra N-
acetyllactosamines) 
Tetra-antennary 
(including extra N- 63.6 % 63 % 66.4 % 64.3 % 
acetyllactosamines) 
Tetra-antennary 
(excluding extra N- 25.6 % 28.8 % 33.2 % 33.9 % 
acetyllactosamines) 
Tri -antennary 
19.4 % 15.3 % 14.2 % 15.1 % 
Bi-antennary 4.1 % 6.6% 6.5% 7.5 % 
Exposed galactose 00457 00404 00402 00411 
residues 
Sialic Acids 2.235 2.253 2.368 2.33 
Extra N- .. 0.326 0.296 0.29 0.257 
acetyllactosamines 
Mean pI value 3.30 3.18 3.13 3.06 
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N-acetyllactosaminylation) to increase in successive eluted fractions. The proportion 
of extra N-acetyllactosamines, by contrast, decreased. 
The proportion oftri-antennary oligosaccharide chains was less than 20% and tended 
to decrease in successive eluted fractions; the figure for bi-antennary chains was even 
lower (less than 10%) but tended to increase. 
Epo Fraction A had the highest number of galactose-terminated branches (around 0.45 
moles per mole of glycan), whereas the other three fractions showed very little 
fraction-to-fraction variation (they were all in the range of 0.40-0.41 moles per mole 
of glycan). For pharmaceutical Epo, the amount of galactose exposure in the different 
eluted fractions did not follow a recognisable trend. 
3.3.3.5. Unmodified AS-E2 and AS-E2IECL bioassays 
Proliferation curves obtained when testing Epo Fractions A-D in the AS-E2/ECL 
bioassays were extremely similar and so potencies (whether from the unmodified 
AS-E2 or the AS-E2/ECL bioassay) were derived from three independent experiments 
using the WRANL program and then combined using the COMPOT program (Section 
2.2.4.1.). Epo Fraction A was selected as the standard with which to calculate relative 
potencies of the other samples. The combined estimates of potency are set out in 
Table 3.3.7a for the unmodified AS-E2 bioassay and 3.3.7b for the AS-E2/ECL 
bioassay. A representative graph from each of the two types of assay (AS-E2 and 
AS-E2/ECL) is shown in Fig. 3.3.19 (a and b respectively). 
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Table 3.3.7. Table ofthe combined estimate of potencies ofEpo 
Fractions A to D (derived from three independent experiments). 
(a) by unmodified AS-E2 bioassay. 
(b) by AS-E2IECL bioassay. 
(a) 
Epo Fraction Potency of sample 95 % Confidence 
relative to interval 
Fraction A 
A 1 -
B 1.023 0.995 - 1.052 
C 1.026 0.998 - 1.055 
D 1.014 0.995 - 1.035 
(b) 
Epo Fraction Potency of sample 95 % Confidence 
relative to interval 
Fraction A 
A 1 -
B 1.068 1.034 - 1.102 
C 1.136 1.100 - 1.173 
D 
-
1.040 1.007 - 1.074 
Fig. 3.3.19. (Facing page) Proliferative response of AS-E2 cells to 
Epo Fractiorls A to D (graphs representative of 3 independent 
experiments). 
(a) by unmodified AS-E2 bioassay. 
(b) by AS-E2IECL bioassay 
Fraction A (_), B (.), C (e) and D (0). In (b), units along the x-axis 
represent the concentrations prior to treatment with ECL. Data 
represent mean +/- s.e.m. of triplicated samples (where an error bar is 
not shown, it lies within the dimensions of the symbol). 
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The four Epo Fractions, A-D, were statistically indistinguishable in the unmodified 
AS-E2 bioassay, with Fractions B, C and D all having 9S% confidence intervals of 
between 0.99 and 1.0S. 
13S 
In the AS-E2/ECL bioassay, Epo Fractions B-D were more potent than Epo Fraction 
A, to a statistically significant degree (P<O.OS), but not statistically different from 
each other. If using a decrease in mean pI as an indication of increase in sialylation, 
and by consequence potency, Epo Fractions A, Band C (mean pI values of3.296, 
3.18 and 3.126 respectively) followed the expected trend of increasing in relative 
potency (if A was set as 1, B was 1.068 and C was 1.136). Epo Fraction D did not fit 
in with this pattern, however, having a potency lower than both B and C (1.04), 
despite its mean pI value being the lowest, atJ.063. Consequently, it would perhaps 
be expected to have the highest number of sialic acids - and therefore (but not 
necessarily), the lowest number of exposed galactose residues - and be the least likely 
to be depleted in the agarose-conjugated ECL step. Surprisingly, glycoanalysis 
registered Fraction D as having more exposed galactose residues than Fractions B and 
C (see Table 3.3.6.) and so the observed lower activity was in agreement in that 
respect. 
The AS-E2/ECL assay has been rationally designed to be responsive to the exposure 
of galactosyl residues. Sample set 1 proves that it is. Here, however, there is not a 
clear-cut relationship between mean pI and the number of exposed galactoses, and 
therefore there cannot be expected to be one between AS-E2/ECL activity and pI. 
Also, unlike sample set 1, there was no strongly defined relationship between pI and 
in vivo activity. So for this sample set derived from a pharmaceutical batch of Epo, it 
can be postulated that whatever was causing the isoform distribution, and presumably 
variation in activity, was not to do with exposed galactose residues. 
3.3.3.6. Correlation of in vivo and in vitro bioactivity with non-biological data 
(IEF and glycan mapping) 
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Pearson correlation analysis was performed using Minitab to compare the results 
obtained by the two in vivo assays with the proportions of each sugar deduced in 
Table 3.3.6. The results are in Table 3.3.8. Before commenting on the correlations, it 
must be mentioned that, because of the small sample size, these statistics must be 
interpreted with caution. In addition, the results of the polycythaemic and the 
normocythaemic Epo mouse bioassays correlated with a Pearson correlation 
coefficient of 0.764. This is perhaps not as high as would be expected from two 
assays measuring the same property of the same hormone. The lower than expected 
correlation may be attributed to the small number of sample sets being measured, the 
relative similarity between the samples being tested in terms of mean pI, and the low 
level of precision afforded by the method used to test them. 
There was also a problem in that N-glycan fractions 13 (trisialylated tetra-antennary 
and unidentified tetrasialylated tetra-antennary structures) and 18 (mix of 
tetrasialylated tetra-antennary structures including one N-acetyllactosamine, and 
trisialylated tetra-antennary structures including two N-acetyllactosamines) identified 
by glycoanalysis (see Table 3.3.5.) were made up of more than one species of 
oligosaccharide, thereby adding to the uncertainty as to what the proportions of each 
individual sugar are. These two N-glycan fractions were omitted from calculations 
assessing saccharide content but could nevertheless make crucial differences to the 
figures in Table 3.3.6. 
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Polycythaemic Normocythaemic Mean pI 
mouse assay mouse assay value 
R value 
(P-value) 
Tetrasialylated tetra-antennary 0.777 0.925 -0.872 
carbohydrates (extra N- (0.223) (0.075) (0.128) 
acetyllactosamines included) 
Tetrasialylated tetra-antennary 0.617 0.959 -0.964 
carbohydrates (extra N- (0.383) (0.041) (0.036) 
acetyllactosamines excluded) 
Tetra-antennary carbohydrates 0.982 0.938 -0.439 
(extra N -acetyllactosamines (0.018) (0.062) (0.561) 
included) .. 
Tetra-antennary carbohydrates 0.620 0.736 -0.967 
(extra N -acetyllactosamines (0.380) (0.264) (0.033) 
excluded) 
Tri-antennary carbohydrates -0.387 -0.645 0.870 
(0.613) (0.355) (0.130) 
Bi-antennary carbohydrates 0.169 0.673 -0.959 
(0.831) (0.327) (0.041) 
Exposed galactose residues -0.229 -0.507 0.811 
(0.771) (0.493) (0.189) 
Sialic acids 0.863 0.930 -0.798 
(0.137) (0.070) (0.202) 
Extra N -acetyllactosamines -0.254 -0.806 0.973 
(0.746) (0.194) (0.027) 
Mean pI value -0.4 -0.855 -
(0.6)- (0.146) 
Table 3.3.8. Measurement of association between the in vivo assays 
. 
(polycythaemic and normocythaemic) and carbohydrate proportions identified 
by glycoanalysis, using Pearson correlations. 
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Subject to these caveats, it may perhaps be said that the normocythaemic assay can 
provide the most useful results since, as mentioned in Section 3.3.3.3., it is the more 
accurate and precise of the two in vivo assays. 
The proportion of tetrasialylated tetra-antennary sugars has been shown to correlate 
strongly with the in vivo biological activity ofEpo (Yuen et ai, 2003). What is 
immediately apparent is that the in vivo assays described here, in particular the 
normocythaemic assay, exhibit a positive correlation with the proportion of tetra-
antennary carbohydrates, regardless oftetrasialylation or poly-Iactosaminylation, the 
majority of the correlation values being above 0.7. The fact that this correlation held 
true even if sialylation was not taken into account may be explained by the fact that if 
there is a tendency to have more branching then there is also a tendency to have more 
sialylation, as indicated by the positive correlation between tetrasialylated tetra-
antennaryand all tetra-antennary sugar content (R=0.82 1 , P=0.179). 
There was no correlation between in vivo activities and tri-antennary carbohydrate 
content: R values for both assays were >-0.7, in agreement with Yuen et al (2003) 
who found no positive correlation between these two variables. It was the same case 
for comparisons with bi-antennary content, i.e. R values were <0.7. 
Surprisingly, there was little to no correlation between exposed galactose residues and 
either of the in vivo Epo bioassays (R=-0.507 and R=-0.229 for the normocythaemic 
and polycythaemic assays respectively). Mean pI value negatively correlated 
(R=-0.855, P=0.146) and sialic acid positively correlated (R=0.93, P=0.070) with the 
normocythaemic assay, pI and sialic acid being two variables that are arguably, 
although not necessarily, linked to galactose exposure (it being possible for there to be 
low levels of both branching and sialylation and yet still sialylation of all termini). 
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The presence of extra N-acetyllactosamines appeared to have an adverse effect on 
biological activity as measured by the normocythaemic assay (R=-0.855, P=O.l46). 
The in vivo results in Figs. 3.3.16-17. and the figures in Table 3.3.6. then underwent 
correlation analysis with the results obtained by the two in vitro cell-based assays (see 
Table 3.3.9.). The AS-E2/ECL bioassay did not correlate with either the 
normocythaemic (R=0.467, P=0.533) or the polycythaemic (R=0.615, P=0.385) 
mouse Epo bioassay, although it did negatively correlate with the number of exposed 
galactose residues (R=-0.790, P=0.21O), the variable the assay was designed to assess. 
The unmodified AS-E2 assay correlated even more strongly with the number of 
exposed galactose residues than did the AS-E2/ECL assay (R=-0.964, P<0.05) but this 
is not reliable as the relative potencies were statistically indistinguishable from each 
other. 
3.4. Discussion 
One of the aims of this project was to set up a cell-based bioassay for Epo, one step of 
which involved the incorporation of a plant lectin whose role was to mimic the action 
of the liver. Plant lectins are proteins with highly specific sugar-binding properties. 
One such lectin, Erythrina crista-galli lectin (ECL), has the same binding specificity 
(i.e. galactose residues) as the ASGP-R (Bhattacharyya et aI, 1989), although the two 
proteins do not share any sequence homology (Loris, 2002). In this assay, any Epo 
displaying carbohydrate structures terminating in galactose residues was bound to 
ECL-agarose and then removed by centrifugation (as outlined in Fig. 3.1.1.). The 
resulting supernatant was then tested in a cell proliferation assay using the AS-E2 
Epo-dependent cell line. The rationale was that samples containing a higher 
proportion of desialylated Epo would be depleted of more Epo molecules and thus 
140 
Table 3.3.9. Measurement of association between the in vitro assays (AS-E2 
and AS-E2IECL), in vivo assays (polycythaemic and normocythaemic) and 
carbohydrate proportions identified by glycoanalysis, using Pearson 
correlations. 
AS-E2 bioassay AS-E2IECL 
bioassay 
--
R value 
(P-value) 
Polycythaemic 0.268 0.615 
mouse assay (0.732) (0.385) 
Normocythaemic 0.377 0.467 
mouse assay (0.623) (0.533) 
Exposed galactose -0.964 -0.790 
residues (0.036) (0.210) 
Sialic acids 0.604 0.751 
(0.396) (0.249) 
Mean pI value -0.650 -0.511 
(0.350) (0.489) 
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stimulate less cell proliferation. All samples were also tested in the unmodified 
AS-E2 bioassay to verify that initial concentrations and activities were the same, and 
that differences in the AS-E2/ECL bioassay were not due to such discrepancies. 
The first sample set subjected to the AS-E2/ECL assay was Epo desialylated using 
agarose-conjugated neuraminidase. Using a solid-phase version of this enzyme meant 
that termination of the reaction could be controlled more precisely (only a simple 
spin-down step is required) and there was no need to use inhibitors. 
The standard cell-based assay employed alamarBlue to measure metabolic activity. It 
was not strictly a proliferation assay in the same way as the tritiated thymidine 
incorporation or BrdU proliferation methods, which both measure DNA synthesis. 
However, the alamarBlue assay was seen as a proliferation assay in the sense that an 
increase in metabolic activity was indicative of a greater number of cells, which could 
be due to an increase in proliferation or an increase in cell survival (Epo stimulating 
both proliferation and survival pathways (reviewed in Ghaffari et at, 2003». 
The AS-E2/ECL bioassay included a pre-incubation step with solid-phase lectin, as 
simply adding ECL to the wells during the course of the assay did not give the same 
results. ECL did not act as a competitive antagonist (Fig. 3.3.8.). This was consistent 
with findings that residues involved in receptor binding do not overlap glycosylation 
sites. Asn147, Arg150, Gly151, Thr4o_Lys52 form the first, high-affinity receptor binding 
site and Val 11 , Argl4, Tyr15, Ser lOO, Arg103, Ser104 and Leu lO8 form the second, 
low-affinity receptor binding site (Cheetham et at, 1998). Site-directed mutagenesis 
studies found the following four regions to be important for bioactivity: amino acids 
11-15, 45-51, 100-108 and 147-151 (Elliott et at, 1997), none of which were 
glycosylation sites. 
The in vivo mouse assay for Epo was extremely sensitive to desialylation, as a 
comparison between untreated Epo and the slightly desialylated Epo sample 
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(t=20 min) will readily show. Loss of sialic acids corresponding to a shift of just 0.3 
mean pI units resulted in a 73% reduction in biological activity using the 
polycythaemic mouse bioassay (see Fig. 3.3.7.). The modified in vitro AS-E2/ECL 
bioassay was less sensitive, measuring only a 29% decline in biological activity. We 
can speculate as to the reasons for this discrepancy. The liver is one of the largest 
organs in the body and constitutes a major reservoir of asialoglycoprotein receptors. 
Exposure of just 1 or 2 galactose residues per molecule of Epo could be enough to 
allow the liver to remove Epo from the circulation. Indeed, Van Den Hamer et al 
(1970) predicted that ferroxidase (a copper transport glycoprotein found in the blood) 
would require only two galactose residues to be exposed in order to effect clearance. 
In the in vitro agarose-conjugated ECL system, however, a critical number of 
galactose residues appeared to need to be exposed on Epo before it was efficiently 
removed but once that number was reached, the system became especially adept at 
depleting the solution of such molecules. 
A similar difference in loss in sialylation between the Epo Fractions separated by 
anion-exchange chromatography (indicated by a 0.24 mean pI unit difference between 
Fractions A and D) did not result in such a large drop in in vivo activity. Instead of the 
73% drop observed for Epo sample t=20 min compared to t=O min, there was only a 
25.5% drop (by normocythaemic assay) between Fractions A and D. It may be that 
changes in sialylation ofEpo molecules at a certain threshold level of sialylation, 
around pI values of3.0 units, do not affect activity to such an extent. Morimoto et al 
(1996) found that there was no further increase in the activity of Epo fractions 
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separated by anion-exchange which had more than 12.4 moles sialic acid per mole of 
Epo. 
In the anion-exchange separated third sample set, an increased number of extra 
N-acetyllactosamines coincided with decreased biological activity. 
Poly N-acetyllactosamine repeats have, in addition to the number of exposed 
galactoses, been implicated in clearance by the ASGP-R (Fukuda et aI, 1989). Doubts 
can be cast on this finding, though, as tomato lectin, having a preference for 
N-acetyllactosamine repeats, was used to isolate glycoproteins containing a higher 
proportion of them. This enriched fraction was then used in in vivo assays and found 
to be cleared more rapidly from the circulation, even though tomato lectin also tends 
to bind non-sialylated sugars rather than sialylated sugars (Merkle & Cummings, 
1987). In the case of the anion-exchange separated Epo Fractions, 
N-acetyllactosamine repeats associated with exposed galactose residues with a 
correlation coefficient of R =0.702 (P=0.298). It could have been a matter of exposed 
galactose residues mediating clearance by the ASGP-R of the liver rather than 
anything to do with N-acetyllactosamine repeats. 
Epo Fraction D had slightly more galactose residues exposed than Fraction C 
(approximately an extra 0.01 mole of galactose per mole of glycan) and fewer sialic 
acids, something which might not have been expected in the case of the most acidic 
sample (based on the IEF gel). The possibility cannot be ruled out, therefore, that 
unintentional sugar degradation, for instance by contamination with glycosidases, may 
have occurred in this fraction. 
Each set of samples used in this study represented different types of material that 
might be encountered when assessing the quality of Epo for batch release. Sample 
set 1 represented Epo that might possibly have been exposed to neuraminidase (e.g. in 
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Table 3.4.1. Methods that can detect changes in isoform distribution and an 
assessment of how sensitive they were when performing tests on each of the 
three Epo sample sets. 
Sample set 1 Sample set 2 Sample set 3 
(neuraminidase (different (ion-exchange 
treated) culture. and fractionated 
purification pharmaceutical 
conditions) grade Epo) 
In vivo assay -/-/-/ -/-/ x 
In vitro AS-E2 x x x 
assay 
In vitro -/-/ -/ x 
AS-E2/ECL 
assay 
IEF -/-/ -/-/ -/-/ 
Glycan Not applied -/-/-/ -/-/-/ 
mapping 
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the fonn of a culture medium/serum contaminant); sample set 2 represented Epo that 
had been generated by different culture and purification methods; and sample set 3 
was intended to reflect the range of isofonns that could possibly be present in a single 
batch of phannaceutical-grade Epo. Table 304.1. lists the methods available for 
detecting changes in isofonn distribution and describes how, in tenns of sensitivity, 
they perfonned during tests on each of the three sample sets. In vivo assays 
differentiated with statistical significance between the different samples within set 1. 
These types of assay were less successful in discriminating between the fractions in 
sample sets 2 and 3. This can be explained by these sample sets spanning a narrower 
range of mean pI values. 
As expected, the unmodified AS-E2 assay failed to differentiate between the samples 
in any of the sample sets. 
The modified AS-E2/ECL assay was able to reveal differences in activity between the 
samples within sample set 1 and, to a lesser extent, within sample set 2. The samples 
in sample set 3 were all but indistinguishable using this technique. 
While IEF had the ability to detect variation within all sample sets, it was unable to 
provide the same level of detailed infonnation as glycan mapping. 
3.S. Conclusion 
A variety of methods are available for measuring or predicting Epo bioactivity. This 
chapter describes how a non-radioactive cell-based assay for Epo has been developed 
that incorporates an immobilised fonn of the galactose-binding plant lectin, ECL, thus 
rendering the assay sensitive to sialic acid content. This assay was tested alongside an 
established array of techniques to evaluate their sensitivity in distinguishing between a 
range of different Epo sample sets: experimentally desialylated Epo; Epo produced by 
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different culture and purification procedures; and a batch of pharmaceutical-grade Epo 
separated into fractions by anion-exchange HPLC. The strategy of developing an 
Epo-dependent sialylation-sensitive cell-based bioassay worked particularly well 
when assaying sample set 1, which was designed to vary only in terms of sialylation 
level. Sample set 3, however, revealed a limitation in that although pharmaceutical 
Epo separated into fractions by anion-exchange HPLC could be differentiated in terms 
ofisoform distribution by IEF, it was not distinguishable by AS-E2/ECL assay. The 
in vivo assays fared little better in this respect, and sialic acid/galactose content did not 
correlate well with mean pI. The invariance in galactose content provided an 
explanation for the insensitivity of the modified Epo bioassay. 
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Chapter 4. Development of a sialylation-sensitive cell-based 
bioassay; stable transfection of an Epo-dependent cell line 
with the asialoglycoprotein receptor 
Summary and Overview 
Chapter 4 describes the development of a sialylation-sensitive in vitro assay by stable 
transfection of an Epo-dependent cell line with a vector encoding the 
asialoglycoprotein receptor. It features the following sequence of studies: 
(i) Isolation of cDNAs encoding the two subunits of the asialoglycoprotein receptor 
(ASGP-R) and vector construction (Sections 4.2.1., 4.2.2., 4.3.1., and 4.3.2.); 
(ii) Detection of vector-driven ASGP-R expression by Western blot and fluorescence 
microscopy (Sections 4.3.4. and 4.3.5.); 
(iii) Comparison of the potencies of intact and desialylated Epo obtained in assays 
employing untransfected/empty vector-transfected and asialoglycoprotein 
receptor-transfected Epo-dependent cells (Section 4.3.6.1); 
(iv) Demonstration of the galactose-inhibitability of the sialylation-sensitive effect 
(Section 4.3.6.2.); 
(v) Discussion of the results (Section 4.4). 
4.1. Introduction and aims of the study 
While the AS-E2/ECL lectin bioassay described in Chapter 3 provides evidence to 
back up the principle that rational manipulation of in vitro bioassays can in some 
circumstances allow prediction of in vivo activity, it does have a number of 
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drawbacks: the lectin pre-incubation step needed prior to serial dilutions of samples 
being made brings with it additional inherent errors; lectin-to-agarose coupling 
efficiency may well vary between batches; and plant lectin is arguably "artificial", 
bearing little relevance to in vivo physiological processes. The aim of the work 
described in this chapter was to copy more closely what happens in the body by 
introducing the liver receptor responsible for clearing incompletely sialylated 
glycoproteins from the circulation into an Epo-dependent cell line. Such a receptor 
would effectively sequester and internalise Epo containing exposed galactose residues, 
thus competing with the Epo-R and precluding this population of cytokine molecules 
from transmitting a proliferation signal (see Fig. 4.1.1. for a schematic representation 
of the decoy strategy). Decoy receptors already exist in nature; they include a 
truncated Epo-R lacking cytosolic signal transduction domains (Nakamura et ai, 
1992;Nakamura & Nakauchi, 1994), the murine Interleukin-l type II receptor, which 
has been hypothesised to be a surface receptor that blocks the ability of cells to 
respond to IL-l (Donaldson et ai, 1998), and TRID (TRAIL receptor without an 
intracellular domain), a receptor for TRAIL (Tumor necrosis factor-related 
apoptosis-inducing ligand) that consists of a TRAIL-binding extracellular domain and 
a transmembrane domain but that lacks an intracellular domain. The latter is thought 
to act as a decoy receptor for TRAIL, thus protecting the cell from TRAIL-induced 
apoptosis (Pari et ai, 1997). 
As stated in the introduction, the ASGP-R is a type II membrane receptor. Instead of 
having an N-terminal signal sequence that navigates the polypeptide through the 
cell-surface membrane, as in type I receptors, the ASGP-R contains a transmembrane 
domain that acts as an internal signal sequence, directing the C-terminal domain to 
appear on the outside of the cell (Spiess & Lodish, 1986). Consequently, its structure 
Fig. 4.1.1. (Facing page) Schematic representation of the decoy receptor 
strategy. Epo, regardless of the sialic acid content, binds the Epo-R, but 
Epo lacking terminal sialic acids will also bind the asialoglycoprotein 
receptor (ASGP-R), effecting the removal of this population of molecules 
from the surrounding medium and lowering the concentration. 
149 
o 
~. 
• • 
Asialogl ycoprotein 
receptor 
o Epa 
• Sialic acid 
~. 
• • o o 
~. 
• • 
-No signal transduction 
-Internalisation and 
degradation of bound 
ligand 
o ~. • • 
~. 
• • o 
Epo 
receptor 
Signal 
transduction 
-" 
0'1 
o 
151 
consists of a cytosol-facing NH2-tenninal domain, a single-span transmembrane 
domain, an extracellular stalk region and a carbohydrate recognition domain that binds 
tenninal galactose or N-acetylgalactosamine residues. 
It is composed of two subunits (HI and H2) encoded by two separate genes. HI can 
function on its own but not as effectively as when the H2 sub-unit is also expressed 
(Braitennan et ai, 1989). For optimal binding efficacy, therefore, it was imperative 
that Epo-dependent cells be stably transfected with genes for both subunits. 
While HI is invariant, H2 is reported to exist as at least three splice variants (Paietta et 
ai, 1992, differing in the presence or absence of a 57-nucleotide and a I5-nucleotide 
insert. The H2a splice variant contains a 57-nucleotide and a 15-nucleotide insert, the 
fonner encoding a 19 amino acid cytoplasmic region, whereas the latter corresponds 
to a 5-residue motif, Glu-Gly-His-Arg-Gly (ToIchinsky et ai, 1996), that lies 
immediately C-tenninal to the membrane-spanning domain. The 5 amino acid insert 
is a cleavage signal that results in proteolysis and secretion of the H2a ectodomain. If 
the 5 amino acid insert is not removed by cleavage, H2a is retained and degraded in 
the endoplasmic reticulum (Tolchinsky et ai, 1996). H2b contains the 19 amino acid 
insert in the cytoplasmic domain but lacks the 5-residue insert at the exoplasmic end 
of the transmembrane domain. H2c lacks both inserts. 
In contrast to H2a, both H2b and H2c reach the cell surface and are oligomerised with 
HI in ASGP-R complexes. According to immunoprecipitation studies focusing 
specifically on H2b, however, they are not in the same ASGP-R complex (Yik et ai, 
2002). In spite of this, they have similar binding affinities for asialo-alpha-l-acid 
glycoprotein, endocytose and degrade 'asialo-alpha-I-acid glycoprotein at similar 
~ 
rates, and have ligand-bound complexes that dissociate at a similar pH (Yik et ai, 
2002). In addition, the presence or absence of the 19 amino acid insert does not affect 
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palmitoylation ofH2 at cysteine residues 54 and 58. Yik et ai speculate that H2b and 
H2c may be involved in different endocytic pathways, of which there are two: the 
State 1 and the State 2 pathways. In the State 2 pathway, internalised ligand is 
dissociated more rapidly (Oka & Weigel, 1983). It is thought that phosphorylation 
increases the rate of endocytosis and that the 57-nucleotide insert, found in H2b but 
not in H2c, is necessary for serinel2 phosphorylation (Paietta et ai, 1992a;Geffen et ai, 
1991). Accordingly, since the H2b subunit is thought to mediate a faster rate of 
endocytosis, it was chosen, along with the HI subunit, for co-expression in an 
Epo-dependent cell line. 
4.2. Experimental procedures 
4.2.1. peR-amplification of first-strand cDNA and cloning of the ASGP-R 
Messenger RNA was extracted from the liver cell line Hep-G2 (Knowles et ai, 1980), 
followed by first-strand cDNA synthesis as described in Sections 2.1.1. and 2.1.2. 
The ASGP-R HI and H2 subunits were PeR-amplified with primers designed 
according to the published sequences in the GenEMBL database. The HI, H2a and 
H2c subunit Accession numbers are E12702, X55284 and E12703 respectively. Since 
the H2b subunit had not been submitted to the database, it was deduced from the 
literature (Yiket ai, 2002). The same primer pair is suitable for all the H2 splice 
variants, as any differences in sequence are some distance away from the 5' and 3' 
ends. 
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The following primers were used: 
Primer name Primer sequence Restriction site 
HI-5' (forward) 5' -gacgatgctagccagccctatcatgaccaaggagta-3' -NheI underlined 
HI-3' (reverse) 5' -gacgatacgcgtttaaaggagaggtggctcctggct-3' -MluI underlined 
H2-5'(forward) 5' -gacgattctagagggccccatcatggccaaggactt -3' -XbaI underlined 
H2-3' (reverse) 5' -gacgatgcggccgctcaggccacctc gccggtggca-3' -NotI underlined 
The primers had recognition sites for restriction enzymes introduced (underlined) that 
enabled ligation into the vector pIRES. 
PCR-amplification of HI produced an expected product of875 bp. Amplification of 
H2 produced a product of approximately 933 bp (see Fig. 4.2.1. for the DV 
photographic record). These PCR products were ligated into pGEM-T (Promega) as 
described in Section 2.1.4., transformed into JM109 E. coli cells (Section 2.1.5.) and 
digested by the relevant restriction endonuclease (see Table above) and separated on 
1 % agarose gels (Section 2.1.9.) to check for correct-sized inserts. 
4.2.2. Identification of the H2b splice variant 
Analytical peR was performed on the H2 clones in order to identify the H2b splice 
variant; 
Name Primer sequence 
57-5' (forward) 5' -gggccccatcatggccaaggactt-3' 
57-3' (reverse) 5' -gaggagctccatctggcaggccac-3' 
Primers 57-5' and 57-3' enabled dIfferentIatIOn between clones In whIch the 57 bp 
insert was present (H2b) and those in which it was absent (H2a and H2c). 
123456 M 
bp 
~ 1000 
~ 750 
Fig. 4.2.1. peR amplification of ASGP-R HI (expected product 
size=-875 bp) and H2 (expected product size=-931 bp) subunits using the 
listed primers and HepG2 first-strand cDNA as a template. Ethidium 
Bromide-stained 1 % agarose gel loaded as follows: 
-Lane 1; primers HI-5' and HI-3' (2J..lM final concentration). 
-Lane 2; primers HI -5' and HI-3' (20 J..lM). 
-Lane 3; primers H2-5' and H2-3' (2J..lM). 
-Lane 4; primers H2-5 ' and H2-3 ' (20 J..LM). 
-Lane 5; positive control ~-actin primers 2 J..lM. 
-Lane 6; beta actin primers alone. 
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Primer 57-5' recognised a region 64 bp upstream of the potential site of the 57 bp 
insert, while primer 57-3' formed complementary base pairs with a site 340 bp 
downstream. 
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The presence of the 57 bp insert in a clone resulted in a 480 bp peR fragment being 
produced while its absence produced a 423 bp fragment. These peR products were 
separated on a slightly higher percentage of agarose gel {1.5%) in order to facilitate 
differentiation between differences in size on so small a scale. 
Primers 15-5' and 15-3' were used to differentiate between clones that contained the 
extra 15 bp insert (H2a) and those that did not (H2b and H2c). 
Name Primer sequence 
15-5' 5.' -aaagtgagggtcacagaggtgcac-3' 
15-3' 5' -tcaggccacctcgccggtggcatt-3' 
The strategy used for detecting the presence of the 57 bp insert could not be used for 
the 15 bp insert, since a difference of just 15 nucleotides is too small to be seen on an 
agarose gel. Instead, primer 15-5' was designed to recognise the extra 15 bp insert 
while primer 15-3' was complementary for a region 656 bases downstream of the 
mini-exon. If a clone contained the 15 bp insert, a 704 bp peR fragment (including 
primers) was produced. Absence ofa peR fragment indicated absence of the 15 bp 
insert. There was admittedly a greater risk of false negative results (for instance if the 
peR reaction failed) but, with this in mind, all clones were further verified by 
sequencmg. 
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4.2.3. Plasmid construction 
Clones identified as containing the correct HI and H2b sequences were sub-cloned 
into the pIRESblast mammalian expression vector (described in Section 2.2.3.2.). 
This was achieved in two steps, the first being ligation into the pIRES vector 
(Clontech), resulting in the pIRES(HI-IRES-H2b) construct. The pIRES vector (as 
distinct from the pIRESblast vector) contains two mUltiple cloning sites separated by 
an Internal Ribosome Entry Site (IRES) sequence, its purpose being the co-expression 
of two genes of interest. This vector was not considered suitable for stable 
transfections, though, as the selectable marker is not coexpressed with the genes of 
interest. 
The second step was PCR-amplification o/the entire tripartite cassette, designated 
Hl-lRES-H2b, with primers incorporating CIa! and EcoRI restriction ends: 
Name Primer sequence Restriction site 
ClaI-HI-5' 5' -gac gatatcgatcagccctatcatgaccaaggagta-3' -ClaI underlined 
EcoRI-H2b-3' 5' -gacgatgaattctcaggccacctcgccggtggca-3' ~EcoRI underlined 
Apart from having different restriction sites, primers ClaI-HI-5' and EcoRI-H2b-3' are 
identical to primers HI-5' and H2-3' respectively. 
The -2.4 Kbp ClaI-HI-IRES-H2b-EcoRI fragment produced by PCR (see Fig. 4.2.2.) 
was TA-cloned into PGEM-T, checked by nucleotide sequence analysis and then 
ligated into the multiple cloning site of pIRESblast between restriction sites ClaI and 
EcoR!. A clone with the correct insert was isolated and designated p[HI-IRES-
H2b]IRESblast. An endotoxin-free maxi~prep batch ofp[HI-IRES-H2b]IRESblast 
was prepared using the EndoFree Plasmid Maxi Kit (Qiagen) and used in stable 
transfections. 
bp 
3000 ~ 
2000 ~ 
M 1 2 
Fig. 4.2.2. peR amplification of [ASGP-R-Hl]-[IRES]-[ASGP-R-H2b] 
with EcoRI and Clal restriction ends using the listed primers and 
pIRES(HI -IRES-H2b) as a template. Ethidium Bromide-stained 1 % 
agarose gel loaded as follows: 
-Lane 1; Clal-HI-5' and EcoRI-H2b-3' primers (2 JlM final 
concentration). 
-Lane 2; Clal-HI -5' and EcoRI-H2b-3' primers (20 JlM). 
Expected product size = -2600 bp 
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4.2.4. Expression of immunoactive ASGP-Rs: Western blotting 
Western blots using an anti-ASGP-R-HI antibody (Calbiochem) were performed in 
order to check expression ofthe ASGP-R in stably transfected cells (Section 2.3.5.). 
A Western blot using an anti-tubulin antibody (Santa Cruz Biotechnology, USA) was 
carried out in order to check protein loading. 
4.2.5. Expression of functional ASGP-R: binding of fluorophore-Iabelled 
asialo-alpha-l-acid glycoprotein 
Fluorescence microscopy was carried out as described in Section 2.3 .13. to determine 
whether cells stably transfected with the ASGP-R were capable of binding an 
asialoglycoprotein (asialo-alpha-I-acid glycoprotein). 
4.2.6. Bioassays 
Bioassays were performed (as in Section 2.2.4.) using the AS-E2 cells that had been 
stably transfected with the ASGP-R-HI and -H2b subunits. Untransfected AS-E2 
cells or AS-E2 cells stably transfected with empty vector were used as the control. 
In a set of experiments to investigate the effect of ASGP-R inhibitors on the cell 
assays, desialylated alpha-I-acid glycoprotein (120 IlM) or lactose (100 mM) were 
included in the assay medium at an excess concentration (IOO,OOOx in the case of 
desialylated alpha-I-acid glycoprotein). 
4.2.7. Plate plan 
Fig. 4.2.3. shows a typical plate plan used in the 96-well bioassays. 
Fig. 4.2.3. Plate plan for stably transfected cell-based Epo bioassay. Wells 
marked "U" contain untransfected AS-E2 cells or empty vector-transfected 
cells, while wells marked "T" contain lectin-transfected AS-E2 cells. Blue 
wells contain dilutions of non-neurarninidase-treated Epo untreated with 
neuraminidase (sample t=O min), whereas red wells contain neuraminidase-
treated Epo (sample t=20 min, sample t=480 min or sample t=1800 min). 
The top dose (1) corresponds to 0.33 nM. Grey outer wells contain medium 
only. 
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4.3. Results 
4.3.1. Verification ofp[Hl-IRES-H2bJIRESblast by seguencing 
A map ofthe intended p[HI-IRES-H2b]IRESblast vector is shown in Fig. 4.3.1 along 
with the primers used to confirm by sequencing that the construct was correct. 
4.3.2. The H2b splice variant was identified using analytical primers 
An issue encountered was the requirement to identify the H2b splice variant amongst 
the other possible variants. This was done using primer pairs 57-5'/57-3' and 
15-5'/15-3' (Section 4.2.2.). Fig. 4.3.2. shows the splice variants ofthe ASGP-R-H2 
sequence and the sites of primers used for splice variant identification. Analytical 
PCR was performed on ASGP-R-H2 cDNA-containing pGEM-T mini-prep DNA (see 
Fig. 4.3.3a for a photograph of the PCR-amplified bands, and Fig. 4.3.3b for an 
interpretation of the results). Clones were obtained of the four possible splice 
variants: H2a, H2b and H2c, plus the H2 splice variant - unnamed in the literature -
that lacks the 57 bp but not the 15 bp insert. Another putative splice variant, which 
lacks 174 bp instead of 57 bp (and unmentioned in the literature), was also identified 
(clone 1 in Fig. 4.3.3.). 
p[H1-IRES-H2b]IRESblast 
7296 bp 
c 
Fig. 4.3.1. The design of the intended vector and the primers used for 
verification by sequencing 
Primers: Primer sequence (5' end): 
5' 3' 
~ cgcttttgagagggagtactc 
IT=) gaggagctccatctggcaggccac 
caactcacaac gtggcactg 
cgactcactatagggagacc 
Fig. 4.3.2. (Facing page) Asialoglycoprotein receptor H2 subunit sequence, 
showing the different possible splice variants and primers used for their 
identification. 
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The 57 bp and 15 bp inserts are highlighted in yellow and green respectively. 
The primers used for identification of the 57 bp and 15 bp insert are shown as 
red and blue arrows respectively. The conserved splice donor (GT) and splice 
acceptor (AG) sites present in the intron borders are shown in bold type. The 
174 bp insert spliced out in one clone (underlined) is referred to in the 
discussion. The transmembrane domain is encoded by bases 372 to 435. 
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1 CTGCGGGAGC CAGGCGTCCG CTCTCCACAC CTITCACAGA TCCTACCCAG 
51 GCCACCACCC CGAACCCCTC CGACCCTGCG TTCCATCCCA CCATCAACCT 
101 CCACGTGAAT CTGCACCTCT GCCCCAGCCC CAGCCCTCAG AGCAACCTCA 
Start 
151 GCCCAGCCCA GCCCAGCTCC AGCTCCAGCT CCAGCCCGGG CCCCA TCA TG 
" 201 GCCAAGGACT TTCAAGAT AT CCAGCAGCTG AGCTCGGAGG AAAATGACCA 
251 TCCTITCCAT CAAGGTGAGG GGCCAGGCAC TCGCAGGCTG AATCCCAGGA 
301 GAGGAAATCC ATTTITGAAA GGGCCACCTC CTGCCCAGCC CCTGGCACAG 
351 CGTCTCTGCT CCATGGTCTG CTTCAGTCTG CTTGCCCTGA GCTTCAACAT 
451 u,--r",--r1. GCTGCAAGCC GAGCTGCGGA GCCTGAAGGA AGCTITCAGC 
501 AACTTCTCCT CGAGCACCCT GACGGAGGTC CAGGCAATCA GCACCCACGG 
551 AGGCAGCGTG GGTGACAAGA TCACATCCCT AGGAGCCAAG CTGGAGAAAC 
601 AGCAGCAGGA CCTGAAAGCA GATCACGATG CCCTGCTCTT CCATCTGAAG 
,< 
65 1 CACTTCCCCG TGGACCTGCG CTTCGTGGCC TGCCAGA TGG AGCTCCTCCA 
701 CAGCAACGGC TCCCAAAGGA CCTGCTGCCC CGTCAACTGG GTGGAGCACC 
75 1 AAGGCAGCTG CT ACTGGTTC TCTCACTCCG GGAAGGCCTG GGCTGAGGCG 
801 GAGAAGT ACT GCCAGCTGGA GAACGCACAC CTGGTGGTCA TCAACTCCTG 
85 L GGAGGAGCAG AAATTCA TTG T ACAACACAC GAACCCCTTC AAT ACCTGGA 
901 TAGGTCTCAC GGACAGTGAT GGCTCTTGGA AATGGGTGGA TGGCACAGAC 
951 TATAGGCACA ACT ACAAGAA CTGGGCTGTC ACTCAGCCAG AT AA TTGGCA 
1001 CGGGCACGAG CTGGGTGGAA GTGAAGACTG TGTTGAAGTC CAGCCGGATG 
105] GCCGGCTGGA ACGATGACTT CTGCCTGCAG GTGT ACCGCT GGGTGTGTGA 
,< 
1101 GAAAAGGCGG AATGCCACCG GCGAGGTGGC CTGACCCCAG CACACCTCTG 
Stop 
1 15] GCT AACCCA T ACCCCACACC TGCCCAGCTC TGGCTTCTCT GTTGAGGA TT 
120] TTGAGGAAAG GAAGAAACAC TGAGACAGGG GTATGGGGAA GAGCTGAGCA 
125 1 AAGAGAGAAA GGAGGTAGTT TAAGAGTCCC TGACCCTGGA GGACTGAGAT 
1301 CCCACCTCCT TCTGT AA TTC A TTGT AA TT A TT A T AA TCGT CAGCCTCTTC 
] 351 AA TGGCGTAG GAAAGAAGAA ACAAATGCTT GA 
Fig. 4.3.3. (Facing page) Splice variant identification of ASGP-R H2 
clones. 
(a) Analytical PCR of ASGP-R-H2 cDNA clones. Ethidium Bromide-
stained 1 % agarose gel loaded as follows: 
-Lanes 1-6; Clones 1-6 PCR amplified with primers 57-5' & 57-3' to 
establish whether they contain the 57 bp insert (slightly slower migration 
indicates presence of insert). 
-Lanes 7-12; Clones 1-6 PCR amplified with primers 15-5' and 15-3' to 
establish whether they contain the 15 bp insert (presence of -700 bp 
amplified fragment indicates presence of insert). 
(b) Table summarising the results obtained from the Ethidium Bromide-
stained gel. A clone missing the 57 bp insert but containing the 15 bp 
insert is indicated by "1" (it is not named in the literature). 
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(a) 
(b) 
bp 
1000~ 
750~ 
500~ 
~88~ 
Clone 
1 
2 
3 
4 
5 
6 
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1 2 3 4 5 6 7 8 9 10 1112 
57 bp 15 bp Identity 
insert insert 
- (174 bp - ? 
missing) 
- - H2c 
- - H2c 
+ - H2b 
+ + H2a 
- + ? 
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4.3.3. Screening of transfection reagents 
The AS-E2 cell line was transfected with a luciferase-based reporter plasmid (pGL3 , 
Promega) using a range oftransfection reagents (FuGENE 6 (Roche Diagnostics), 
GeneJuice (Novagen) and SuperFect (Qiagen» and screening was carried out by 
luciferase activity assay. 
FuGENE6 GeneJuice SuperFect 
Mock -transfected 417 394 402 
cells (negative 
control) 
pGL3-transfected 3092 9759 1285 
cells (1 s( reading) 
pGL3-transfected 2962 11887 991 
cells (2nd reading) 
Readings were carried out on a Turner luminometer and are in arbitrary units. 
Use of the GeneJuice transfection reagent resulted in at least a threefold increase in 
luciferase activity over the other two reagents screened, indicating better efficiency in 
transfections and thus increasing the chance of obtaining a stable transfection event. 
GeneJuice was therefore used in all subsequent transfections. 
4.3.4. Expression of the ASGP-R in AS-E2 cells 
AS-E2 cells were transfected with the p[H1-IRES-H2b ]IRESblast vector as described 
in Section 2.2.3.1. and selected with blasticidin (10 f.lglml). After 10 passages a 
polyclonal cell line designated AS-E2(H1-IRES-H2b) was derived. 
Cells were harvested by centrifugation, dissolved in SDS-loading buffer and loaded on 
an SDS-PAGE gel (Sections 2.3.1 , 2.3.3. and 2.3.4.) along with untransfected cells 
which were used as a negative control and Hep-G2 cells as a positive control (see 
Fig. 4.3.4.). 
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Fig. 4.3.4. (Facing page) SDS-PAGEIWestern blot of ASGP-R-H1 expressed recombinantly 
in AS-E2 cells and endogenously in Hep-G2 cells, using an anti-ASGP-R antibody. A 
Western blot for tubulin is also provided, to give an indication of protein loading. Triton X-
100 lysates were made, normalised for protein content by BCA assay, run on SDS-PAGE, 
transferred to membrane and Western blotted with the relevant antibody (following protocol 
in Sections 2.3.1-5.). 
(a) Probed with anti-ASGP-R-H1 (Calbiochem). 
-Lane 1; untransfected AS-E2 cell lysate. 
-Lane 2; lysate from AS-E2 cells stably transfected with cDNA encoding ASGP-R-H1 and 
ASGP-R-H2b. 
-Lane 3; Hep-G2Iysate. 
(b) Probed with anti-tubulin (Santa Cruz Biotechnology). 
-Lane 1; untransfected AS-E2 cell lysate. 
-Lane 2; lysate from AS-E2 cells stably transfected with cDNA encoding ASGP-R-H1 and 
ASGP-R-H2b. 
-Lane 3; Hep-G2 lysate. 
(a) kDa 
64.2 ~ 
48.8 ~ 
37.1 ~ 
(b) kDa 
64.2 ~ 
48.8 ~ 
37.1 ~ ~:: I~ 
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Expression of ASGP-R-Hl was detected by Western blotting with mouse monoclonal 
antibodies that recognise ASGP-R-Hl (Calbiochem). A protein ofMr = 46 kDa, the 
size expected for the asialoglycoprotein receptor, was expressed by stably transfected 
cells but was absent from untransfected cells (Fig. 4.3.4a). Separate antibodies against 
ASGP-RHl and ASGP-RH2 from Santa Cruz were also used in a Western blot but 
these were unable to differentiate between untransfected AS-E2 cells and the Hep-G2 
lysate positive control (results not shown). Protein loading was assessed by blotting 
with anti-tubulin antibody (Fig. 4.3.4b). There was a fainter band for tubulin in the 
Hep-G2 lysate lane indicating reduced protein loading. The bands for ASGP-R-Hl 
were equal in intensity, indicating that the expression ofthe ASGP-R in 
p[HI-IRES-H2b]IRESblast-transfected AS-E2 cells was not quite as high as in the 
Hep-G2 cell line. 
4.3.5. Fluorescence Microscopy 
While it shows that a protein expressed by the p[H 1-IRES-H2b ]IRESblast cells is 
recognised by the anti-ASGP-RHl antibody, the Western blot in Section 4.3.4. does 
not indicate whether a receptor is expressed that actively binds asialoglycoproteins. 
An attempt was therefore made to evaluate this crucial property by fluorescence 
microscopy. An asialoglycoprotein frequently used in such ASGP-R studies, 
alpha-I-acid glycoprotein, was prepared by sialidase treatment (as in Section 2.3.1 0.) 
and conjugated to the fluorochrome Alexa Fluor 488 (a low molecular weight green 
dye with absorption/emission spectra similar to those offluorescein). AS-E2 cells 
transfected with empty vector (pIRESblast) and with p[HI-IRES-H2b]IRESblast were 
incubated with the above reagent prior to their actin cytoskeleton and nuclei being 
stained (by Hoechst and Phalloidin 594 respectively) to aid in cell localisation 
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(Section 2.3.13.). It was possible to distinguish between the two cell lines (see 
Fig. 4.3.5.), with green areas (indicating asialoglycoprotein binding) being visible in 
the p[H1-IRES-H2b ]IRESblast-transfected cells but not in the empty 
vector-transfected cells, confirming that the transfected cell line expressed an 
asialoglycoprotein-binding receptor. 
Fig. 4.3.5. (Facipg page) Expression of functional ASGP-R: binding of 
fluorophore-Iabelled asialo-alpha-l-acid glycoprotein. 
Fluorescence images of cells stained with Phalloidin-574 (red), Hoechst 
(blue) and Alexa-Fluor conjugated-asialo-alpha-l-acid glycoprotein 
(green). See Section 2.3.13. for explanation and protocol. 
(a) AS-E2 cells stably transfected with pIRESblast empty vector. 
(b) AS-E2 cells stably transfected with pIRESblast[Hl-IRES-H2b], a 
vector encoding the two asialoglycoprotein subunits. 
Cells are approximately 20 /lM in diameter. 
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(a) 
(b) 
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4.3.6. Bioassays 
4.3.6.1. Evaluating sensitivity to desialylation in the ASGP-R-transfected AS-E2 
cell line 
The empty vector- and p[HI-IRES-H2b]IRESblast-transfected AS-E2 polydonal cell 
lines were used in a bioassay comparing the intact Epo (t=O min) and the most 
desialylated Epo sample (t=1800 min) from Section 3.3.1. As can be seen in 
Fig. 4.3.6., the two cell lines responded differently to the two forms of Epo. In the 
empty vector-transfected AS-E2 cells, desialylated Epo (t=1800 min) produced a 
greater response than did intact Epo (sample t=O min), having 1.239 times its potency 
(Table 4.3.1.). By contrast, desialylated Epo (t=1800 min) produced a lower response 
in the p[HI-IRES-H2b]IRESblast-transfected AS-E2 cells compared with intact Epo 
(sample t=O min), registering only 0.705 times its potency. The effect seen in 
Fig. 4.3.6. was reproducible in three separate experiments. The HIH2b-transfected 
cells showed the difference in the 0.05-0.2 nM range ofEpo concentrations. 
Differences between the preparations were lost at higher than saturating 
concentrations. 
The experiment was repeated, but with the extensively desialylated Epo sample 
t=1800 min replaced by the less desialylated t=480 min and t=20 min Epo samples in 
order to determine at what point the assay no longer distinguished between two 
differentially sialylated Epo samples. The mean pI ofEpo sample t=480 min (5.83) is 
approximately midway between that ofEpo samples t=1800 min (6.65) and t=O min 
(4.21). Fig. 4.3.7. shows that, compared to the empty-vector-transfected cell line, the 
p[HI-IRES-H2b]IRESblast assay still produces statistically significant differentiation 
(as evidenced by the non-overlapping 95% confidence intervals in Table 4.3.2.) 
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Fig. 4.3.6. (Facing page) Proliferative response of empty vector-transfected 
AS-E2 cells and AS-E2 cells stably transfected with the asialoglycoprotein 
receptor HI and H2b subunits to both intact and the most extensively 
desialylated Epo (samples t=O min and t=1800 min from Chapter 3). 
(a) Empty vector (pIRESblast)-transfected AS-E2 cells. 
(b) AS-E2 cells transfected with the ASGP-R-Hl- and -H2b-encoding vector 
(pIRESblast[H 1-IRES-H2b D. 
Sample t=O min (_) and sample t=1800 min (e). Data are presented as the 
mean +/- s.e.m. of triplicated samples (where an error bar is not shown, it lies 
within the dimensions of the symbol). The effect seen was reproducible and 
achieved in 3 separate experiments. 
Cell Line Potency of sample 95 % Confidence 
t=1800 min relative interval 
to sample t=O min 
AS-E2 cells 1.239 1.137 - 1.353 
transfected with 
empty vector 
(pIRESblast) 
AS-E2 cells 0.705 0.653 - 0.759 
transfected with the 
ASGP-R Hl- and 
H2b-encoding vector 
(pIRESblast[Hl-
IRES-H2bD· 
Table 4.3.1. Potencies of desialylated Epo (sample t=1800 min) relative to 
intact Epo (sample t=O min) as calculated by the RANDOM program (see 
Section 2.2.4.1. for more detail). 
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Fig. 4.3.7. (Facing page) Proliferative response of empty vector-
transfected AS-E2 cells and AS-E2 cells stably transfected with the 
asialoglycoprotein receptor HI and H2b subunits to both intact and mid-
desialylated Epo (samples t=O min and t=480 min from Chapter 3). 
(a) Empty vector (pIRESblast)-transfected AS-E2 cells. 
(b) AS-E2 cells transfected with the ASGP-R-Hl- and -H2b-encoding 
vector (pIRESblast[HI-IRES-H2bD. 
Sample t=O min (_) and sample t=480 min (.). Data are presented as 
the mean +/- s.e.m. of triplicated samples (where an error bar is not 
shown, it lies within the dimensions of the symbol). 
Cell Line Potency of sample 95 % Confidence 
t=480 min relative interval 
to sample t=O min 
AS-E2 cells 0.961 0.917 - 1.006 
transfected with 
empty vector 
(pIRESblast) 
AS-E2 cells 0.802 0.763 - 0.842 
transfected with the 
ASGP-R Hl- and 
H2b-encoding vector 
(pIRESblast[Hl-
IRES-H2bD· 
Table 4.3.2. Potencies of desialylated Epo (sample t=480 min) relative 
• 
to intact Epo (sample t=O min) as calculated by the RANDOM program. 
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between Epo samples t=480 min and t=O min. The difference between the two was 
less marked, however, in that sample t=480 min displayed approximately the same 
level activity as that of intact Epo sample t=O min in the empty-vector-transfected cell 
assay (96%) but was of a lower activity in the p[H 1-IRES-H2b ]IRESblast assay 
(80%). 
The assay could not distinguish between the intact and slightly desialylated Epo 
samples (Epo samples t=O min and t=20 min respectively), with the t=20 min Epo 
sample having the same potency in relation to intact Epo (sample t=O min), 
irrespective of the cell line in which it was being assayed (in both cases it was 
equivalent to 87% oft=O min, Fig. 4.3.8). 
The maximum proliferation of the two AS-E2 cell lines (empty vector- and 
ASGP-R-transfected) was unaffected by the transfection of AS-E2 cells with 
ASGP-R-H1 and ASGP-R-H2b since presumably once the ASGP-R binding sites 
were fully occupied the rest of the Epo could simply continue binding Epo-R, which 
has a very high binding affinity (the ASGP-R has a 10 nM dissociation constant for 
asialo-alpha-1-acid glycoprotein (Bider et ai, 1995) while that of the low-affinity Epo 
receptor is around ten times lower at 0.8-1.3nM (Dong et ai, 1992). Neither the 
receptor nor the signal pathways were affected in any way so there was no difference 
in maximal proliferation. 
4.3.6.2. The effect of asialo-alpha-l-acid glycoprotein 
In order to show that the decoy receptor effect observed in Section 4.3 04.1. was 
specifically attributable to the action of the ASGP-R, the assay was performed twice 
more in the "presence of either an excess of sialidase-treated (and therefore 
asialo-)alpha-1-acid glycoprotein (Sigma, UK) or fully sialylated alpha-I-acid 
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Fig. 4.3.8. (Facing page) Proliferative response of empty vector-
transfected AS-E2 cells and AS-E2 cells stably transfected with the 
asialoglycoprotein receptor HI and H2b subunits to both intact and 
slightly desialylated Epo (samples t=O min and t=20 min from Chapter 
3). 
(a) Empty vector (pIRESblast)-transfected AS-E2 cells. 
'"'-
(b) AS-E2 cells transfected with the ASGP-R-Hl- and -H2b-encoding 
vector (pIRESblast[H 1-IRES-H2b D. 
Sample t=O min (_) and sample t=20 min (.). Data are presented as the 
mean +/- s.e.m. of triplicated samples (where an error bar is not shown, 
it lies within the dimensions of the symbol). 
Cell Line Potency of sample 95 % Confidence 
t=20 min relative to interval 
sample t=O min 
AS-E2 cells 0.873 0.805 - 0.946 
transfected with 
empty vector 
(pIRESblast) 
AS-E2 cells 0.871 0.809 - 0.936 
transfected with the 
ASGP-R Hl- and 
H2b-encoding vector 
(pIRESblast[H 1-
IRES-H2bD· 
Table 4.3.3. Potencies of desialylated Epo (sample t=20 min) relative to 
intact Epo (sample t=O min) as calculated by the RANDOM program. 
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glycoprotein. As stated above (Section 4.3.3.), asialo-alpha-I-acid glycoprotein is 
frequently used in ASGPR-binding studies and is therefore ideal for competitively 
binding this receptor. Intact alpha-I-acid glycoprotein was used as a control. The 
results are shown in Fig. 4.3.9. In the assays represented in Figs. 4.3.9.a and b, the 
medium included an excess of fully sialylated alpha-I-acid glycoprotein, a protein not 
expected to affect cell proliferation. In the empty vector-transfected AS-E2 assay, 
extensively desialylated Epo (sample t=I800 min) had 86% ofthe potency of intact 
Epo (sample t=0 min). In the pIRESblast[HI-IRES-H2b]-transfected cell assay, 
extensively desialylated Epo (sample t=I800 min) had 62.5% of the potency ofintact 
Epo (sample t=O min). These two assays were repeated (Figs. 4.3.9c and d), this time 
with asialo-alpha-I-acid glycoprotein in the medium. The resulting excess of exposed 
galactose residues was expected to saturate all the ASGP-R galactose-binding sites, 
cancel out any function this receptor performs in the assay and effect a return to the 
dose response curve recorded in the empty vector-transfected AS-E2 cell assay. In the 
empty vector-transfected AS-E2 cell assay in the presence of asialo-alpha-I-acid 
glycoprotein, sample t=I800 min was as active relative to sample t=O min as in the 
presence of intact alpha-I-acid glycoprotein (87.7%). In the 
pIRESblast[H 1-IRES-H2b ]-transfected cell assay, the activity of desialylated Epo 
sample t=I800 min in relation to intact Epo sample t=0 min rose to 71.6%.The same 
effect was observed when using an excess concentration of the ASGP-R-inhibiting 
sugar lactose (100 mM) but not when using the same concentration of glucose, which 
does not bind the ASGP-R (results not shown). In conclusion, lower rates of 
proliferation were observed in the pIRESblast[HI-IRES-H2b]-transfected cell line 
when stimulated with desialylated compared to intact Epo. The difference was 
reduced when the ASGP-R ligand 
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Fig. 4.3.9. (Facing page) Proliferative response of empty vector-transfected 
AS-E2 cells and AS-E2 cells stably transfected with the asialoglycoprotein 
receptor HI and H2b subunits to both intact and desialylated Epo (samples 
t=O min and t= 1800 min) in the presence of intact alpha-I-acid glycoprotein 
-. 
(AAGP) or asialo-AAGP. 
(a) Empty vector (pIRESblast)-transfected AS-E2 cells in the presence of 
intact AAGP. 
(b) AS-E2 cells transfected with the ASGP-R Hl- and H2b-encoding vector 
(pIRESblast[HI-IRES-H2b]) in the presence of intact AAGP. 
(c) Empty vector-transfected AS-E2 cells (pIRESblast) in the presence of 
asialo-AAGP. 
(d) AS-E2 cells transfected with the ASGP-R Hl- and H2b-encoding vector 
(pIRESblast[HI-IRES-H2b]) in the presence of asialo-AAGP. 
In all graphs, sample t=O min (_) and sample t=1800 min (e). Data are 
presented as the mean +/- s.e.m. of triplicated samples (where an error bar is 
not shown, it lies within the dimensions of the symbol). A table is provided 
summarising the potencies of sample t=1800 min relative to sample t=O min 
in each of the four assays (calculated using the RANDOM program). 
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asialo-alpha-1-acid glycoprotein was included in the assay, with proliferation levels 
for desialylated Epo returning to those obtained for intact Epo. This showed that the 
ASGP-R was responsible for the lower rates of proliferation. 
4.4. Discussion 
4.4.1. Optimisation of stable transfection protocol 
The technique of obtaining protein-of-interest-expressing stable transfectants is 
acknowledged as being a potential rate-limiting step in expression studies. Two major 
amendments to the vectors used were necessary before a reliable method of obtaining 
recombinant protein-expressing stably transfected clonal cell lines could be achieved. 
The final vector used had the following features: 
(1) Constitutive, non-amplified expression of the gene of interest; 
(2) Blasticidin selection; 
(3) IRES technology. 
Preliminary attempts were made at stably transfecting AS-E2 cells using the 
pBudCE4.1 vector from Invitrogen, which uses the Zeocin selectable marker and has 
two unlinked expression cassettes: one driven from a CMV promoter, the other from 
an EF-1a promoter. No stable cell lines resulted as Zeocin did not kill cells quickly or 
efficiently enough. The Zeocin resistance gene was therefore replaced with a 
blasticidin resistance gene from the pcDNA 6.2-DEST Gateway vector (Invitrogen). 
Blasticidin is reputed to be the fastest and most potent selection reagent available 
(Izumi et ai, 1991). It is a peptidyl nucleoside antibiotic derived from Streptomyces 
griseochromogenes, and works by specifically inhibiting protein synthesis, more 
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specifically peptide-bond formation in the ribosomal complex. Blasticidin can be 
used to select for transfected cells carrying bsr (Endo et ai, 1988) or BSD (Kimura et 
ai, 1994) resistance genes (the BSD gene from Aspergillus terreus in the case of 
pcDNA 6.2-DEST Gateway). Switching to this new version of the vector made it 
possible to generate antibiotic-resistant clonal cell lines, six of which were screened 
by Western blot using the anti-ASGP-R antibody, giving a negative result in each 
case, possibly because of deletion or inactivation of the ASGP-R genes following 
integration. Even if such stable cell lines expressing the ASGP-R proteins had arisen, 
expression levels can be unpredictable and decrease during extended cultivations since 
there is no selection pressure ensuring transcription (Fussenegger et ai, 1998). These 
drawbacks prompted a second change in vector design - one that exploited the 
benefits of the Internal Ribosome Entry Site (IRES). 
4.4.2. The Internal Ribosome Entry Site (lRES) 
The integration of transfected DNA into mammalian genomes is unpredictable and 
occurs by non-homologous recombination (Fussenegger et ai, 1999). Selecting cell 
lines in which all cells express the gene of interest at reasonable levels is a laborious 
process, further hampered by the fact that expression can be adversely affected by the 
plasmid becoming integrated in a transcriptionally silent region of the genome or by 
the fact that for integration into the genome to occur the plasmid must undergo 
recombination with the chromosome, an event that could cause disruption to 
expression if it takes place within the gene of interest. If the antibiotic resistance gene 
and the gene of interest are transcribed from different promoters (i.e. are unlinked) 
-
then antibiotic-resistant cell lines may be produced, but there is no guarantee that the 
gene of interest will also be expressed (Fussenegger et ai, 1998). The chances of 
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success have been put at little better than 30%, with the authors ofthe paper (Rees et 
aI, 1996) finding just one recombinant protein expressor among 19 clonal cell lines 
screened when using pcDNA3.1. Using an IRES-containing vector is one way of 
overcoming these problems. The IRES, first discovered in picornaviruses (Jang et aI, 
1988;Jang et aI, 1989), is a highly structured region of RNA that allows translation of 
two proteins from a single mRNA, termed di-cistronic translation. In the standard 
model of transcription, ribosomes enter at the 5' cap structure and reach the initiation 
codon (ATG), whereupon they begin translation. In the case of the IRES vector, 
transcription from both the antibiotic-resistance gene and the gene of interest is driven 
from the same promoter (see Fig. 4.4.1. for a diagram describing how the IRES 
functions). In essence, the IRES provides a built-in guarantee that any resistant cells 
will produce mRNA for both subunits. An IRES sequence was inserted between the 
two genes of interest to ensure expression of both the HI and H2b subunits. 
This strategy has been used by Fussenegger et al (1998; 1997). They made a 
quattrocistronic mammalian expression vector by ligating the cassette 
"MCSI-IRESI-MCSII-IRESII-MCSIII" (where MCS stands for multiple cloning site) 
into the pIRESneo vector (Clontech). They reasoned that, following selection with 
neomycin, the IRES sequences ensure that all proteins of interest are expressed over 
time. 
Rees et al (1996) reported that adjustable expression was possible using the pIRESneo 
vector by gradually increasing the concentration of neomycin in the medium. This 
was not observed when increasing the concentration of blastic id in in the medium of 
cells transfected with the pIRESblast vector generated in Section 2.2.3.2. 
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Fig. 4.4.1. Schematic representation ofthe IRES cassette at (a) DNA 
and (b) rnRNA levels. 
Ribosomes enter the rnRNA at the 5' end, translating the gene of 
interest (as in the standard model of transcription). They also enter at 
the IRES, translating the blasticidin resistance gene. This ensures that 
if the blasticidin resistance gene is being expressed, the rnRNA 
encoding the gene of interest must also have been synthesised (the 
former does not have its own promoter and it is therefore not possible 
for its rnRNA alone to be transcribed) . 
. (a) DNA 
Gene of interest 1 . Od· ° Poly A signal B astiCI ill resIstance en 
(b)mRNA 
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The IRES sequence imposes the constraint that the gene inserted after the IRES will 
be expressed at lower levels. HI on the surface of Hep-G2 exceeds H2 by a factor of 
about three (Henis et ai, 1990) and was therefore chosen for ligation into the higher 
expressing first multiple cloning site. 
4.4.3. Putative new splice variant 
The peR-amplified band from clone 1 in FigA.3.3. migrated faster than the other peR 
bands, suggesting the possible presence of a new splice variant of H2. Sequencing 
revealed a 174 bp deletion which, since it is still in frame, would not create a nonsense 
mutation (see Fig. 4.3.2.). It is not clear whether the region spliced out, which 
corresponds to the transmembrane domain of the ASGP-R-H2 subunit, is an artefact 
created by an indiscriminate splicing event occurring between the consensus splice 
sites of two different introns or a new splice variant encoding another soluble form in 
addition to those created by the 15 bp mini-exon (Lederkremer & Lodish, 1991). 
It has been suggested that the 15 bp insert may almost invariably end up being spliced 
out and that a stage is being amplified that has not yet been completely processed. 
Lederkremer et al (1991) reported that 70% of3T3 cells infected with 
virion-packaged H2a expressed the H2b subunit. 
4.4.4. Soluble receptors 
Heaney and Golde (Heaney & Golde, 1996) describe soluble receptors as being 
produced either by proteolytic cleavage of an expressed membrane-bound receptor to 
produce a soluble form, or by an alternative mRNA splice resulting in a transcript 
missing the transmembrane-encoding region. The role of soluble receptors has not 
been fully established, although the fact they are so abundant suggests it may be 
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important. Possibilities include: inhibition by extracellular ligand sequestration 
(thereby preventing binding to the membrane-bound receptor and consequent signal 
transduction), ligand stabilisation, increase in sensitivity to ligand by enhanced 
delivery to the membrane-bound receptor, and down-regulation of the membrane-
bound receptor (by transformation into a soluble non-signal transducing form) 
(Heaney & Golde, 1996). 
The discovery of what is potentially a new soluble variant raises the question of 
whether such a receptor could be exploited, for example for use in inhibition assays. 
This would not be a viable alternative, however, because, as mentioned in Section 
1.15., the soluble form does not achieve the same high-affinity binding as does the 
membrane-bound form (Baenziger & Fiete, 1980). Moreover, since plant lectins did 
not act as competitive antagonists (Section 3.3.1.7.) it is doubtful whether soluble 
ASGP-R would. 
4.4.5. Limitations of using the ASGP-R 
Baenziger and Fiete (Baenziger & Fiete, 1980) found that a peptide with four 
galactose-terminating mono-antennary sugar chains can be bound and endocytosed by 
the ASGP-R of rat hepatocytes, whereas two such sugar chains were insufficient for 
internalisation; the implication being that a critical number of exposed galactose 
residues is required before endocytosis will take place. This would constitute a 
significant limitation. Epo with one or two chains featuring a single exposed 
galactose would presumably not be cleared. 
The affinity to N-acetylgalactosamine of ASGP-R is roughly a hundred times that to 
galactose (I~bst & Drickamer, 1996). While this could potentially give misleading 
results, GaINAc~ 1 ~4G1cNac~ oligosaccharide structures have not been detected in 
recombinant glycoproteins produced in CHO cells, the most commonly used 
production cell line (Smith et aI, 1990). 
4.5. Conclusion 
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In conclusion, a mammalian expression vector has been derived which should offer 
stable, constitutive co-expression ofthe HI and H2b subunits ofthe ASGP-R. The 
Epo-dependent AS-E2 cell line was stably transfected with the ASGP-R expression 
vector. HI subunit - but not H2b subunit - expression was confirmed by Western 
blot. The resulting genetically engineered cell line was thus rendered capable, to a 
certain extent, of differentiating between intact and desialylated Epo. 
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Chapter 5. Development of a sialylation-sensitive cell-based 
bioassay; genetic manipulation of an Epo-dependent cell line 
to display cell-surface galactose-specific plant lectins 
Summary and Overview 
Chapter 5 describes an attempt to develop a sialylation-sensitive in vitro assay by 
stable transfection of an Epo-dependent cell line with a vector encoding a 
galactose-binding plant lectin. It features the following sequence of studies: 
(i) Isolation of cDNAs encoding galactose-binding plant lectins and mammalian 
transmembrane domains and their ligation into a mammalian expression vector 
(Sections 5.2.1 - 6); 
(ii) Attempt to detect expression by Western blot and fluorescence microscopy 
(Sections 5.3.3. and 5.3.4.); . 
(iii) Comparison of the potencies of intact and desialylated Epo obtained in assays 
employing untransfectediempty vector-transfected and Epo-dependent cells stably 
transfected with a vector encoding a transmembrane-directed galactose-binding plant 
lectin (Section 5.3.5.); 
(iv) Discussion ofthe results (Section 5.4.). 
5.1. Introduction and aims of the study 
Chapter 4 described an assay in which Epo-dependent AS-E2 cells were stably 
transfected with the galactoselN-acetylgalactosamine-specific asialoglycoprotein 
receptor. This receptor acted as a decoy receptor, binding desialylated Epo and 
depleting the quantities present in the surrounding medium. The objective of the 
project outlined in this chapter was similar, but aimed to exploit the properties of the 
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plant lectins described in Chapter 3 by engineering cells to display them at their 
surface. These proteins also have an affinity for carbohydrates but with different, and 
potentially more useful, binding characteristics compared with the ASGP-R. Lectins 
from some plant species have stronger binding affinities for galactose and binding is 
not as dependent upon the oligosaccharide ligand having three terminal galactose 
residues. The hypothesis was that an Epo-dependent cell line displaying cell-surface 
plant lectins would be more sensitive and better able to resolve the differences 
between fully sialylated and desialylated Epo samples, rather than exhibit a bias 
towards tri-galactose terminating sugar chains. 
5.1.1. Advantages of plant lectins over the ASGP-R 
Asialo-fetuin binds the ASGP-R on hepatocyte membranes with a Kd value of 18 nM 
(Maitra et ai, 1990). In contrast, the extensively studied galactose-binding plant 
lectin, ricin B chain, bound to asialo-fetuin with higher affinity (Kd of9 nM, (Frankel 
et ai, 1996». 
Another paper reported Kd values of 0.124 nM and 0.094 nM for two different 
galactose-binding sites regarding the binding of ricin B chain to immobilised 
asialo-fetuin (Wales et ai, 1991). While the ASGP-R and ricin B chain were 
unfortunately not compared directly in the same study, the indications are that the 
ASGP-R binds with weaker affinity to the same ligand compared with the B chain of 
ricin. 
These affinity binding studies used completely desialylated fetuin, but an important 
consideration is the more rapid decline in ASGP-R-binding activity, compared with 
the galactos~-binding plant lectins, as the number of galactose-terminated branches 
decreases. Studies using Ricinus communis agglutinin and Erythrina indica as plant 
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lectin models revealed that their binding to galactose-terminating sugars was based on 
a single statistical model rather that the "cluster effect" described in Chapter 1. Any 
increase in binding was consistent with an increase in the local concentration of 
galactose residues (Bhattacharyya & Brewer, 1988). 
Asialotransferrin contains one bi-antennary glycans structure and one tri-antennary 
glycans. If just one branch is sialylated, the amount which accumulates in the liver is 
halved, illustrating how the action ofthe liver is severely affected in the absence of a 
minimum number of exposed galactose residues (Regoeczi et ai, 1980). In essence, 
the rate of clearance was not proportional to the number of galactose residues 
exposed, which may have implications for the sensitivity of the assay when used to 
compare less desialylated Epo samples. 
There are several galactose-binding lectins, including lectins from Ricinus communis, 
Erythrina crista-galli, Arachis hypogaea (peanut), Artocarpus integrifolia and Vicia 
villosa. R. communis and E. crista-galli would be suitable for use in an assay 
involved in binding galactose-exposing glycoproteins as these two lectins bind 
galactose with the commonly found Galp 1-4GlcNAcp 1 linkage. A. hypogaea, 
A. integrifolia and Vicia villosa would have limited use in such an assay as they bind 
types of galactose residue (Galpl-3GaINAcal-Ser/Thr or GaINAca-Ser/Thr) that are 
rarely found in mammalian glycoproteins. 
5.1.2. Ervthrina crista-galli lectin 
Of all the galactose-binding plant lectins, E. crista-galli lectin (ECL), the lectin used 
in Chapter 3, appeared the most promising for use in an assay designed to target 
galactose-exposing glycoproteins. As well as preferentially binding saccharides 
terminating in GalfJ(1,4)GlcNAc, it also binds with the highest affinity. Gupta et ai 
(1993) used inhibition of haemagglutination assays and found that ECL binds such 
ligands with higher affinity than do E. corallodendron and E. indica lectins, and with 
roughly twice as great an affinity as ricin. Debray et al (1986) compared four 
Erythrina lectins using immobilised lectin columns and analysed elution profiles of 
galactose-containing oligosaccharides. E. crista-galli consistently had the highest 
affinity compared with E. corallodendron, E. Iysistemon and E. latissima. 
ECL, a 241 amino acid-long divalent ion-dependent protein (Stancombe et aI, 
2003;Svensson et aI, 2002), is derived from the Cockspur coral tree, E. crista-galli. It 
takes on a homodimeric structure, the dimer interface being made up of mostly 
hydrophobic interactions (Svensson et aI, 2002), which was thought might affect its 
ability to be displayed as a monomer on the surface of a cell. Accordingly, the 
galactose-binding lectins of R. communis were also chosen as candidates for 
cell-surface display owing to their ability to exist in monomeric form (Venkatesh & 
Lambert, 1997). 
5.1.3. The Ricinus communis lee tins 
R. communis seeds contain two lectins: ricin (RCA60), of molecular weight 60 kDa, 
and Ricinus communis agglutinin (RCAI20), of 120 kDa (Debray et aI, 1981). RCA60 
is a toxin composed of a cytotoxic A chain (267 amino acids) and a galactose-binding 
B chain (262 amino acids) (Hegde & Podder, 1998). The B chain binds galactose 
residues exposed on a cell's surface, thus enabling the toxic A chain to enter the cell 
and inhibit protein synthesis by cleaving an adenine base from the ribosomal RNA 
(Hegde & Podder, 1998). RCAI20 is a tetramer consisting of two dimers similar to 
ricin, held together by non-covalent forces. It is less toxic then RCA60. The B chain 
t': Id . I b I domains each of which binds to a single galactose (Sphyris et 
10 s mto two g 0 u ar , 
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ai, 1995). Venkatesh and Lambert (1997) blocked the two galactose-binding sites but, 
having shown that there was still residual galactose -binding activity, concluded that 
there must be a third site. The A and B chains are linked by an intra-disulphide bridge 
and yet are able to remain associated even in its absence through hydrophobic 
interactions (Hegde & Podder, 1998). The genes for ricin and Ricinus communis 
agglutinin were first cloned in 1985 from the castor bean (Ricinus communis) (Halling 
et ai, 1985;Roberts et ai, 1985). Their B chains share 84% homology, with all but 41 
residues being identical. 
Studies have focused on the inhibition of red blood cell agglutination in an attempt to 
identify the differences in binding characteristics between the two R. communis lectins 
(Debray et ai, 1981). RCA60 binds oligosaccharides terminating in galactose residues 
with two-to-fourfold greater affinity, but its drawback in terms of an assay is that it 
cannot differentiate as effectively between non-sialylated and sialylated forms of 
sugar, having slightly greater affinity for sialic acid-terminating oligosaccharide 
structures than does RCAI20 (Debray et ai, 1981). It was therefore decided to try both. 
Low levels of sialyl-a(2~6)-lactose binding by RCAJ20 were detected, but not of 
sialyl-a(2~3)-lactose (Debray et ai, 1981). This was attributed to the former being 
more accessible to the lectin due to the sialyl group's greater degree of rotational 
freedom. Any binding of sialylated sugars would adversely interfere with the assay, 
the principle aim of which is to selectively sequester only galactose-terminating 
glycoproteins. This is not a major problem, though, as Chinese Hamster Ovary 
(CHO) cells, the cells used to produce biotherapeutic glycoproteins, do not possess the 
alpha-2,6-sialyltransferase (Ma et ai, 1997). 
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5.1.4. Designing chimeric decoy receptors 
The aim of this part of the project was to produce a chimeric galactose-binding decoy 
receptor consisting of an N-terminal signal peptide, an extracellular plant lectin 
domain, a flexible linker and a transmembrane domain. Fig. 5.1.1. is a schematic 
representation of the chimeric decoy receptor. 
The ricin B chain has previously been expressed as a fusion protein on the surface of 
fd phage (Swimmer et aI, 1992) so as to be able to screen a library of mutants of the 
lectin for altered binding activities. The wild-type form was still able to bind sugars 
as a monomer and could tolerate being part of a fusion protein and having extra 
domains attached C-terminally. It did, however, differ in that it was not displayed on 
the surface membrane of a cell. 
The plant lectins would be expected to fold correctly after being extruded through the 
cell membrane, as the endogenous forms have plant-specific signal peptides that direct 
their extrusion through the plant cell membrane (Hegde & Podder, 1998;Stancombe et 
aI, 2003). The ricin B chain has also been expressed in E. coli fused with a 
heterologous signal peptide directing its secretion into the periplasmic space (Hussain 
et aI, 1989). In the case of the project described in this chapter, the lectin constructs 
were instead engineered in such a way as to contain the mammalian Epo-R signal 
sequence. 
The ricin B chain expressed as a fusion protein on the surface of fd phage contained a 
[Ser-GlY3]4 flexible amino acid linker whose purpose was to facilitate presentation of 
the recombinant lectin as a separately folded domain (Swimmer et aI, 1992). The 
chimeric receptors discussed in this chapter contained a similar [Gly4Ser]4 flexible 
linker. 
Fig. 5.1.1. (Facing page) Schematic representation of the design of a surface-
expressed decoy receptor incorporating a galactose-binding plant lectin 
domain. 
The signal peptide (a) is responsible for directing the galactose-binding 
lectin (b) to and through the cell surface membrane. 
The flexible linker (c) ensures the lectin is presented as a separately folded 
domain. 
The Epo-R's WSAWS motif (d) - YEGFS in the case of the GH-R - is 
included in view of its importance in terms of processing the Epo-R to the 
cell surface and preventing retention in the endoplasmic reticulum. 
The transmembrane domain (e) derived from either the Epo-R or mutant 
GH-R (the latter containing an internalisation motif (f) but lacking any 
signal-transduction capability) anchors the fusion protein in the cell surface 
membrane. 
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Por the galactose-binding plant lectins to be displayed on the cell's surface, the fusion 
protein needed to incorporate a stretch of approximately 20 hydrophobic amino acids 
that anchored it in the membrane. The human Epo and rabbit growth hormone (OH) 
receptors were chosen as templates. The rabbit form ofthe OH-R was used as it had 
previously undergone mutation analysis aimed at studying the relationship between 
degradation and activation (Alves dos Santos et aI, 2001). 
The extracellular membrane-proximal Trp-S er-AI a-Trp-Ser (WSA WS) motif of the 
Epo-R has been found to be necessary for receptor processing to the cell surface and 
preventing retention in the ER (Y oshimura et aI, 1992), and was therefore included in 
the design ofthe Epo-R-based chimeric receptor. It was equally important for any 
chimeric receptor to be completely devoid of proliferation-stimulating activity. 
Responsibility for such activity resides in the cytoplasmic domain. Researchers have 
produced truncated forms of the Epo-R in order to ascertain exactly which regions are 
involved. Many ofthese truncated versions ofthe Epo-R have been expressed in 
BaP/3 cells (D'Andrea et aI, 1991). The BaF/3 cell line is a murine 
interleukin-3-dependent cell line that does not express Epo-R but, when transfected 
with wild-type Epo-R, becomes sensitive to Epo by virtue ofIL-3 and Epo sharing 
common signal transduction pathways. An intracellular region of approximately 100 
amino acids adjacent to the transmembrane domain is responsible for transduction of 
proliferation signals (D'Andrea et aI, 1991). The most C-terminal region of Epo-R 
(approximately 40 amino acids) is inhibitory and involved in negative regulation of 
such signals (reviewed in Youssoufian et aI, 1993). If the Epo-R is truncated at 
residue 267 there is no proliferation signal (Flint-Ashtamker et aI, 2002). 
The OH-R, like the Epo-R, belongs to class I of the cytokine receptor family and so 
contains a proline-rich Box-l and a Box-2 motif in the cytoplasmic domain (Strous & 
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van Kerkhof, 2002). Rabbit GH-R contains a total of620 amino acid residues, of 
which 246 are extracellular, 24 constitute the transmembrane domain, and 350 are 
intracellular (Leung et ai, 1987). When rabbit GH-R had four of its box-l domain 
prolines changed to alanines, it no longer transmitted proliferation signals but was still 
able to undergo degradation (Alves dos Santos et ai, 2001). These are potentially 
useful properties for a decoy receptor whose aim it is to remove certain populations of 
Epo molecules from the medium without inducing proliferation. 
The work outlined in this chapter involved creating fusion constructs made up of 
regions from plant and animal proteins and, while it is true that exchanging cytokine 
receptor regions has been carried out (c£ Epo-Rlepidermal growth factor receptor 
(EGF-R) (Pacifici & Thomason, 1994) and GH-Rlgranulocyte colony-stimulating 
factor receptor [G-CSF-R] chimeras (Ishizaka-Ikeda et ai, 1993» and can be tolerated 
in terms of the fact that the chimeric receptors can still transduce proliferation signals, 
it is not known if a plant lectin can replace a cytokine receptor domain. 
5.2. Experimental Procedures 
5.2.1. RNA isolation and first-strand cDNA synthesis 
Total RNA was isolated from E. crista-galli and R. communis seeds using a plant 
RNeasy Plant mini-kit (Qiagen), whilst messenger RNA was extracted from AS-E2 
cells using the QuickPrep Micro mRNA purication kit from Amersham (as described 
in Section 2.1.1.). First-strand cDNA synthesis was performed according to Section 
2.1.2. 
5.2.2. peR-amplification of galactose-binding plant lectins 
The plant lectins were peR-amplified (Section 2.1.3.) without their signal peptides 
from the appropriate seed first-strand cDNA using the following primers: 
Name Function Primer sequence 
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ECL-5' Forward primer for ECL 5' -gaaaccatatcgtttagcttcagcg-3' 
gene 
ECL-3' Reverse primer for ECL 5' -atcgtttgtttctggcaacgaggc-3' 
gene 
RCA-5' Forward primer suitable 5' -gctgatgtttgtatggatcctgag-3 ' 
for amplification of both 
RCA60 and RCA120 genes 
RCA-3' Reverse primer suitable 5' -aaataatggtaaccatatttgg-3 
for both RCA60 and 
RCA120 genes 
PCR products were run on a 1 % agarose gel to verify that they were of the correct size 
(see Fig. 5.2.1. for amplification of the ECL gene and Fig. 5.2.2. for amplification of 
what is presumably a mixture of the two RCA genes). The PCR product was ligated 
into pGEM-T (Promega) by TA cloning, and then transfonned into JMI09 bacteria 
(Sections 2.1.4. and 2.1.5. respectively). Identification of the ECL, RCA60 and 
RCA120 genes was achieved by sequencing (Section 2.1.10.) and comparison with 
GenEMBL Accession numbers AY158072 (Stancombe et ai, 2003), E01356 and 
E01357 respectively. Sequences of the clones were verified as correct. 
5.2.2.1. Site-directed mutagenesis (SDM) 
Cysteine4 of RCA60 and RCA120 was changed to a serine by site-directed mutagenesis 
(following the protocol in Section 2.1.14.), as carried out by Swimmer et al (1992). 
The RCA60 and RCA120 B chains have four intrasubunit disulfide bridges and a 
bp 
1000 ~ 
750 ~ 
1 2 
Fig. 5.2.1. PCR amplification of Erythrina crista-ga/li lectin using the listed 
primers and Erythrina crista-galli first-strand cDNA as a template. Ethidium 
Bromide-stained 1 % agarose gel loaded as follows: 
-Lane 1; primers ECL-5' and ECL-3' (2 ~M final concentration). 
-Lane 2; primers ECL-5' and ECL-3' (20 ~). 
Expected product size= -710 bp. 
202 
bp 
1000 ~ 
750 ~ 
M 123456 
Fig. 5.2.2. PCR amplification of the RCA60 and RCA I20 B chains 
using RCA-5' and RCA-3' primers (complementary to both genes) 
and Ricinus communis first-strand cDNA as a template. Ethidium 
Bromide-stained 1 % agarose gel loaded as follows: 
-Lane 1; 2 JlM (primer final concentration), 1 mM MgCI2. 
-Lane 2; 2 JlM, 1.5 mM MgCI2. 
-Lane 3; 2 JlM, 1 mM MgCI2• 
-Lane 4; 20 JlM, 2 mM MgCI2. 
-Lane 5; 20 JlM, 1.5 mM MgCI2. 
-Lane 6; 20 JlM, 2 mM MgCI2. 
Expected product size= -780 bp. 
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remaining half-cysteine (cys4) which forms an intersubunit disulfide bridge with 
Cys299 of the A chain. It was decided to change this residue to a serine by 
site-directed mutagenesis in case an unbonded cysteine caused structural folding 
problems. 
The following two primers were used for the SDM: 
Name Function Primer sequence 
204 .' 
CysSDMfor Forward primer for 5' -cctgggctgatgttwatggatcct 
changing cys 4 to ser gagc-3' 
CysSDMrev Reverse primer for 5' -gctcaggatccatactaacatcagc 
changing cys4 to ser ccagg-3' 
The sequences underlined mdIcate the serine codon AOT that was changed from the 
cysteine codon TOT. 
5.2.3. Introduction of a 5' Epo receptor signal peptide by peR 
The plant lectin-encoding vectors described in Section 5.2.2. were then used as 
template DNA for addition by PCR of the Epo-R (OenEMBL accession number 
M60459) signal peptide, initial attempts to do this from plant RNA having been 
unsuccessful. 
205 ! 
The following primers were used (RCA primers being suitable for both RCA60 and 
RCA12o genes, owing to their high percentage homology): 
Name Function Primer sequence Restriction site 
Sig pep-ECL-5' Forward primer for 5' -gacgatgcggccgcgggctg -NotI underlined 
introducing Epo-R tatcatggaccacctcggggcgtc -ECL 
signal peptide at 5' cctctggccccaggtcggctccct complementary 
end of ECL gene ttgtctcctgctcgctggggccgc region in bold 
ctgggtggaaaccatatcgttta 
gcttcagcg-3 ' 
ECL! PstI-3 '* Reverse primer for 5' -gacgatctgcagatcgtttgttt -PstI underlined 
introducing PstI ctggcaacgaggc-3 ' 
restriction site 3' of 
the ECL gene 
Sig pep-RCA-5' Forward primer for 5' -gacgatgcggccgcgggctg -NotI underlined 
introducing Epo-R tatcatggaccacctcggggcgtc -RCA 
signal peptide at 5' cctctggccccaggtcggctccct complementary 
end of RCA60 or ttgtctcctgctcgctggggccgc region in bold 
RCAl20 gene ctgggctgatgtttgtatggatcc 
tgag-3' 
RCJ\JPstI-3'* Reverse primer for 5' -gacgatctgcagaaataatgg -PstI underlined 
introducing PstI taaccatatttgg-3' 
restriction site 3' of 
the RCA genes 
*The Pst! restriction sites were needed for assembly of the lectIll construct later III the 
procedure ... 
PCR products were run on a 1 % agarose gel to check that they were of the correct size 
(Fig. 5.2.3.), re-sub cloned into pGEM-T, transformed into bacteria, and analysed by 
Not! restriction digestion. Only clones that contained genes inserted in such a way as 
to ensure that the 5'-end was next to the pGEM-T T7 promoter (as identified by the 
presence of a Not! fragment) were selected. This step was necessary to permit 
bp 
1000 ~ 
750 ~ 
M 1 2 3 
Fig. S.2.3. PCR amplification of plant lectins (ECL, RCA60 and RCA'20 B 
chains) with incorporation of the Epo-R signal peptide, using the listed 
primers and plant lectin cDNA-containing pGEM-T vectors described in 
Section S.2.2. as a template. Ethidium Bromide-stained 1 % agarose gel 
loaded as follows (all primers used at 20 ~ final concentration): 
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-Lane 1; primers Sig pep-RCA-S' and RCNPstI-3' using pGEM-T[RCA60] as 
a template. 
-Lane 2; primers Sig pep-RCA-S' and RCNPstI-3' using pGEM-T[RCA' 20] 
as a template. 
-Lane 3; primers Sig pep-ECL-S ' and ECLlPstI-3' using pGEM-T[ECL] as a 
template. 
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subsequent assembly of the gene fusion construct. Such clones were further verified 
by sequencing. 
5.2.4. peR-amplification of the Epo-R transmembrane domain 
The cDNA encoding the transmembrane domain of the Epo-R (amino acid residues 
200-267) was PeR-amplified using the following primers: 
Name Function Primer sequence Restriction site 
FlinklEpo-R Forward primer for 5' -gacgatctgcagggaggtgg -PstI underlined 
TM-5' introducing a flexible aggttcaggaggtggaggttcag -Epo-R 
linker ([GlY4Ser]4) at 5' gaggtggaggttcaggaggtgga complementary 
end of the Epo-R ggttcagctgagccgagcttcgg region in bold 
transmembrane domain cggcttc-3' 
Epo-R Reverse primer for 5' -gacgatgagctcccagcaca -Sac! underlined 
TM-3' introducing stop codon ctggctactcgctctctgggctgc -BstXI in italics 
into Epo-R in order to cgatgc-3' -Stop codon in 
produce a truncated form bold 
of the receptor (see text for 
details) 
The peR products (see Fig 5.2.4.) were cloned into the pGEM-T vector (Promega) 
and transformed into JM109 bacteria. The Epo-R transmembrane sequence was 
compared with GenEMBL Accession No. M60459 and verified as correct. 
bp 
500 ~ 
400 ~ 
300 ~ 
200 ~ 
100 ~ 
M 1 
Fig. 5.2.4. peR amplification of the Epo-R transmembrane domain 
incorporating a 5' flexible linker using the listed primers and AS-E2 first-
strand cDNA as a template. Ethidium Bromide-stained 1 % agarose gel 
loaded as follows: 
-Lane 1; primers Flink/Epo-R TM-5' and Epo-R TM-3' (20 flM final 
concentration). Amplified region consists of the EpoR transmembrane 
domain (-200 bp) plus a 70 bp artificiallinker. Bands seen at -150 bp 
and -400 bp are presumed to be non-specific. 
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5.2.5. Assembly of the plant lectin/Epo-R chimeric construct and Iigation into 
pIRESblast 
The next step was to ligate the plant lectin genes to the Epo-R transmembrane 
encoding region. See Fig. 5.2.5. for a schematic representation of the chimeric 
transmembrane-anchored lectin sub-cloning strategy. The final step involved ligating 
the [RCA6o-Epo-R TM] and [RCA12o-Epo-R TM] constructs into pIRESblast as 
NotIlEstXI fragments to create vectors p[RCA60-EpO-R TM]IRESblast and 
p[RCAl2o-Epo-R TM]IRESblast respectively. 
5.2.6. Replacement of the Epo-R transmembrane domain-encoding region with 
that of the growth hormone receptor transmembrane and degradation domains 
.. 
GH-R cDNA corresponding to the transmembrane and degradation domains of the 
GH-R 4Pro ~Ala mutant gene (bases 697-1101lamino acids 233-367) were 
PCR-amplified with appropriate restriction sites at both ends using the 
rGHRBOXloutknock plasmid (generously donated from Dr. G. Strous, University 
Medical Centre, Utrecht, Netherlands) as a template. 
Fig. 5.2.5. (Facing page) Schematic representation ofthe 
sub-cloning strategy for constructing a mammalian expression 
vector encoding a transmembrane domain-anchored plant lectin. 
An in-frame fusion is used to create an open reading frame 
encoding a protein that extends from the signal sequence of the 
Epo-R gene (amino acids 1-24) into the ricin or Ricinus communis 
agglutinin B chain, followed by the flexible linker and, lastly, the 
region of the EpoR gene that spans the WSXWS motif, the 
transmembrane domain and the cytoplasmic domain as far as 
residue 268. 
The cassettes encoding the fusion protein constructs were then 
cloned into pIRESblast as NotIlBstXI fragments. 
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A unique BstEII restriction site was identified just upstream of the Epo-Rjlexible 
linker and the transmembrane domain and so primers were designed to amplify the 
GH-R transmembrane internalisation domain that contained a 5' BstEII site, a 
jlexible linker ([GlY4Serh) and a 3' BstXI site: 
Name Function Sequence Restriction 
site 
Flink/GH-R Forward primer for 5' -gacgatggttaccattatttctgcaggga -BstEII 
TM-5' introducing a flexible ggtggaggttcaggaggtggaggttcagg underlined 
linker ([GlY4Ser]J) at aggtggaggttcaagacagcgaagctctg -GH-R 
5' end ofthe GH-R aaaaatatggc-3 ' complement-
transmembrane ary region in 
internalisation bold 
domain 
GH-R Reverse primer for 5' -gacgatccagcacactggctagcttagaa -BstXI 
TM-3' introducing stop gtcggtctgtgtctgatcc-3 ' underlined 
codon into GH-R in -Stop codon 
order to produce a in bold 
truncated form of the 
receptor 
The PCR products (see FIg 5.2.6.) were cloned mto the pGEM-T vector (Promega) 
and transformed into JMI09 bacteria. The GH-R transmembrane sequence was 
compared with GenEMBL Accession No. AFl5252 and verified as correct. 
The BstEIVBstXI fragments of the p[RCA60-EpO-R TM]IRESblast and 
p[RCA120-EpO-R TM]IRESblast vectors were cut out and replaced by the 
corresponding GH-R BstEWBstXI fragment generated above. 
Finally, the successful construction of these plasmids (called 
p[RCA60-Gl!-R TM]IRESblast and p[RCA120-GH-R TM]IRESblast respectively) was 
confirmed by nucleotide sequencing. Plasmids were purified using the Endofree 
bp 
750 ~ 
500 ~ 
400 ~ 
M 1 
Fig. 5.2.6. peR amplification of the Growth Hormone Receptor mutant 
(4Pro-7Ala) transmembrane/internalisation domain with 5' BstEII 
restriction end and flexible linker and 3' BstXI restriction end using the 
listed primers and rGHRBOXloutknock plasmid as a template. Ethidium 
Bromide-stained 1 % agarose gel loaded as follows: 
Lane 1; Flink/GH-R TM-5 ' and GH-R TM-3' primers (20 IlM final 
concentration). 
Amplified region consists of the GH-R transmembrane and internalisation 
domain ( -400 bp), plus a 45 bp artificiallinker. 
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Maxi Prep Kit (Qiagen) endotoxin-free purification kit according to its standard 
protocol. 
5.2.7. Establishment of AS-E2 cells stably transfected with plant 
lectinlTM-expressing vector constructs 
214 ; 
To generate stably transfected cell lines expressing plant lectin chimeric receptors, 
cells were transfected with endotoxin-free maxiprep DNA following the protocol 
outlined in Section 2.2.3.1. Resistant colonies were obtained following blasticidin 
selection (Section 2.2.3.3.). After being sub cultured for 10 passages, AS-E2 cells 
transfected with both the plant lectin chimeric receptors and the empty pIRESblast 
vector were screened for expression ofimmunoactive receptor (Western blotting) and 
functional binding (fluorescence microscopy). PCR-amplification was used to 
determine whether transfected blasticidin-resistant cell lines contained recombinant 
DNA (Section 2.2.3.4.). 
5.2.8. Bioassays 
Bioassays were performed (as in Section 2.2.4.) using the AS-E2 cells stably 
transfected with the p[RCA60-EpO-R TM]IRESblast, p[RCAJ2o-Epo-R TM]IRESblast, 
p[RCA60-GH-R TM]IRESblast and p[RCAI20-GH-R TM]IRESblast. Untransfected 
AS-E2 cells or AS-E2 cells stably transfected with empty vector were used as the 
control. 
5.2.9. Plate plan 
The plate pl~ was ofthe same type as that used in Chapter 4 (see Fig. 4.2.3.). 
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5.3. Results 
5.3.1. AS-E2 cells engineered to display ECL at the cell surface (ECL-TM) were 
not viable 
A total of three attempts at stable transfection of AS-E2 cells with a vector expressing 
a transmembrane-anchored E. crista-galli lectin (ECL-TM) proved unsuccessful, with 
all cells dying by day 28. Since, as stated in Section 5.1.2., E. corallodendron forms 
dimers with a hydrophobic dimer interface (Elgavish & Shaanan, 2001), it had been 
thought that ECL might not work, possibly because of a potentially unstable 
hydrophobic region. Although toxicity is another possible reason, treating AS-E2 
cells with ECL freely present in the medium had no deleterious effect (see Fig. 3.3.8. 
in Chapter 3). 
5.3.2. Survival of AS-E2 cells stably transfected with RCA60- TM and RCA12o-TM 
and retention of Epo-dependency 
AS-E2 cells genetically engineered to display RCA60 and RCA120 survived and 
retained their Epo-dependency. There had been a concern that Epo-dependency might 
have been abolished as many plant lectins have been reported to have a mitogenic 
effect on cells (Ashraf & Khan, 2003). 
5.3.3. Screening of stably transfected cell lines 
Expression of the chimeric receptors was verified by Western blot using an antibody 
specific for RCA60 and RCA120 from Vector Laboratories. Bands were not detected in 
p[RCA60-EpO-R TM]IRESblast- and p[RCA120-EpO-R TM]IRESblast-transfected 
Fig. 5.3.1. (Facing page) SDS-PAGElWestern blot using an antibody 
specific for both RCA60 and RCA I20 (Vector Laboratories) to 
investigate whether AS-E2 cells stably transfected with the 
p[RCA60/120-Epo-R TM]IRESblast vectors were successfully 
expressing RCA60 or RCA I20 B chain. Triton X-lOO lysates were made, 
run on SDS-PAGE, transferred to membrane and Western blotted with 
an antibody specific for RCA60 and RCA I20 (Vector Laboratories) 
(following protocol in Sections 2.3.1-5.). 
-Lane 1; lysate from AS-E2 cells stably transfected with the empty 
pIRESblast vector. 
-Lane 2; lysate from AS-E2 cells stably transfected with 
p[RCA60-Epo-R TM]IRESblast vector encoding a membrane-anchored 
RCA60 chimeric protein (expected molecular weight -40 kDa). 
-Lane 3; lysate from AS-E2 cells stably transfected with 
p[RCAl2o-Epo-R TM]IRESblast vector encoding a membrane-
anchored RCA I20 chimeric protein (expected molecular 
weight -40kDa). 
-Lane 4; Ricin B chain isolated from highly purified RCA60, molecular 
weight 32 kDa (Vector Laboratories). 
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AS-E2 cells (Fig. 5.3.1.). A lane was loaded with ricin B chain isolated from highly 
purified RCA60 (Vector Laboratories) as a positive control. 
A polyc1onal anti-Epo-R antibody from Santa Cruz Biotechnology raised against 
amino acids 21-214 mapping near the N-terminus ofthe Epo-R, and therefore 
potentially recognising only 14 amino acids of the RCAlEpo-R fusion proteins, also 
proved negative (results not shown). 
5.3.4. Fluorescence microscopy 
Fluorescence microscopy was used to ascertain whether or not the chimeric 
receptor-transfected AS-E2 cells had an increased ability to bind galactose residues. 
Cells were incubated in Alexa Fluor 488-conjugated asialo-alpha-l-acid glycoprotein 
(green), a glycoprotein containing exposed galactose residues, as well as stained for 
actin (red) and DNA (blue) as described in Section 2.3.13. 
p[RCA60-EpO-R TM]IRESblast did not stain more strongly than empty 
vector-transfected cells, indicating that there was no recombinant 
asialoglycoprotein-binding activity (Fig. 5.3.2a and b respectively). This was also the 
case for p[RCA120-Epo-R TM]IRESblast and p[RCA120-GH-R TM]IRESblast-
transfected cells (results not shown). 
Fig. 5.3.2. (Facing page) Investigating whether expression of a 
functional galactose-binding chimeric protein had been achieved in 
lectin display vector-transfected AS-E2 cells: binding of 
fluorophore-Iabelled asialo-alpha-l-acid glycoprotein. 
Fluorescence images of cells stained with Phalloidin-574 (red), 
Hoechst (blue) and Alexa-Fluor conjugated-asialo-alpha-l-acid 
glycoprotein (green). See Section 2.3.13. for explanation and 
protocol. 
(a) AS-E2 cells stably transfected with 
pIRESblast empty vector. 
(b) AS-E2 cells stably transfected with 
pIRESblast[RCA6o-Epo-R TM]. 
Cells are approximately 20 ~ in diameter. 
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5.3.5. Bioassays 
Intact Epo and the most desialylated Epo sample from Section 2.3.10. (Epo samples 
t=O min and t= 1800 min respectively) were used in assays using the various cell lines 
stably transfected with plant lectins. Fig. 5.3.3. shows the results comparing 
proliferative assays using (a) untransfected, (b), p[RCA60-EpO-R TM]IRESblast-
transfected and (c) p[RCA12o-Epo-R TM]IRESblast-transfected AS-E2 cells. The 
curves of samples t=O min and t= 1800 min are the same in each ofthe three graphs, 
indicating that neither of the RCA-Epo-R TM-transfected cell lines is, in relation to 
the untransfected AS-E2 cell line, able to distinguish between intact Epo and 
desialylated Epo. 
If the above failure to observe an effect w(is due to there not being sufficient numbers 
of galactose-binding sites on the surface of each cell, the next logical step to take 
would be to see if the incorporation of an internalisation domain improved results. 
Accordingly, the assay was repeated, this time using the 
p[RCA60-GH-R TM]IRESblast- and p[RCAI20-GH-R TM]IRESblast-transfected cell 
lines (Fig. 5.3.4.). No differentiation was made between samples t=O min and 
t=1800 min, however, consistent with there having been no chimeric receptor 
expression in the first instance. 
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Fig. 5.3.3. (Facing page) Proliferative response of AS-E2 cells stably transfected 
with the empty eIRESblast, pIRESblast[RCA6o-Epo-R TM] and 
pIRESblast[RCA120-Epo-R TM] vectors to intact and extensively desialylated Epo 
(samples t=O min and t=1800 min respectively from Chapter 3). 
(a) AS-E2 cells transfected with the empty pIRESblast vector. 
(b) AS-E2 cells transfected with the RCA6o-encoding vector 
(pIRESblast[RCA6o-Epo-R TMD· 
(c) AS-E2 cells transfected with the RCA120-encoding vector 
(pIRESblast[RCA120-Epo-R TMD. 
Sample t=O min (_) and sample t=1800 min (e). Data represent mean +/- s.e.m. of 
triplicated samples. 
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Fig. 5.3.4. (Facing page) Proliferative response of untransfected AS-E2 cells and 
AS-E2 cells stably transfected with the RCA60 or RCA120 B chain gene fused to 
the transmembrane domain of the mutant growth hormone receptor (activation 
disabled but internalisation competent) to intact and extensively desialylated Epo 
(samples t=O min and t=1800 min respectively from Chapter 3). 
(a) Untransfected AS-E2 cells. 
(b) AS-E2 cells transfected with the RCA6o-encoding vector 
(pIRESblast[RCA6o-GH-R TMD· 
(c) AS-E2 cells transfected with the RCA120-encoding vector 
(pIRESblast[RCA120-GH-R TMD· 
Sample t=O min (_) and sample t=1800 min (e). Data represent mean +/- s.e.m. 
of triplicated samples (where an error bar is not shown, it lies within the 
dimensions of the symbol). 
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5.3.6. peR-amplification from cell extracts 
Using vectors containing the IRES sequence between the gene of interest and the 
antibiotic-resistance gene was done to ensure that antibiotic-resistant cells contained 
genomic DNA for both genes from which mRNA would be transcribed. However, it 
was decided to verify that the gene for the chimeric lectin display protein had not been 
spontaneously deleted resulting in antibiotic-resistant cell lines containing only 
the antibiotic-resistant gene, something which could explain the antibiotic-resistance 
coupled with the lack of detectable chimeric protein expression. This was done by 
performing RCA B chain PCR-amplification (as in Section 2.1.3.2.) on cell extracts 
from empty pIRESblast- and pIRESblast[RCA12o-Epo-R TM]-transfected cells 
prepared by proteinase K digestion (Section 2.2.3.4.). 
A band of the expected size (-780 bp) was amplified by RCA-specific primers 
(primers RCA-5' and RCA-3' from Section 5.2.2.) from the 
pIRESblast[RCAI2o-Epo-R TM] vector (the positive control) and from the 
pIRESblast[RCA12o-Epo-R TM]-transfected cell extract (Fig. 5.3.5.a). Bands were 
amplified by actin-specific primers (primers actin-5' and actin-3' from Section 
2.2.3.4.) from the empty pIRESblast- and pIRESblast[RCA12o-Epo-R TM]-transfected 
cell extracts but not from the water negative control (Fig. 5.3.5.b). This showed that 
both cell extracts contained PCR-amplifiable DNA and that the proteinase K digestion 
had worked. In conclusion, the pIRESblast[RCAI2o-Epo-R TM]-transfected cell line 
had not lost DNA amplifiable by primers specific for the RCA genes. 
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Fig. 5.3.5. (Facing page) PCR amplification of RC A (expected product size=-780 
bp) and actin (expected product size=-630 bp) from cell extracts to determine 
whether the pIRESblast[RCA120-Epo-R TM]-transfected blasticidin-resistant cell 
line contained recombinant RCA B chain-amplifiable DNA. 
(a) PCR amplification of RCA DNA using the RCA-5' and RCA-3' primers 
(Section 5.2.2.). Ethidium Bromide-stained 1 % agarose gel loaded as follows 
. (primers used at 20 JlM final concentration): 
-Lane 1; primers RCA-5' and RCA-3' using pIRESblast[RCA120-Epo-R TM] 
vector DNA as a template (positive control). 
-Lane 2; primers RCA-5' and RCA-3' using empty pIRESblast vector-transfected 
AS-E2 cell extract as a template. 
-Lane 3; primers RCA-5' and RCA-3' using pIRESblast[RCA120-Epo-R TM]-
transfected AS-E2 cell extract as a template 
-Lane 4; primers RCA-5' and RCA-3' using sterile water as a template (negative 
control). 
(b) PCR amplification of actin DNA using the actin-5' and actin-3' primers (Section 
2.2.3.4.). Ethidium Bromide-stained 1 % agarose gel loaded as follows (primers 
used at 2 J.1M final concentration): 
-Lane 1; primers actin-5' and actin-3' using sterile water as a template (negative 
control). 
(Fig. 5.3 .5. continued) 
-Lane 2; primers actin-5 ' and actin-3' using empty pIRESblast vector-
transfected AS-E2 cell extract as a template. 
-Lane 3; primers actin-5' and actin-3' using 
pIRESblast[RCA120-Epo-R TM]-transfected AS-E2 cell extract as a 
template. 
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5.4. Discussion 
Although any membrane-spanning sequence would in theory have been suitable for 
facilitating the display of galactose-binding plant lectins on the surface of an 
Epo-dependent cell line, that of Epo-R and its signal peptide were chosen because any 
processing machinery and accessory proteins involved in its being delivered to the 
surface of the cell would be present in AS-E2 cells. 
The main objective was to display plant lectins on the cell surface to see if this 
approach worked in principle and if the lectins were still capable of binding 
asialoglycoproteins. A strategy explored simultaneously was to include a domain 
capable of directing internalisation and recycling, as it would be more advantageous if 
asialoglycoproteins were continually removed from the surrounding medium and 
degraded to make more binding sites available for desialylated Epo instead of just 
being sequestered on the surface of the cell membrane. ASGP-R could have been 
considered as a model for internalisation of the plant lectin display protein, especially 
as it does not transmit a proliferation signal, has high expression - 225,000 receptors 
per HepG2 cell according to (Schwartz et aI, 1982) - and recycles rapidly at 
approximately once every 15 minutes. It is, however, a type II receptor with its 
C-terminus exterior to the cell, a fact which would mean that the lectin domain would 
have to be positioned at the C-terminal end of the receptor, and this domain would not 
get directed N -terminal first through the membrane as lectins do in their native form. 
In addition, its mechanism involves releasing ligand upon acidification in the 
endosome, followed by degradation in the lysosome (Geffen et aI, 1989). Although 
Ricinus communis lectins (Frenoy et aI, 1986;Frenoy, 1986) and lectins of the 
Erythrina genus (Konozy et aI, 2003;Konozy et aI, 2002) experience a decrease in 
affinity for ligand when the pH drops below neutrality, there was no guarantee that 
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asialo-Epo would dissociate from the plant lectin chimeric receptors to the same 
extent, thereby allowing unbound receptors to recycle back to the cell surface. It was 
therefore felt to be prudent to use the internalisation domain from the growth hormone 
receptor - a system that undergoes degradation of the ligand and its receptor. The 
Epo-R gets degraded but would not have been suitable as this degradation is 
inextricably linked with activation. Internalisation can take place irrespective of 
activation (Beckman et aI, 1999) but the Epo-R fails to undergo degradation if 
activation is abrogated by tyrosine kinase inhibitors (Walrafen et aI, 2005;Yang et aI, 
1996). 
The growth hormone receptor, however, can undergo degradation independently of 
any signal transduction. When four prolines (residues 299, 300, 302 and 304) were 
changed to alanines within the rabbit GH-R's box-l domain, Jak2 phosphorylation and 
activation were abolished, whereas ubiquitination and degradation proceeded 
normally (Alves dos Santos et aI, 2001). 
The RCAlGH-R chimeras incorporated residues 233 to 367 of the GH-R, since 
contained within them is the 10-amino acid ubiquitin-dependent endocytosis (UbE) 
motif Asp-Ser-Trp-Val-Glu-Phe-Iso-Glu-Leu-Asp (DSWYEPIELD), the 
ubiquitin-conjugation system being necessary for internalisation (van Kerkhof et aI, 
2000). The GH-R's Tyr- Glu-Gly-Phe-Ser (YEGPS) motif was retained as this 
corresponds to the stabilising Trp-Ser-Ala-Trp-Ser (WSAWS) motif in the Epo-R. 
Ligand-induced GH-R dimerisation may no longer have been possible by the 
GH-R-based chimeric receptor but although dimerisation is necessary for signal 
transduction, as shown using growth hormone mutated in such a way as to prevent 
two receptors from being bound at the same time, internalisation and degradation have 
been shown to still continue normally without it (Puh et aI, 1992;Harding et aI, 1996). 
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Lectins form dimers and tetramers, most likely because the capacity for increased 
polyvalency promotes agglutination. The non-viability of the ECL-transfected cells 
may be a result ofECL's requirement for dimerisation. Ifresults using either of the 
RCA lectins had been more promising, one option could have been to do some 
site-directed mutagenesis studies to try to make the ECL used in the ECL-TM display 
constructs monomeric, drawing inspiration from work by Narhi et al in which surface 
residues were changed to more charged residues thereby making them more stable and 
less likely to aggregate (2001). Cho et al (1996), in particular, made mutations in the 
gene for galaptin, another galactose-binding lectin, and succeeded in making the 
protein monomeric. The residues involved at the ECL dimer interface have been 
reported (Turton et ai, 2004). Over half are apolar or polar rather than charged amino 
acids and could potentially be targeted by site-directed mutagenesis; the most likely 
d'd b' . 1 . 191 d l' 203 can 1 ates emg ISO eucme an va me . 
Additionally, vector constructs could have been further optimised by replacement of 
the different regions. Transmembrane segments from different receptors could have 
been tried for this but maybe another option would have been to use one ~om an 
inhibitory receptor (although it is not known whether a negative signal could still be 
transmitted). Examples include receptors for tumour necrosis factor-a, interferon-y, 
or transforming growth factor-~I' all of which are powerful inhibitors of 
erythropoiesis (Zermati et ai, 2000). 
There are numerous stages at which things could have gone wrong: folding, insertion 
into the cell surface membrane, level of expression, or retention of galactose-binding 
activity. If it were decided to take this work further, the first step might be to establish 
whether the problem oflack of chimeric protein expression was at the DNA level or 
the protein expression level. Expression of RC A protein by AS-E2 cells could not be 
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detected by Western blot, despite the fact that in the other projects in which the vector 
pIRESblast was used, protein could be detected unless it was toxic to the cells, in 
which case no cells survived the blasticidin selection stages (Dr A. Macadam, 
personal communication, and other projects not described in this thesis). There was, 
however, the possibility that a potential toxicity of the lectin-containing genes could 
lead to selection of clones that have lost them. This was ruled out when the 
pIRESblast[RCA12o-Epo-R TM]-transfected cell line was confirmed as containing 
DNA amplifiable by RCA-specific primers. Spontaneous point mutations could still 
have arisen, though, that introduced stop codons, resulting in truncated forms of the 
protein. Such types of mutations would need to be identified by sequencing. Toxicity 
of the lectin display proteins could be reve.~led by transientIy transfecting the AS-E2 
cell line with the empty pIRESblast vector or a lectin display protein-encoding vector 
and then counting live cell and dead cell numbers. Expressing the RCA60 and RCA l 20 
lectin B chain domains on their own could be carried out to check that they can be 
synthesised in the AS-E2 human cell line. It is unlikely that this is a problem, 
however, as there are already reports of ricin being successfully expressed in 
mammalian (murine) cells (Krek et al, 1995). An alternative strategy would be to use 
the lectin display protein-encoding cDNA in an in vitro expression system to establish 
whether the proteins have the potential to be successfully synthesised in a different 
system and whether the lack of expression was specific to the mammalian expression 
system. If, in the future, RCA60/120 were successfully expressed on the surface of 
cells, it may still not be effective without recycling, potentially an even more 
complicated objective to achieve. 
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5.5. Conclusion 
In conclusion, an attempt was made to genetically engineer the Epo-dependent AS-E2 
cell line to express either the ECL or RCA60/120 galactose-binding plant lectins at the 
extracellular surface of the cell. Cells stably transfected with an ECL-encoding vector 
did not survive and cells stably transfected with RCA6olI2o-encoding vectors gave 
negative results for RCA60/120 by Western blot, indicating lack of expression. As 
expected from the lack of protein expression, cell-based assays using cells stably 
transfected with RCA6olI2o-encoding vectors, whether or not they contained an 
internalisation and degradation motif, failed to differentiate between intact and 
extensively desialylated Epo. 
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Chapter 6. Discussion 
6.1. Epo as a pharmaceutical analysis problem 
Epo has been on the market since 1989. In addition to its most commonly used role in 
stimulating proliferation of red blood cells, it has also been shown to be involved in 
regulating endothelial progenitor cells, neurones, myocardiocytes and vascular smooth 
muscle (Bahlmann et aI, 2004; reviewed in Buemi et aI, 2002): 
• There is an Epo receptor on smooth muscle cells and endothelial cells which, 
when bound by ligand, can trigger the release of endothelin and inhibit nitric 
oxide synthase (nitric oxide being a vasodilator), resulting in contraction of the 
smooth muscle and vasoconstriction, and bringing about an increase in blood 
pressure (Buemi et aI, 1993;Squadrito et aI, 1999); 
• Endothelial cells treated with Epo upregulate their numbers of vascular 
endothelial growth factor (VEGF), thereby potentiating proliferative effects 
and indicating a possible role in neovascularisation and wound-healing 
(Alvarez Arroyo et aI, 1998); 
• Epo-R is expressed early on in brain development and has a neuroprotective 
role, e.g. in combating cerebral ischaemia and concussive brain injury (Grasso 
et aI, 2002) and preventing glutamate-induced cell death (Cerami et aI, 2002). 
The brain makes its own erythropoietin but it is slightly smaller due to reduced 
sialylation, presumably because, this form of Epo does not cross the blood 
brain barrier and come into contact with the general circulation where it could 
be cleared by the ASGP-R (Masuda et ai, 1994). 
Epo is no longer under patent (Schellekens, 2004) and many more companies are 
starting to manufacture it. It is therefore becoming increasingly urgent to find an 
appropriate test for Epo that does not use animals. 
6.2. Control specifications for Epo 
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The current approach to control of pharmaceutical Epo, as set out in the European 
Pharmacopoeia, specifies that only the normocythaemic or the post-hypoxic 
polycythaemic in vivo mouse bioassays can provide definitive information on 
biological activity as they alone take into account all factors (known and unknown) 
affecting activity. 
The control of other glycoproteins (e.g. follicle-stimulating hormone (FSH), 
luteinising hormone (LH), thyroid-stimulating hormone (TSH) and human chorionic 
gonadotropin (he G» encounters the same problems in terms ofthe numbers of 
animals needed to test batches due to the wide variability of animal tests and 
consequently the large numbers of replicates required. For instance, it can take 
between 150 and 200 immature rats to obtain a statistically valid potency value for 
just one batch of FSH. Several hundred samples are submitted for testing each year, 
meaning that tens of thousands of animals are being killed annually (Driebergen & 
Baer, 2003). 
Replacement assays would need to tackle the issues of structure-activity relationships 
and heterogeneity. There exists a complex relationship that is not yet fully understood 
between the carbohydrate structure of glycoproteins such as Epo and in vivo biological 
activity. It is difficult to directly translate information on a glycoprotein's 
carbohydrate structure into a prediction of its biological activity. The concept of 
purity cannot be applied in the case of glycoproteins as there is so much inherent 
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variability in the glycosylation process - there potentially exist hundreds of isofonns 
within a single batch. 
6.3. Factors determining the in vivo biological activity of Epo 
In essence, in vivo activity is governed by a balance between the body's clearance 
mechanisms and Epo's affinity for binding its target receptor. As covered in 
Section 1.12., the factors reported to be involved include: 
• Clearance mediated by the liver's asialoglycoprotein receptor of 
galactose-exposing glycoproteins; 
• Clearance by the kidneys of glycoproteins containing bi-antennary structures; 
• Receptor-mediated clearance. 
6.4. Exposed galactosyl residues as a potential analytical target 
Analysis has shown that sialylation is the feature that varies most between batches of 
recombinant erythropoietin, while the sugar backbone structures remain the same -
"the relative ratios ofbi-antennary, tri-antennary, tetra-antennary and tetra-antennary 
saccharides with one, two or three N-acetyllactosaminyl repeats were almost identical 
among different samples" (Sasaki et ai, 1987). 
The first and subsequent Epo batches Sasaki et at analysed varied in tenns of 
sialylation, as shown in the following compositions: 
Level of sialylation First batch Other batches 
Mono-sial ylated 7% Not reported 
Di-sialylated 41% 18-21% 
Tri-sialylated 48% 64-67% 
Tetra-sialylated 4% 10-13% 
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This work was supported by LeFloch et at (2004) who removed sialic acids from 
recHuEpo, analysed oligosaccharides by high-perfonnance capillary electrophoresis 
(HPCE) and showed that the profiles were.very similar over the course ofthe batch 
culture, although if sialic acids were not removed then the profiles changed over the 
course of the culture and especially in the presence of serum. 
While receptor-binding assays, for example, are generally acknowledged as not being 
sufficient to show whether a sample is biologically active, a receptor-binding assay 
may be "adequate for (quality control) ifit has been shown to be sensitive to the 
variations known to occur in a growth factor preparation" (Robinson, 1999). 
Similarly, for batch release, physico-chemical tests can be used to demonstrate that a 
biological is structurally identical to that which has been shown to be effective in 
clinical studies even though potency has not been demonstrated directly. It can be 
argued that since the factor which varies in the case ofEpo (i.e. the level of 
sialylation) is known, assays can be designed with galactose as an analytical target in 
mind. This can be done physico-chemically (by glycan mapping and, to some extent, 
by IEF or other charge-based procedures) or by incorporating a galactose-dependent 
step or mechanism into in vitro bioassays. 
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6.4.1. In vitro bioassays as analytical tools 
Cell-based bioassays were employed because they can be used to determine the 
biological activity of proteins in a way that physico-chemical methods, ELISAs and 
receptor-binding cannot. There is, in fact, resistance to replacing the in vivo mouse 
assay with purely physico-chemical methods. It is argued that although 
physico-chemical and biochemical tests are extremely good for analysing the precise 
molecular structural features of heterogeneous glycoproteins, it is not simply a 
question of translating such data into an assigned specific biological activity, and that 
only a bioassay can measure biological activity (Robinson, 1999). Cell-based 
bioassays take into account all aspects of biological activity; receptor binding, 
activation of signal transduction and the final biological outcome, e.g. prol~feration, 
prevention of apoptosis, cell migration, differentiation etc (Mire-Sluis, 1999;Thorpe et 
ai, 1997). Radioimmunoassays and ELISAs, for instance, are not completely reliable 
because they have the potential to also detect inactive precursors or breakdown 
products (Krystal, 1983). In vivo assays go one step further in that they are able to 
assess all aspects of a protein's biological activity, including glomerular filtration, 
clearance by the liver and metabolism by target organs. 
Although undeniably sensitive, in vivo assays tend to be more labour-intensive and 
expensive than in vitro assays, and fail to provide the same level of precision. A 
considerable number of mice are frequently required in order to obtain a statistically 
valid potency value. They therefore tend to be employed only in cases such as that of 
glycoproteins when the parameters measured are not taken into account in the in vitro 
d 1- dd·t·on to being more precise immortalised, factor-dependent cell proce ure. n all ' 
1· . 1 d easier to use and analyse (ThOlpe et ai, 1997), and llles are more economlca an 
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interassay variation is lower (Robinson, 1999). In vitro assays, such as those outlined 
in Chapters 3-5, which purely target exposed galactosyl residues would be unable to 
make a distinction between the following: completely deglycosylated Epo; Epo that is 
missing both sialic acid and galactose residues; fully sialylated bi-antennary Epo; and 
the ideal, fully sialylated, tetra-antennary Epo. Asialo- agalacto-Epo, however, could 
feasibly be depleted by agarose-conjugated succinylated wheat germ agglutinin which, 
according to reports, binds to N-acetylglucosamine, but not ifit is sialylated 
(Monsigny et ai, 1979). The properties of Concanavalin A might equally be exploited 
as it preferentially binds bi-antennary sugars (Treuheit et ai, 1992). 
6.4.2. Incorporation of galactosyl-binding into the in vitro bioassay 
The studies in which neuraminidase- desialylated Epo is tested by the solid-phase 
AS-E2/ECL assay described in Chapter 3 provide proof of principle that this strategy 
can permit discrimination between differentially sialylated Epo samples. 
An asset of the asialoglycoprotein receptor-expressing AS-E2 cell line bioassay of 
Chapter 4 is that it employs fewer manipulation steps compared with the AS/E2-ECL 
assay described in Chapter 3. For this reason, the same serially diluted Epo samples 
can be simultaneously compared in the genetically manipulated cell bioassays and in 
the unmodified Epo bioassay. Potential errors that might have arisen during serial 
dilution or as a result of degradation will thus be detected. This assay is not as 
sensitive, however, a problem that could be surmounted in three ways: 
(1) using a stronger galactose-binding lectin, i.e. certain plant lectins (which also 
have the advantage of not bdng so dependent on an oligosaccharide branch 
~ 
possessing three exposed galactose residues); 
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(2) having a decoy receptor capable of internalisation, degradation and/or 
recycling; 
(3) increasing decoy receptor cell surface expression in order to compete with the 
high affinity of the Epo-R. This could be achieved by using the dihydrofolate 
reductase (DHFR) or glutamine synthetase (GS) genes to amplify the gene of 
interest, or making alterations to the signal peptide and transmembrane 
segment for optimal expression. 
The third method, involving gene amplification, was attempted but problems arose 
during the vector ligation stages due to unknown reasons. A brief description follows 
of the intended strategy. 
6.4.2.1. Proposed strategy for increasing ASGP-R expression 
Gene amplification involves an increase in the copy number of a gene without a 
proportional increase in other genes in the genome (reviewed in Omasa, 2002). Two 
ofthe most common gene amplification systems are the DHFR and the GS 
amplification systems. A vector containing the amplification gene is introduced into a 
host cell line and then cells are grown in increasing concentrations of a drug that 
inhibits the gene - methotrexate in the case of the DHFR gene (Hakala, 1957) and 
methionine sulfoximine in the case of the GS gene (Sanders & Wilson, 1984). Cells 
are selected for containing increased copy numbers of the amplification gene. A gene 
of interest included in the vector alongside the amplification gene has the potential to 
be co-amplified. It has been proposed that the mechanism by which gene 
amplification takes place involves expansion of chromosome regions or chromosome 
~ 
breakage leading to the fonnation of extra chromosomal structures such as double 
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minute chromosomes (Paul son et aI, 1998). An attempt was made to create a vector 
containing: 
{[gene ofinterest]-[IRES]-[amplification gene]-[IRES]-[blasticidin resistance gene]}. 
A disadvantage ofDHFR-directed amplification is that it can only be used in 
DHFR-negative cells, whereas AS-E2 cells are DHFR-positive. This constraint can 
be avoided by modifying the DHFR gene by site-directed mutagenesis to contain an 
arginine instead ofa leucine at position 22 (Simonsen & Levinson, 1983). The 
mutated version ofDHFR is not able to bind its inhibitor methotrexate as strongly, 
and therefore much higher concentrations of methotrexate are needed before it gets 
inhibited and can direct gene amplification. Meanwhile, all endogenous DHFR 
activity has been completely abrogated by the higher methotrexate levels. The OS 
amplification system can be used in any cell type as well. Such a vector containing 
IRES sequences between the gene of interest, the amplification gene and the 
antibiotic-resistant gene would reduce the need to screen clones and would be more 
likely to ensure amplification of the gene of interest. A vector that contains the IRES 
sequence and the OS gene has been reported to enable selection "superior to a 
conventional expression vector in both levels of protein expression and amplification 
efficiency" (Pu et aI, 1998). 
There are also other, smaller changes that could be made that may increase 
expression. For example, the ASOP-R-Hl subunit has an atypical Kozak sequence 
and changing its ATCATOA sequence to ACCATOO may improve expression levels. 
The plant lectin display vector constructs could use the artificial "secrecon" signal 
sequence, as research has found this to be the best signal sequence for protein 
secretion (B~rash et ai, 2002) and it may also work for receptor expression. 
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If a receptor is introduced into a cell line with a view to conferring sensitivity to, for 
example, a cytokine, then high receptor-expression levels are not crucial as a response 
is still elicited. In the case of Epo, a half-maximal response in a cellular proliferation 
assay is produced at an Epo concentration of 0.01 nM, whereas half the Epo-R binding 
sites are bound at the higher concentration of 0.18 nM (Syed et ai, 1998), prompting 
the authors to speculate that only 6% of receptors need to be bound for half-maximal 
proliferation. The aim of the research described in this thesis is a different one 
altogether and requires high levels of expression to sufficiently lower the 
concentration ofthe surrounding medium. 
6.4.2.2. Sialylation and in vitro activity 
An additional factor that must be taken into consideration is the increase in in vitro 
activity that has been reported when using desialylated Epo in comparison with fully 
sialylated Epo. This effect has been observed in bone marrow cells (Imai et ai, 1990) 
and in the TP-l cell line (Takeuchi et ai, 1990) (three to fourfold increases being 
reported). Similar results were obtained using colony-forming assays; colony-forming 
unit (CPU) activity was 100% for intact fully sialylated Epo, decreased to 67% for 
deglycosylated (possibly due to lack of stability), but increased to 180% for 
desialylated Epo (Tsuda et ai, 1990). In in vivo assays the latter two samples were 
devoid of activity. Such an effect was not observed to as significant a degree when 
using the unmodified AS-E2 bioassay. This is important because getting correlation 
with the in vivo assays using the assays outlined in this thesis would have been even 
more of a challenge if desialylated Epo samples had been several times more potent 
than a comparable concentration of intact Epo. 
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The difference in effect of sialylation on in vitro activity may be attributable to there 
being two known classes of Epo receptor: the high-affinity form has a Kd value of 
0.08-0.1 nM for intact Epo, whereas the low-affinity form has a Kd value of 
0.8-1.3 nM (Dong et ai, 1992). By contrast, the Kd values for asialo-Epo are 
0.02-0.03 nM and 0.9-1.2 nM respectively. The strength of interaction between the 
high-affinity receptor and Epo increases with desialylation, whereas desialylation does 
not appear to affect Epo binding to the low-affinity receptor. The AS-E2 cells used in 
the assays outlined in this thesis possess only the low-affinity receptor (Miyazaki et ai, 
1997). Accessory proteins may exist that confer high affinity to the Epo receptor. If 
CHO cells are fused with low-affinity receptor-expressing cells, the Epo receptor 
becomes a high-affinity one (Hermine et al, 1996) implying that CHO cells contain a 
protein or proteins that change the receptor's binding characteristics. The lower 
affinity of fully sialylated Epo is ascribed to the higher negative charge conferred by 
sialic acid (Imai et ai, 1990), but how can this be reconciled with the fact that, as 
mentioned in Section 3.4., the sugars project some distance away from the receptor? 
Darling et al (2002) used surface plasmon resonance to show that sialic acids and 
carbohydrates in general inhibit the binding of Epo to isolated Epo-R. The isolated 
Epo-R was in the form of an Epo-R chimera bound to protein A and so was 
presumably free of any accessory proteins that could be causing the difference in the 
high-affinity binding cells. Long-range electrostatic forces were suggested to be 
involved as increasing the ionic strength reduced the rate of Epo binding to its 
receptor.This appears to contradict Dong et al (1992) who state that low-affinity 
Epo-R-expressing cells do not show a preference for asialo-Epo over fully sialylated 
Epo. 
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Schooley et al (1985) report an even greater rate of DNA synthesis if sialidase is 
included in the assay, leading the author to conclude that ifit is accepted that 
desialylation allows Epo to gain easier access to its receptor by removing a large 
negative charge, then it could equally be argued that there is a negative charge on the 
surface of cells which can be removed by sialidase and which hinders receptor 
engagement. 
Steinberg et al (1986) suggest that Epo produced when the body is under stress may 
be less well processed and consequently cleared more rapidly but would bind its , 
receptor with more affinity~ The case of follicle-stimulating hormone (FSH) may shed 
some light on the subject. FSH's state of glycosylation affects its activity, possibly 
allowing for a more finely tuned response,to the hormone (Ulloa-Aguirre et aI, 2003). 
Much like Epo, clearance of FSH is governed by the number of exposed galactose 
residues. Less sialylated FSH isoforms are released prior to ovulation, coinciding 
with a reduction in its half-life (Zambrano et aI, 1995). Ulloa-Aguirre et al (2003) 
found that less acidic FSH isoforms elicited a faster response (induction oftPA 
enzyme activity in the ovaries of rats) compared with the more acidic form of the 
hormone and speculated that this could compensate for a relatively shorter half-life-
"even a brief exposure of the target cell to short-lived but highly potent gonadotropin 
forms may be sufficient to evoke a biological response." 
6.4.2.3. The viability of targeting the galactosyl residue 
The approach of targeting galactose residues works only if the variation seen in Epo 
activity is of a kind that is caused solely by galactosyl exposure. Although the 
-
literature suggests that this is the case, the anion-exchange-separated fractions of 
sample set 3 did not conform to this prediction: all the fractions had fairly similar 
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numbers of exposed galactose residues (apart from Epo Fraction A which contained 
more) but the in vivo biological activity tended to increase, indicating some other 
factor was also playing a part in governing potency. Conversely, while Epo Fractions 
A and B differed in numbers of galactosyl residues exposed per glycan (0.457 
compared to 0.404 respectively), their in vivo activity remained the same. Galactose 
exposure and in vivo activity did not correlate well (Pearson correlation R=-0.507 for 
the normocythaemic assay). Sialic acid content correlated better (Pearson correlation 
R=0.930), possibly suggesting that the presence ofprotective sialic acid caps was 
doing more than just preventing Epo from being cleared. Further investigation is 
needed into the possible causes before putting forward any predictions in terms of 
biological activity. 
6.4.3. Non-biological approaches to identifying activity-determining features 
6.4.3.1. The utility of charge-based separations 
Charge-based methods can show the range of isoforms relating to differentially 
sialylated variants. IEF and capillary zone electrophoresis have thus been assessed in 
terms of their ability to provide quantitative information on the distribution ofEpo 
isoforms (Bristow & Charton, 1999). Mulders et al (1999) propose using IEF for also 
predicting follicle-stimulating hormone activity (FSH). An international collaborative 
study on the use of isoelectric focusing or capillary zone electrophoresis to predict the 
bioactivity of follicle-stimulating hormone (Storring et ai, 2002) concluded that the 
work showed promise, the techniques concerned being precise and accurate enough to 
"distinguish between FSHs which might meet or fail European Pharmacopoeia 
requirements" . 
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A variation suggested by Hennentin et ai uses a hypothetical "Z number" to predict in 
vivo biological activity (1996, 2002). This is calculated by multiplying the proportion 
of each type of sialylated structure (tetra-sialylated, tri-sialylated, di-sialylated, 
mono-sialylated and asialylated), as detennined by high perfonnance anion exchange 
chromatography and pulsed amperometric detection (HP AEC-P AD), by the charge 
conferred by the corresponding number of sialic acids (4, 3, 2, 1 ,and 0 respectively). 
The higher the Z number, the more biologically active was the batch of Epo. 
These charge -based procedures do have some drawbacks, however, namely the fact 
that poly N-acetyllactosamine (Galp 1 ~4GlcNAcp 1 ~3) repeats have, in addition to 
the number of exposed galactoses, been implicated in clearance by the ASGP-R 
(Fukuda et ai, 1989). Such a pennutation.could be more difficult to detect on an IEF 
gel. The issue of differentiating between different levels of branching could be 
equally problematic. 
6.4.3.2. The utility of glycan mapping 
Sugars affect activity and glycan mapping can provide extremely detailed infonnation 
on carbohydrate structure; for example, on the percentage of tetrasialylated or 
tetra-antennary glycan content. Tetrasialylated glycan content was shown to correlate 
well with in vivo biological activity in the case ofthe pharamceutical Epo preparations 
of sample set 2 (as reported in (Yuen et ai, 2003». In the case of the 
anion-exchange-separated fractions of sample set 3, both tetra-antennary and 
tetrasialylated content exhibited good correlations with activity measured by the 
nonnocythaemic assay - the majority having Pearson correlation coefficients higher 
than 0.9. It must be borne in mind, however, that the in vivo values involved in these 
correlations were very closely grouped and did not differ from each other to any 
statistically significant extent. 
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Glycan mapping is, again, not a method that provides information on activity at the 
receptor and cellular level. Although it can provide an extrememely detailed analysis 
of carbohydrate structure, the real challenge consists in fully interpreting that 
information. 
There is a further complication in that, as mentioned in Section 1.2., glycoprotein 
oligosaccharide chains can vary immensely in terms of type of glycosylation (N- or 
O-type), number of branches, and level of sialylation, galactosylation, fucosylation 
and poly-lactosaminylation. A carbohydrate chain with any combination of these can 
occur at a glycosylation site. It is therefore exceedingly difficult to isolate and purify 
just one form. Accordingly, the precise roles assigned by the different oligosaccharide 
structures is by no means clear. A side-project was therefore undertaken to try to 
simplify matters by creating Epo that was sialylated at just one site. Such a protein 
would be easier to separate into its five fractions (1-4 sialic acids and one isoform 
without sialic acids). The five fractions could then be tested in vivo to see ifthere was 
a radical jump in activity between the tetra-sialylated form of Epo and all other forms 
(as suggested by the Yuen et al (2003) paper) or, alternatively, ifthe increase in 
activity was incremental and regular. Although beset with purification and 
concentration problems, that project is still ongoing. 
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Table 6.1. Methods available (including cell-based assays developed during 
the course of this project) for detecting changes in isoform distribution and 
how sensitively they behaved when testing each of the three Epo sample sets. 
Sample set 1 Sample set 2 Sample set 3 
(neuraminidase- (different culture (ion-exchange 
treated) and purification . fractionated 
conditions) pharmaceutic-
al grade Epo) 
In vivo assay ./././ ././ .)C 
In vitro AS-E2 .)C .)C .)C 
assay 
In vitro ././ ./ .)C 
AS-E2/ECL 
assay 
Stably ./ Not applied Not applied 
transfected 
ASGP-R 
expressing 
AS-E2 cells 
AS-E2 cells .)C Not applied Not applied 
stably 
transfected 
with cell-
surface 
displayed 
galactose-
binding plant 
lectin 
IEF ././ ././ ././ 
Glycan 
-
Not applied ./././ ./././ 
mapping 
6.5. Conclusions, future developments and specification 
recommendations 
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Table 6.1. summarises the power of the assays developed during the course of these 
studies as well as the techniques previously available to resolve differences in 
glycosylation within sample setes. Each method has its advantages and drawbacks. 
The following conclusions can be drawn in light of the information set out in the 
table: 
1. The normocythaemic and post-hypoxic polycythaemic mouse assays are 
currently the only accepted procedure for assessing Epo biological activity. 
Although comprehensive, these assays present major drawbacks in that they 
require the use of animals, feature wide confidence intervals and are 
labour-intensive. 
2. The cell-based bioassays offer ease of use, narrow confidence intervals and 
valuable information on biological activity at the target cell level. They suffer 
from a lack of sensitivity and the fact that they take into account only one 
carbohydrate structural feature (galactose exposure). The immobilised plant 
lectin assays appeared promising; although not as sensitive as in vivo assays, 
they revealed a statistically significant difference between intact Epo (Epo 
sample t=O min) and slightly desialylated Epo (sample t=20 min) of sample set 
1. The AS-E2 cells stably transfected with the ASGP-R were not as successful 
in this respect. In essence the problem is that although the most desialylated 
sample (t=1800 min) is detected as having a lower biological activity than does 
intact Epo in this cell bioassay, this variation between samples far exceeds 
what would be expected in recombinant batch production. 
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3. IEF is cheap, robust, not technologically demanding and provides good 
discrimination between different isoforms (this was the case in particular of 
the fractions in sample set 3 in Fig. 3.3.15.). Ifsialic acid content is a better 
indicator of activity, then IEF would be more appropriate than galactose 
exposure-dependent methods, as variation in pI is effected by sialic acids but 
not directly by galactose exposure. IEF does not go as far as glycan mapping 
in terms of the amount of detailed information provided, however. 
4. Glycan mapping provides very detailed information about structure but it does 
not provide any information on activity of the protein in eliciting a response 
from its target cell. There are still uncertainties regarding sugar 
structurelactivityrelationships butat least information is provided on issues 
such as polylactosamine and bi-antennary content. 
A good compromise may be to combine glycan mapping (for the most substantial 
analysis) or IEF (if an economic or technological trade-off is required) with an 
Epo-responsive cell-based bioassay. Continuing research into sugar structure-in vivo 
activity relationships would be necessary to enhance the interpretation of results 
obtained by glycan analysis. 
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Chapter 7. Summary 
Adequate glycosylation, in particular, sialylation, plays a critical role in the in vivo 
biological activity of Epo whereas it is mostly irrelevant to its in vitro activity. 
Current in vitro ELISA- or cell-based assay results for Epo do not correlate with the in 
vivo bioassay results as the former assays do not take into account the body's various 
mechanisms for clearing the different glycoprotein isoforms, in particular, the role the 
liver plays in eliminating desialylated glycoproteins from the circulation. The aims of 
this project were to develop cell-based bioassays that were sialylation-sensitive and to 
assess their efficacy compared with the in vivo bioassays currently prescribed by the 
European Pharmacopoeia, as well as with an unmodified Epo-dependent cell line 
bioassay and two physico-chemical techniques (IEF and glycan mapping). 
Three approaches were used to render cell-based bioassays sialylation-sensitive. 
In the first approach, Epo was incubated with a solid-phase galactose-binding lectin 
(Erythrina crista-galli), mimicking passage through the liver in vivo, prior to serial 
dilutions of the Epo being used in a standard Epo-dependent cell line (AS-E2) 
bioassay. This assay was tested using Epo samples treated with neuraminidase for 
varying lengths oftime. Incorporation of the ECL incubation step renderered the 
modified in vitro bioassay sensitive to desialylation, such that Epo desialylated almost 
to completion had less than 10% ofthe activity of untreated Epo. These results 
positively correlated with those obtained by in vivo assay in that in vivo activity was 
progressively abolished by desialylation through neuraminidase-treatment. In vitro 
activity, as measured by the unmodified AS-E2 assay, was essentially unaffected. In 
addition to the neuraminidase-treated Epo sample set, Epo produced by a range of 
different purification procedures (thus eliciting variation in terms ofisoforms) and a 
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batch of pharmaceutical grade Epo separated by anion-exchange HPLC into fractions 
that varied by charge were also tested. 
In the second approach to render cell-based bioassays sialyltion-sensitive, the AS-E2 
cell line was stably transfected with the liver's asialoglycoprotein receptor, the 
receptor responsible for clearing glycoproteins containing galactose-terminated sugar 
chains. The objective was to introduce a receptor into an Epo-dependent cell line that 
would act as a decoy receptor, effectively sequestering and internalising Epo 
containing exposed galactose residues, and thus preventing such Epo molecules from 
binding the Epo receptor and transmitting a proliferation signal. 
In the third approach, an attempt was made to stably transfect the AS-E2 cell line with 
a cell-surf ace-displayed plant-derived galactose-binding chimeric protein. The 
rationale behind this strategy was the same as that for the second approach except that 
the asialoglycoprotein receptor would be replaced by a plant lectin. Certain plant 
lectins have stronger binding affinities for galactose than the asialoglycoprotein 
receptor and their binding is not as dependent upon the oligosaccharide ligand having 
three terminal galactose residues. 
These studies provided proof of principle that rational manipulation of in vitro 
bioassays could render these procedures responsive to factors known to affect 
bioactivity in vivo, and could therefore allow prediction of in vivo activity without 
using live animals. 
Ofthe assays developed, the cell-based assay incorporating the immobilised-lectin 
binding step was the most successful strategy investigated. Although not as sensitive 
as the in vivo assay at detecting differences in potency, it did have narrower 
-
confidence intervals. 
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The asialoglycoprotein receptor-expressing Epo-dependent cell line assay was 
drastically less sensitive in terms of detecting differences in potency but it had the 
advantage of fewer handling steps and dilutions and could be directly compared with 
the untransfected cell bioassay. 
It was not possible to test the hypothesis that plant lectin-displaying AS-E2 cells were 
more sensitive at detecting lower levels of desialylation or exhibited less of a bias 
towards tri-galactose terminating sugar chains, as there was serious doubt as to 
whether the cells successfully expressed the chimeric plant lectin:transmembrane 
domain protein. 
The assays described in this thesis had the disadvantage that they take into account 
only one factor, namely the percentage of galactose exposure. Although it has been 
suggested that the latter is the main issue governing activity and the one most likely to 
vary in batch production, other factors are at play, possibly even some unknown ones. 
For instance, it has yet to be clarified to what extent the level ofpolylactosaminylation 
or the desialylated bi-antennary content may affect in vivo activity. Indeed, analysis 
carried out on pharmaceutical-grade charge-separated Epo fractions revealed that 
certain fractions differing in in vivo biological activity did not have varying levels of 
galactose exposure. 
Replacing the animal test for Epo presents a considerable challenge, as it alone is able 
to take into account simultaneously the many factors affecting activity. Until we fully 
understand how sugars affect activity, designing an assay that can truly represent that 
activity will remain difficult. The attempts outlined in this thesis go some way to 
developing an in vitro cell-based test which, although it falls short in terms of 
-
sensitivity and does not take into account all aspects of sugars and multiple clearance 
mechanisms, does at least correlate with the in vivo assay. 
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Glycoanalysis appears to have the most potential for replacing the in vivo tests as it is 
extremely accurate and can assess all types of variation in oligosaccharide structure. 
The best course of action, however, might be to recommend that it be combined with a 
cell-based bioassay, as the latter provides valuable information on whether the Epo 
protein structure is suitable for eliciting a proliferation response from its target cells. 
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Appendix 
All reagents were obtained from Sigma unless otherwise stated. 
All autoclaving was carried out for 22 minutes at 121°C, 1.05 bar. 
Referred to in Section 2.1.5. 
Recipefor Luria-Bertani (LB) medium: 
Reagent 
Tryptone (Merck Biosciences, UK) 
Yeast extract (BD Biosciences, UK) 
N aCI (BDH Analar, UK) 
Amount 
109 
5g 
5g 
MilliQ water was added to a final volume of 1 litre and autoclaved. 
Recipe for LBamp plates: 
Reagent Amount 
Tryptone (Merck Biosciences, UK) 109 
Yeast extract (BD Biosciences, UK) 5g 
NaCI (BDH Analar, UK) 5g 
Agar (BD Biosciences, UK) 15 g 
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MilliQ water was added to a final volume of 1 litre and autoclaved. The solution was 
allowed to cool to -50°C and ampicillin (Sigma, UK) added to a final concentration of 
100/-tg/ml. The medium (-20 ml) was poured into 90mm Petri dishes and allowed to 
cool, then stored at 4°C for up to four weeks. 
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LBamp plates with IPTG/X-Gal: 
LBamp plates were made as above then 100 /-11 of 100mM isopropyl-beta-D-
thiogalactopyranoside (IPTG, Promega, UK) and 20 /-11 of SO mg/ml S-brom-4-chloro-
3-indolyl-beta-D-galactopyranoside (X-Gal, Promega, UK) were spread over their 
surface. 
Recipe for sac (S.uper Qptimal Broth with added glucose for f.atabolite repression) 
medium: 
Reagent Amount 
Tryptone 20g 
Yeast extract Sg 
NaCl .' 0.5 
MilliQ water was added to a final volume of 1 litre and autoc1aved. Filter-sterilised 
MgClz (1 M, 10 ml), filter-sterilised MgS04 (1 M, 10 ml) and filter-sterilised glucose 
(20% [w/v], 20ml) were then added immediately before use. 
Referred to in Section 2.1.7. 
For 100 ml of Solution PI: 
Reagent Mass/volume 
Glucose 0.9 g 
Tris/HCl (0.2S M) pH8.0 IOml 
EDTA (O.SM) pH8.0 2ml 
Concentration 
SO mM 
2SmM 
10mM 
The volume was made up to 100 ml with MilliQ water, autoc1aved and stored at 4°C. 
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For 100 ml Solution P2: 
Reagent Mass Concentration/volume 
NaOH 8g 0.2 M 
SDS 1 g 1% 
. . .. The volume was made up to 100 ml wIth MIlhQ water, filter-stenhsed and stored at 
room temperature. 
For 100 ml Solution P3: 
Reagent Amount/Volume Concentration 
Potassium acetate 29.442 g 3M 
Glacial acetic acid 11.5 ml .. -
The volume was made up to 100 ml with MilliQ water, filter-sterilised and stored at 
4°C. 
Referred to in Section 2.2.3.4. 
Recipe/or PBS used/or washing cells: 
Reagent Amount Final concentration 
Na2HP04 1.44 g 0.01 M 
KH2P04 0.25 g 0.001 M 
KCI 0.25 g 0.003 M 
NaCI 10 g 0.171 M 
.. The reagents were made up to 1 htre wIth MIlhQ water. 
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Referred to in Section 2.3.1. 
Lysis buffer (6 ml total): 
Reagents Initial Volume Final 
concentration concentration 
Tris/HCI (pH 7.4) 200mM 600 J.tl 20 mM 
NaCI 1.5M 600 J.tl 0.15M 
Glycerol 100% 600 J.tl 10% 
Triton-X-I00 20% (v/v) in 300 J.tl 1% 
MilliQ water 
EDTA 0.5 M 12 J.tl ImM 
Leupeptin 100 J.tg/J.tl 60 J.tl 1 J.tg/J.tl 
Phenylmethylsulphonylfluoride 200mM 30 J.tl ImM 
(PMSF) .-
The volume was made up to 6 ml with MilliQ water. 
Referred to in Section 2.3.2. 
SDS loading buffer (6x): 
Reagent Concentration 
Tris/HCI (pH 6.8) 0.35M 
Sodium dodecyl sulphate 10.28% (w/v) 
Glycerol 36% (v/v) 
f3-mercaptoethanol 5% (v/v) 
Bromophenol blue 0.012% (w/v) 
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Referred to in Section 2.3.3. 
SDS running buffer: 
Reagent Amount 
Glycine 14.4 g 
Tris 3.025 g 
SDS 1 g 
The volume was made up to 1 htre wIth MilliQ water. 
Referred to in Section 2.3.4. 
Blot transfer buffer: 
Reagent Amount 
Glycine 14.4 g 
Tris 3.0 g 
The volume was first made up to 800 ml with MilliQ water and then up to 1 litre with 
methanol. 
Referred to in Section 2.3.7. 
Recipe for Solution A (fixative): 
Reagent Initial 
concentration 
Formaldehyde 37% 
(Sigma, UK» 
NaOH 4M 
.-
Volume Final 
concentration 
50ml 5% 
0.2ml 2mM 
The reagents were made up to 400 ml with MilliQ water and heated to 60°C. 
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Recipe/or Solution B (alkali accelerator): 
Reagent Amount/volume 
Anhydrous sodium carbonate 15 g 
-
Formaldehyde (37%) 250/-LI 
The reagents were made up to 500 ml with MilliQ water. 
Referred to in Section 2.3.12. 
Wash dilution buffer recipe: 
Reagents Amount Final concentration 
NaH2P04.2H20 1.95 g 2.5 mM 
Na2HP04 5.32 g 7.5 mM 
NaCI 146.1 g 500 mM 
Tween-20 5 ml 0.1% (v/v) 
The reagents are made up to 5 litres with MilliQ water and the pH adjusted to 7.2 with 
NaOH. The Tween-20 is added after measuring the pH to avoid frothing during 
mixing. This buffer can be stored for 2-3 months at +4°C. 
Substrate buffer: 
Reagents Amount Final concentration 
Citric acid.H2O 7.3 g 34.7 mM 
Na2HP04 9.47g 66.7 mM 
The reagents are made up to 1 lItre wIth MtlhQ water, and the pH adjusted to 5.0 wIth 
NaOH. This solution can be stored for up to 2 months at +4°C. 
Referred to in Section 2.4. 
Recipe for Albumin-buffered saline solution pH7.2 (ABS): 
Reagent Amount 
-
NaCI 6.95 g 
NaH2P04.2H20 0.851 g 
Na2HP04 3.097 
MilliQ 850ml 
EDTA solution (7% [w/v] in MilliQ 9ml 
water) 
Merthiolate (0.1 % [w/v] in 0.9% [w/v] 90ml 
NaCI solution) 
--
Albumin - I g 
The pH ofthe solution was adjusted to 7.2 usmg NaOH or HC!. The volume was then 
made up to 1 litre with MilliQ water. 
Recipefor citrate buffer (50 ml): 
Reagent Amount 
Sodium citrate 500mg 
NaCI 295mg 
MilliQ water 40ml 
The pH was adjusted to 7.0 and the volume made up to 50 ml with MilliQ water. 
